RAS inhibitors

By forming a high-affinity complex between Ras protein and cytoplasmic chaperone protein, blocking the interaction between Ras and downstream signaling molecules, the problem of difficult to regulate the ineffective Ras protein in the prior art is solved, and Ras mutation is achieved Drive potential treatments for cancer.

CN118922423APending Publication Date: 2024-11-08REVOLUTION MEDICINES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380026429.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-10
Filing Date
2023-01-09
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate untreated target proteins, especially Ras proteins, resulting in a lack of effective drugs for cancers driven by Ras mutations.

Method used

By synthesizing ligands form a high-affinity three-component complex with Ras protein and cytoplasmic chaperone cyclophilin A, the interaction sites between Ras and downstream oncogenic signaling molecules are blocked and the activity of Ras is inhibited.

Benefits of technology

Effectively inhibiting the activity of Ras proteins, potentially providing new anti-cancer therapies, especially for cancers driven by Ras mutations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005034067480000031
    Figure BDA0005034067480000031
  • Figure BDA0005034067480000072
    Figure BDA0005034067480000072
  • Figure BDA0005034067480000081
    Figure BDA0005034067480000081
Patent Text Reader

Abstract

The present disclosure provides macrocyclic compounds capable of inhibiting Ras proteins, as well as pharmaceutical compositions and protein complexes thereof, and their use in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority to U.S. Application No. 63 / 298,098, filed on January 10, 2022, all of which are hereby incorporated by reference in their entirety. Background Art

[0003] The vast majority of small molecule drugs work by binding to functionally important pockets on target proteins, thereby regulating the activity of the protein. For example, cholesterol-lowering drugs known as statins bind to the enzyme active site of HMG-CoA reductase, thereby preventing the enzyme from engaging with its substrate. The fact that many such drug / target interaction pairs are known may mislead some people to believe that small molecule regulators for most (if not all) proteins can be found, which provides a reasonable amount of time, effort and resources. But this is far from the case. At present, it is estimated that only about 10% of all human proteins can be targeted by small molecules. Bojadzic and Buchwald, Curr Top Med Chem 18: 674-699 (2019). The other 90% are currently considered to be difficult to treat or difficult to handle for the above-mentioned small molecule drug discovery. Such targets are often referred to as "undruggable". These undruggable targets include a huge and largely undeveloped reservoir of medically important human proteins. Therefore, there is great interest in discovering new molecular modalities that can regulate the functions of such undruggable targets.

[0004] It is well established in the literature that Ras proteins (K-Ras, H-Ras, and N-Ras) play a critical role in a variety of human cancers and are therefore appropriate targets for anticancer therapy. In fact, in the United States, approximately 30% of all human cancers are caused by mutations in Ras proteins, many of which are lethal. Ras protein dysregulation, either by activating mutations, overexpression, or upstream activation, is common in human tumors, and activating mutations in Ras are often found in human cancers. For example, activating mutations at codon 12 in Ras proteins act by inhibiting GTPase activating protein (GAP) dependency and intrinsic GTP hydrolysis rates, significantly biasing the Ras mutant protein population toward the "on" (GTP-bound) state (Ras (ON)), leading to oncogenic MAPK signaling. Notably, Ras exhibits a picomolar affinity for GTP and can be activated even in the presence of low concentrations of this nucleotide. Mutations at codon 13 (eg, G13C) and codon 61 (eg, Q61K) in Ras also cause oncogenic activity in some cancers.

[0005] Despite extensive drug discovery efforts targeting Ras over the past decades, only two agents targeting the K-Ras G12C mutant (sotorasib and adagrasib) have been approved in the U.S. Additional efforts are needed to discover additional drugs targeting cancers driven by various Ras mutations. Summary of the invention

[0006] Ras inhibitors are provided herein. The methods described herein require the formation of a high-affinity three-component complex between a synthetic ligand and two intracellular proteins that do not interact under normal physiological conditions: a target protein of interest (e.g., Ras), and a cytoplasmic chaperone (presenting protein) (e.g., cyclophilin A) widely expressed in cells. More specifically, in some embodiments, the Ras inhibitors described herein induce new binding pockets in Ras by driving the formation of a high-affinity ternary complex or conjugate between Ras protein and the widely expressed cytoplasmic chaperone cyclophilin A (CYPA). Without being bound by theory, the inventors believe that one way in which the compounds of the present invention and the complexes or conjugates formed therefrom exert an inhibitory effect on Ras is to spatially block the interaction sites between Ras and downstream effector molecules such as RAF and PI3K required to propagate oncogenic signals.

[0007] Therefore, in some embodiments, the present disclosure provides a compound of structural formula I or a pharmaceutically acceptable salt thereof:

[0008]

[0009] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0010] L 1 Not present or a joint;

[0011] W is a crosslinking group comprising vinyl ketone, vinyl sulfone, alkynyl ketone or alkynyl sulfone;

[0012] R 1 is hydrogen, optionally substituted 3 to 10 membered heterocycloalkyl or optionally substituted C 1 -C 6 heteroalkyl;

[0013] R 2 is optionally substituted C 1 -C 6 Alkyl; and

[0014] R 3is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 Heteroalkyl.

[0015] Also provided are pharmaceutical compositions comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. Also provided are pharmaceutical compositions comprising a compound of Table 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[0016] Also provided is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.

[0017] In some embodiments, a method of treating a Ras protein-related disorder in a subject in need thereof is provided, the method comprising administering to the subject a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.

[0018] Further provided is a method for inhibiting Ras protein in a cell, the method comprising contacting the cell with an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.

[0019] Specifically contemplate, any limitation discussed about one embodiment of the present invention may be applicable to any other embodiment of the present invention. In addition, any compound or composition of the present invention may be used in any method of the present invention, and any method of the present invention may be used to produce or utilize any compound or composition of the present invention.

[0020] Definitions and Chemical Terms

[0021] In this application, unless otherwise clearly indicated from the context, (i) the term "a" means "one or more"; (ii) the term "or" is used to mean "and / or" unless it is clearly indicated that the term refers to alternatives that are unique or that the alternatives are mutually exclusive, however, the definition supported by the present disclosure refers to the only alternative and "and / or"; (iii) the terms "comprising" and "including" should be understood to cover the listed components or steps, whether present only by themselves or in combination with one or more additional components or steps; and (iv) when a range is provided, the endpoints are included.

[0022] As used herein, the term "about" is used to indicate that a value includes the standard deviation of the error of the device or method for determining the value. In certain embodiments, the term "about" refers to a value in either direction (greater than or less than) 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or a range within a lower percentage of the value, unless otherwise specified or otherwise apparent from the context (e.g., when the numeral will exceed 100% of the possible value).

[0023] As used herein, in the context of describing adjacent atoms, the term "adjacent" refers to divalent atoms that are directly connected via a covalent bond.

[0024] As used herein, "compounds of the present invention" and similar terms, whether explicitly indicated or not, refer to the Ras inhibitors described herein, including compounds of Formula I and its subformulas, such as compounds of Table 1, and their salts (e.g., pharmaceutically acceptable salts), solvates, hydrates, stereoisomers (including atropisomers) and tautomers.

[0025] The term "wild type" refers to an entity having a structure or activity found in nature in a "normal" (as opposed to mutant, diseased, altered, etc.) state or situation. Those skilled in the art will appreciate that wild-type genes and polypeptides typically exist in a variety of different forms (e.g., alleles).

[0026] It will be appreciated by those skilled in the art that certain compounds described herein may exist in one or more different isomeric forms (e.g., stereoisomers, geometric isomers, atropisomers, tautomers) or isotopic forms (e.g., wherein one or more atoms are substituted with different isotopes of said atoms, e.g., hydrogen is substituted with deuterium). Unless otherwise indicated or clear from the context, depicted structures may be understood to represent any such isomeric or isotopic forms, either individually or in combination.

[0027] The compounds described herein may be asymmetric (e.g., have one or more stereocenters). Unless otherwise indicated, all stereoisomers, such as enantiomers and diastereomers, are encompassed. Compounds of the present disclosure containing asymmetrically substituted carbon atoms can be separated in optically active forms or racemic forms. Methods for preparing optically active forms from optically active starting materials are known in the art, such as by resolving racemic mixtures or by stereoselective synthesis methods. Many geometric isomers of olefins, C=N double bonds, etc. may also be present in the compounds described herein, and all such stable isomers are encompassed in the present disclosure. Cis and trans geometric isomers of the compounds of the present disclosure have been described and can be separated in the form of isomeric mixtures or in separated isomeric forms.

[0028] In some embodiments, one or more compounds described herein may exist in different tautomeric forms. It will be clear from the context that reference to such compounds encompasses all such tautomeric forms unless expressly excluded. In some embodiments, tautomeric forms result from the exchange of a single bond with an adjacent double bond and concomitant migration of a proton. In certain embodiments, tautomeric forms may be prototropic tautomers, which are isomeric protonation states having the same empirical formula and total charge as the reference form. Examples of moieties with proton transfer tautomeric forms are keto-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, amide-imidic acid pairs, enamine-imine pairs, and cyclic forms in which a proton can occupy two or more positions of a heterocyclic ring system, such as 1H-imidazole and 3H-imidazole, 1H-1,2,4-triazole, 2H-1,2,4-triazole and 4H-1,2,4-triazole, 1H-isoindole and 2H-isoindole, and 1H-pyrazole and 2H-pyrazole. In some embodiments, the tautomeric forms may be in equilibrium or sterically locked into one form by appropriate substitution. In certain embodiments, the tautomeric forms are derived from acetal interconversions.

[0029] Unless otherwise specified, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, e.g. 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 32 P. 33 P. 35 S. 18 F. 36 Cl, 123 I and 125 I. Isotope-labeled compounds (e.g. 3 H and 14 C) can be used in compound or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are useful because of their ease of preparation and detectability. In addition, heavier isotopes, such as deuterium (i.e., 2H) substitution may provide certain therapeutic benefits due to enhanced metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, one or more hydrogen atoms are replaced by 2 H or 3 H is replaced, or one or more carbon atoms are 13 C or 14 C-enriched carbon substitutes. Positron-emitting isotopes, such as 15 O. 13 N. 11 C and 18 F can be used in positron emission tomography (PET) studies to examine substrate receptor occupancy. The preparation of isotopically labeled compounds is known to those skilled in the art. For example, isotopically labeled compounds can generally be prepared by substituting an isotopically labeled reagent for a non-isotopically labeled reagent following procedures analogous to those disclosed for the compounds of the invention described herein.

[0030] Non-limiting examples of moieties that may contain one or more deuterium substitutions in the compounds of the present invention (wherein any position "R" may be deuterium (D)) include

[0031] Additional examples include, for example, the following parts

[0032] And similar to R 1 Deuterated part of the type, where R 1 The definition of is found herein (e.g., in compounds of Formula I, Ia, II-5, II-5a, II-6, II-6a, II-6b, and II-6c). Deuteration of moieties within substituent W in compounds of the invention is also contemplated, wherein W is defined herein (see, e.g., Formulas I and II and subformulae thereof and specific examples of W described herein, e.g. Furthermore, deuteration of available positions in any A moiety of the compounds of the formulae described herein is also contemplated, e.g.

[0033] In addition, deuterated substitution may also occur at the linker position of the compounds of the present invention, for example

[0034]

[0035] In another embodiment, silylation substitutions are also contemplated, for example in the following linkers:

[0036]

[0037] As is known in the art, many chemical entities can assume a variety of different solid forms, such as amorphous or crystalline forms (e.g., polymorphs, hydrates, solvates). In some embodiments, the compounds of the invention can be used in any such form, including any solid form. In some embodiments, the compounds described or depicted herein can be provided in hydrate form or in solvate form.

[0038] At various places in this specification, substituents of compounds of the present disclosure are disclosed in groups or in ranges. In particular, it is contemplated that the present disclosure includes every individual subcombination of the members of such groups and ranges. For example, the term "C 1 -C 6 "Alkyl" specifically intends to disclose individually methyl, ethyl, C 3 Alkyl, C 4 Alkyl, C 5 Alkyl and C 6 In addition, where a compound includes multiple positions, and substituents at said positions are disclosed in groups or in ranges, unless otherwise indicated, the disclosure is intended to encompass individual compounds and groups of compounds (e.g., species and subclasses) containing every individual subcombination of members at each position.

[0039] The term "optionally substituted X" (e.g., "optionally substituted alkyl") is intended to be equivalent to "X, wherein X is optionally substituted" (e.g., "alkyl, wherein the alkyl is optionally substituted"). It is not intended that the feature "X" (e.g., alkyl) itself is optional. As described herein, certain target compounds may contain one or more "optionally substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally", means that one or more hydrogens of the designated moiety are replaced with a suitable substituent, such as any of the substituents or groups described herein. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent at each position may be the same or different. For example, in the term "optionally substituted C 1 -C 6 Alkyl-C 2 -C 9 In the "heteroaryl" group, the alkyl portion, the heteroaryl portion, or both may be optionally substituted. Combinations of substituents envisioned by the present disclosure are preferably those that result in stable or chemically feasible compounds. The term "stable" as used herein refers to a compound that is not substantially altered when subjected to conditions that allow its production, detection, and in certain embodiments, recovery, purification, and use for one or more of the purposes disclosed herein.

[0040] Suitable monovalent substituents on the substitutable carbon atoms of the "optionally substituted" group may independently be deuterium; halogen; -(CH 2 ) 0-4 R o ;-(CH 2 ) 0-4 OR o ; -O(CH 2 ) 0-4 R o ;-O-(CH 2 ) 0-4 C(O)OR o ;-(CH 2 ) 0-4 CH(OR o ) 2 ;-(CH 2 ) 0- 4 SR o ;-(CH 2 ) 0-4 Ph, which can be o Substitution; -(CH 2 ) 0-4 O(CH 2 ) 0-1 Ph, which can be o Substitution; -CH=CHPh, which can be R o Substitution; -(CH 2 ) 0-4 O(CH 2 ) 0-1 -pyridyl, which may be R o Substituted; 4-8 membered saturated or unsaturated heterocycloalkyl (eg pyridyl); 3-8 membered saturated or unsaturated cycloalkyl (eg cyclopropyl, cyclobutyl or cyclopentyl); -NO 2 ;-CN;-N 3 ;-(CH 2 ) 0-4 N(R o ) 2 ;-(CH 2 ) 0-4 N(R o )C(O)R o ;-N(R o )C(S)R o ;-(CH 2 ) 0-4 N(R o )C(O)NR o 2 ;-N(R o )C(S)NR o 2 ;-(CH2 ) 0-4 N(R o )C(O)OR o ;-N(R o )N(R o )C(O)R o ;-N(R o )N(R o )C(O)NR o 2 ;-N(R o )N(R o )C(O)OR o ;-(CH 2 ) 0-4 C(O)R o ;-C(S)R o ;-(CH 2 ) 0-4 C(O)OR o ;-(CH 2 ) 0-4 -C(O)-N(R o ) 2 ;-(CH 2 ) 0-4 -C(O)-N(R o )-S(O) 2 -R v ;-C(NCN)NR o 2 ;-(CH 2 ) 0-4 C(O)SR o ;-(CH 2 ) 0-4 C(O)OSiR o 3 ;-(CH 2 ) 0-4 OC(O)R o ;-OC(O)(CH 2 ) 0-4 SR o ;-SC(S)SR o ;-(CH 2 ) 0-4 SC(O)R o ;-(CH 2 ) 0-4 C(O)NR o 2 ;-C(S)NR o 2 ;-C(S)SR o ;-(CH 2 ) 0-4 OC(O)NR o 2 ;-C(O)N(OR v )R o ;-C(O)C(O)R o ;-C(O)CH 2 C(O)R o ;-C(NOR o )R o ;-(CH 2 ) 0-4 SSR o ;-(CH 2 ) 0-4 S(O) 2 R o ;-(CH 2 ) 0-4 S(O) 2 OR o ;-(CH 2 ) 0-4 OS(O) 2 R o ;-S(O) 2 NR o 2 ;-(CH 2 ) 0-4 S(O)R o ;-N(R o )S(O) 2 NR o 2 ;-N(R o )S(O) 2 R o ;-N(OR o )R o ;-C(NOR o )NR o 2 ;-C(NH)NR o 2 ;-P(O) 2 R o ;-P(O)R o 2 ;-P(O)(OR o ) 2 ;-OP(O)R o 2 ;-OP(O)(OR o ) 2 ;-OP(O)(OR o )R o ;-SiR o 3 ;-(C1-4 Straight or branched alkylene)ON(R o ) 2 ; or -(C 1-4 Straight or branched alkylene)C(O)ON(R o ) 2 , where each R o may be substituted as defined below and are independently hydrogen, -C 1-6 Aliphatic group, -CH 2 Ph, -O(CH 2 ) 0-1 Ph, -CH 2 -(5-6 membered heteroaryl ring), or a 3-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definitions, two independently occurring R o Together with its intervening atoms it forms a 3-12 membered saturated, partially unsaturated or aromatic mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, which may be substituted as defined below.

[0041] R o (or two independent R o Suitable monovalent substituents on the ring formed with its intervening atoms may independently be halogen, -(CH 2 ) 0-2 R ● 、-(halogen R ● )、-(CH 2 ) 0-2 OH, -(CH 2 ) 0-2 OR ● 、-(CH 2 ) 0-2 CH(OR ● ) 2 、-O(halogen R ● ), -CN, -N 3 、-(CH 2 ) 0-2 C(O)R ● 、-(CH 2 ) 0-2 C(O)OH, -(CH 2 ) 0-2 C(O)OR ● 、-(CH 2 ) 0-2 SR ● 、-(CH 2 ) 0-2 SH, -(CH 2 ) 0-2 NH 2、-(CH 2 ) 0-2 NHR ● 、-(CH 2 ) 0-2 NR ● 2 、-NO 2 、-SiR ● 3 、-OSiR ● 3 、-C(O)SR ● 、-(C 1-4 Straight or branched alkylene)C(O)OR ● or -SSR ● , where each R ● unsubstituted or, in the case of "halo" being preceded by "halo", substituted only by one or more halogens, and independently selected from C 1-4 Aliphatic group, -CH 2 Ph, -O(CH 2 ) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. o Suitable divalent substituents on a saturated carbon atom of include =0 and =S.

[0042] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0, =S, =NNR * 2 、=NNHC(O)R * 、=NNHC(O)OR * 、=NNHS(O) 2 R * , =NR * , =NOR * 、-O(C(R * 2 )) 2-3 O-or-S(C(R * 2 )) 2-3 S-, where R * is selected at each independent occurrence from hydrogen; C 1-6 an aliphatic group which may be substituted as defined below; or an unsubstituted 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Suitable divalent substituents attached to an adjacent substitutable carbon of an "optionally substituted" group include: -O(CR * 2 ) 2- 3 O-, where R* is selected at each independent occurrence from hydrogen; C 1-6 an aliphatic group which may be substituted as defined below; or an unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0043] R * Suitable substituents on the aliphatic group include halogen, -R ● 、-(halogen R ● ), -OH, -OR ● 、-O(halogen R ● )、-CN、-C(O)OH、-C(O)OR ● 、-NH 2 、-NHR ● 、-NR ● 2 or-NO 2 , where each R ● unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and independently C 1-4 Aliphatic group, -CH 2 Ph, -O(CH 2 ) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0044] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include or Each of these are independently hydrogen; C 1-6 an aliphatic group which may be substituted as defined below; unsubstituted -OPh; or an unsubstituted 3-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definition, two independently present Together with its intervening atoms, it forms a 3-12 membered saturated, partially unsaturated or aromatic monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0045] Suitable substituents on the aliphatic group are independently halogen, -R ● 、-(halogen R ● ), -OH, -OR ● 、-O(halogen R ● )、-CN、-C(O)OH、-C(O)OR ● 、-NH 2、-NHR ● 、-NR ● 2 or-NO 2 , where each R ● unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and independently C 1-4 Aliphatic group, -CH 2 Ph, -O(CH 2 ) 0-1 Ph or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Suitable divalent substituents on a saturated carbon atom of include =0 and =S.

[0046] As used herein, the term "acetyl" refers to the group -C(O)CH 3 .

[0047] As used herein, the term "alkoxy" refers to -OC 1 -C 20 Alkyl groups, wherein the alkoxy group is attached to the remainder of the compound via an oxygen atom.

[0048] As used herein, the term "alkyl" refers to a saturated, straight-chain or branched monovalent hydrocarbon radical containing 1 to 20 (e.g., 1 to 10 or 1 to 6) carbons. In some embodiments, the alkyl group is unbranched (i.e., straight-chain); in some embodiments, the alkyl group is branched. Alkyl groups are, for example, but not limited to, methyl, ethyl, n-propyl and isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl, and neopentyl.

[0049] The term "alkylene" as used herein means a saturated divalent hydrocarbon group obtained from a straight or branched saturated hydrocarbon by removing two hydrogen atoms, and examples thereof are methylene, ethylene, isopropylene, and the like. x -C y "Alkylene" means an alkylene group having between x and y carbons. Exemplary x values ​​are 1, 2, 3, 4, 5, and 6, and exemplary y values ​​are 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 (e.g., C 1 -C 6 , C 1 -C 10 , C 2 -C 20 , C 2 -C 6 , C 2 -C 10 or C 2 -C 20In some embodiments, the alkylene group may be further substituted with 1, 2, 3, or 4 substituents as defined herein.

[0050] Unless otherwise specifically stated, the term "alkenyl" as used herein means a monovalent straight or branched chain group with 2 to 20 carbons (e.g., 2 to 6 or 2 to 10 carbons) containing one or more carbon-carbon double bonds and examples thereof are vinyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl and 2-butenyl. Alkenyl includes cis and trans isomers. Unless otherwise specifically stated, the term "alkenylene" as used herein means a divalent straight or branched chain group with 2 to 20 carbons (e.g., 2 to 6 or 2 to 10 carbons) containing one or more carbon-carbon double bonds.

[0051] The term "alkynyl" as used herein refers to a monovalent straight or branched chain group having 2 to 20 carbons (eg, 2 to 4, 2 to 6, or 2 to 10 carbons) containing a carbon-carbon triple bond and examples thereof are ethynyl and 1-propynyl.

[0052] As used herein, the term "alkynyl sulfone" refers to a wherein R is any chemically feasible substituent described herein.

[0053] As used herein, the term "amino" refers to For example -NH 2 and -N(CH 3 ) 2 .

[0054] The term "aminoalkyl" as used herein refers to an alkyl moiety in which one or more carbon atoms are substituted with one or more amino moieties.

[0055] As used herein, the term "amino acid" refers to a amino acid having a side chain, an amino group and an acid group (e.g., -CO 2 H or -SO 3 H) wherein the amino acid is attached to the parent molecular group via the side chain, amino group or acid group (e.g., side chain). As used herein, the term "amino acid" refers in the broadest sense to any compound or substance that can be incorporated into a polypeptide chain, e.g., via the formation of one or more peptide bonds. In some embodiments, an amino acid has a general structure H 2NC(H)(R)-COOH. In some embodiments, the amino acid is a naturally occurring amino acid. In some embodiments, the amino acid is a synthetic amino acid; in some embodiments, the amino acid is a D-amino acid; in some embodiments, the amino acid is an L-amino acid. "Standard amino acid" refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. Exemplary amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, optionally substituted hydroxynorvaline, isoleucine, leucine, lysine, methionine, norvaline, ornithine, phenylalanine, proline, pyrrolysine, selenocysteine, serine, taurine, threonine, tryptophan, tyrosine, and valine.

[0056] As used herein, the term "aryl" refers to a monovalent monocyclic, bicyclic or polycyclic system formed by carbon atoms, wherein the ring connected to the side-joining group is an aromatic ring. Examples of aryl are phenyl, naphthyl, phenanthrenyl and anthracenyl. The aromatic ring can be connected to its side-joining group at any heteroatom or carbocyclic atom producing a stable structure and unless otherwise specifically stated, any ring atom can be optionally substituted.

[0057] As used herein, the term "C 0 " represents a bond. For example, the term -N(C(O)-(C 0 -C 5 The alkylene-H)- moiety includes -N(C(O)-(C 0 Alkylene-H)-, which is also represented by -N(C(O)-H)-.

[0058] As used herein, the terms "carbocycle" and "carbocyclyl" refer to a monovalent, optionally substituted C 3 -C 12 Monocyclic, bicyclic or tricyclic structure, it can be a bridged ring, a fused ring or a spirocycle, wherein all rings are formed by carbon atoms and at least one ring is a non-aromatic ring.Carbocyclic structure includes cycloalkyl, cycloalkenyl and cycloalkynyl.Examples of carbocyclic radicals are cyclohexyl, cyclohexenyl, cyclooctynyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, indenyl, dihydroindenyl, decahydronaphthyl etc.Carbocyclic ring can be connected to its side-joined group at any ring atom producing a stable structure and unless otherwise specifically stated, any ring atom can be optionally substituted.

[0059] The term "carbonyl" as used herein refers to a C(O) group, which may also be represented as C=O.

[0060] The term "carboxyl" as used herein refers to -CO 2 H, (C=O)(OH), COOH or C(O)OH, or the unprotonated counterpart.

[0061] The term "cyano" as used herein refers to a -CN group.

[0062] The term "cycloalkyl" as used herein means a monovalent saturated cyclic hydrocarbon group which, unless otherwise specifically stated, may be a bridged ring, a fused ring or a spiro ring having three to eight ring carbons, and examples thereof are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cycloheptyl.

[0063] The term "cycloalkenyl" as used herein refers to a monovalent, non-aromatic, saturated cyclic hydrocarbon group which, unless otherwise specifically stated, may be a bridged, fused or spiro ring having three to eight ring carbons and containing one or more carbon-carbon double bonds.

[0064] The term "diastereoisomers" as used herein refers to stereoisomers that are not mirror images of each other and are not superimposable on each other.

[0065] The term "enantiomer" as used herein means each individual optically active form of a compound of the invention having an optical purity or enantiomeric excess (as determined by standard methods in the art) of at least 80% (i.e., at least 90% of one enantiomer and up to 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.

[0066] The term "guanidino" refers to a group having the following structure: wherein each R is independently any chemically feasible substituent described herein.

[0067] The term "guanidinoalkylalkyl" as used herein refers to an alkyl moiety in which one or more carbon atoms are substituted with one or more guanidino moieties.

[0068] The term "haloacetyl" as used herein refers to an acetyl group in which at least one hydrogen is replaced by a halogen.

[0069] The term "haloalkyl" as used herein denotes an alkyl moiety in which one or more carbon atoms are substituted with one or more same or different halogen moieties.

[0070] The term "halogen" as used herein denotes a halogen selected from bromine, chlorine, iodine or fluorine.

[0071] As used herein, the term "heteroalkyl" refers to an "alkyl" as defined herein in which at least one carbon atom is replaced by a heteroatom (eg, O, N or S atom). The heteroatom may be present in the middle or at the terminal of the group.

[0072] As used herein, the term "heteroaryl" refers to a monovalent, monocyclic or polycyclic structure containing at least one fully aromatic ring: that is, they contain 4n+2 π electrons in the monocyclic or polycyclic system and at least one ring heteroatom selected from N, O or S in the aromatic ring. Exemplary unsubstituted heteroaryl groups have 1 to 12 (e.g., 1 to 11, 1 to 10, 1 to 9, 2 to 12, 2 to 11, 2 to 10, or 2 to 9) carbons. The term "heteroaryl" includes bicyclic, tricyclic and tetracyclic groups fused to any of the above heteroaromatic rings with one or more aromatic or carbocyclic rings (e.g., phenyl rings or cyclohexane rings). Examples of heteroaryl groups include, but are not limited to, pyridyl, pyrazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, imidazolyl, thiazolyl, quinolyl, tetrahydroquinolyl and 4-azaindolyl. The heteroaryl ring may be attached to its pendant group at any ring atom that results in a stable structure and unless otherwise specifically stated, any ring atom may be optionally substituted. In some embodiments, the heteroaryl group is substituted with 1, 2, 3, or 4 substituents.

[0073] As used herein, the term "heterocycloalkyl" refers to a monovalent, monocyclic, bicyclic or polycyclic system in which at least one ring is a non-aromatic ring and in which the non-aromatic ring contains one, two, three or four heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, which may be a bridged ring, a fused ring or a spirocyclic ring. The 5-membered ring has zero to two double bonds, and the 6-membered ring and the 7-membered ring have zero to three double bonds. Exemplary unsubstituted heterocycloalkyls have 1 to 12 (e.g., 1 to 11, 1 to 10, 1 to 9, 2 to 12, 2 to 11, 2 to 10 or 2 to 9) carbons. The term "heterocycloalkyl" also refers to a heterocyclic compound with a bridged polycyclic structure, in which one or more carbon or heteroatom bridges non-adjacent members of a monocyclic ring, such as a quinuclidine radical. The term "heterocycloalkyl" includes bicyclic, tricyclic and tetracyclic groups in which any of the above heterocycles is fused to one or more aromatic rings, carbocyclic rings, heteroaromatic rings or heterocyclic rings, such as aryl rings, cyclohexane rings, cyclohexene rings, cyclopentane rings, cyclopentene rings, pyridine rings or pyrrolidine rings. Examples of heterocycloalkyl are pyrrolidinyl, piperidinyl, 1,2,3,4-tetrahydroquinolinyl, decahydroquinolinyl, dihydropyrrolopyridine and decahydronaphthyridinyl. The heterocycloalkyl ring can be connected to its side-joining group at any ring atom that produces a stable structure and unless otherwise specifically stated, any ring atom can be optionally substituted.

[0074] The term "hydroxy" as used herein refers to an -OH group.

[0075] The term "hydroxyalkyl" as used herein refers to an alkyl moiety in which one or more carbon atoms are substituted with one or more -OH moieties.

[0076] The term "isomer" as used herein means any tautomer, stereoisomer, atropisomer, enantiomer or diastereomer of any compound of the present invention. It should be recognized that the compounds of the present invention may have one or more chiral centers or double bonds and, therefore, exist in stereoisomeric form, for example, in double bond isomers (i.e., E / Z geometric isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis / trans isomers). According to the present invention, the chemical structures depicted herein and therefore the compounds of the present invention encompass all corresponding stereoisomers, i.e., stereoisomerically pure (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) form as well as enantiomers and stereoisomer mixtures, such as racemates. Enantiomeric and stereoisomeric mixtures of the compounds of the invention can be typically separated into their component enantiomers or stereoisomers by well-known methods, such as chiral gas chromatography, chiral high performance liquid chromatography, crystallization of the compound in the form of a chiral salt complex, or crystallization of the compound in a chiral solvent. Enantiomers and stereoisomers can also be obtained from stereoisomerically pure or enantiomerically pure intermediates, reagents and catalysts by well-known asymmetric synthesis methods.

[0077] As used herein, the term "linker" refers to a divalent organic moiety that connects a first portion (e.g., a macrocyclic moiety) to a second portion (e.g., a cross-linking group). In some embodiments, the linker produces a compound that achieves an IC50 of 2uM or less in the Ras-RAF disruption assay protocol provided in the following examples and provided herein:

[0078] The purpose of this biochemical assay is to measure the ability of a test compound to promote the formation of a ternary complex between nucleotide-loaded Ras isoforms and cyclophilin A; the resulting ternary complex disrupts binding to BRAF RBD Binding of the construct inhibits Ras signaling through the RAF effectors.

[0079] The culture medium contained 25 mM HEPES pH 7.3, 0.002% Tween 20, 0.1% BSA, 100 mM NaCl and 5 mM MgCl 2 Unlabeled cyclophilin A, His6-K-Ras-GMPPNP (or other Ras variants) and GST-BRAF were added to the assay buffer. RBDCombined in a 384-well assay plate at a final concentration of 25 μM, 12.5 nM and 50 nM, respectively. The compounds present in the plate wells are diluents that start from a final concentration of 30 μM and undergo 10-point 3-fold serial dilutions. After incubation for 3 hours at 25 ° C, a mixture of anti-His Eu-W1024 and anti-GST allophycocyanin is then added to the assay sample wells to a final concentration of 10 nM and 50 nM, respectively, and the reaction is incubated for another 1.5 hours. The TR-FRET signal is read on a microplate reader (Ex 320 nm, Em665 / 615 nm). Compounds that promote the destruction of the Ras:RAF complex are identified as compounds that cause a decrease in the TR-FRET ratio relative to the DMSO control wells.

[0080] This assay can also be used to assess selectivity.In some embodiments, the compounds of the invention are selective for one or more specific Ras mutants (e.g., K-Ras G13C) over other Ras mutants (e.g., K-Ras G12C) or wild type compared to those known in the art.

[0081] In some embodiments, the joint comprises 20 or less linear atoms. In some embodiments, the joint comprises 15 or less linear atoms. In some embodiments, the joint comprises 10 or less linear atoms. In some embodiments, the molecular weight of the joint is less than 500g / mol. In some embodiments, the molecular weight of the joint is less than 400g / mol. In some embodiments, the molecular weight of the joint is less than 300g / mol. In some embodiments, the molecular weight of the joint is less than 200g / mol. In some embodiments, the molecular weight of the joint is less than 100g / mol. In some embodiments, the molecular weight of the joint is less than 50g / mol.

[0082] As used herein, a "monovalent organic moiety" is less than 500 kDa. In some embodiments, a "monovalent organic moiety" is less than 400 kDa. In some embodiments, a "monovalent organic moiety" is less than 300 kDa. In some embodiments, a "monovalent organic moiety" is less than 200 kDa. In some embodiments, a "monovalent organic moiety" is less than 100 kDa. In some embodiments, a "monovalent organic moiety" is less than 50 kDa. In some embodiments, a "monovalent organic moiety" is less than 25 kDa. In some embodiments, a "monovalent organic moiety" is less than 20 kDa. In some embodiments, a "monovalent organic moiety" is less than 15 kDa. In some embodiments, a "monovalent organic moiety" is less than 10 kDa. In some embodiments, a "monovalent organic moiety" is less than 1 kDa. In some embodiments, a "monovalent organic moiety" is less than 500 g / mol. In some embodiments, a "monovalent organic moiety" is in the range between 500 g / mol and 500 kDa.

[0083] As used herein, the term "stereoisomer" refers to all possible different isomeric and conformational forms of a compound (e.g., a compound of any formula described herein), in particular all possible stereochemical and conformational isomeric forms of the basic molecular structure, all diastereomers, enantiomers or conformational isomers, including atropisomers. Some compounds of the present invention may exist in different tautomeric forms, all of which are included within the scope of the present invention.

[0084] The term "sulfonyl" as used herein refers to -S(O) 2 -group.

[0085] The term "thiocarbonyl" as used herein refers to a -C(S)- group.

[0086] The term "vinyl ketone" as used herein refers to a group comprising a carbonyl group directly attached to a carbon-carbon double bond.

[0087] The term "vinyl sulfone" as used herein refers to a group comprising a sulfonyl group directly attached to a carbon-carbon double bond.

[0088] As used herein, the term "alkynone" refers to a wherein R is any chemically feasible substituent described herein.

[0089] Those of ordinary skill in the art reading this disclosure will understand that certain compounds described herein may be provided or utilized in any of a variety of forms, such as salt forms, protected forms, prodrug forms, ester forms, isomeric forms (e.g., optical or structural isomers), isotopic forms, and the like. In some embodiments, reference to a particular compound may refer to a particular form of the compound. In some embodiments, reference to a particular compound may refer to the compound in any form. In some embodiments, for example, a preparation of a single stereoisomer of a compound may be considered a different form of the compound rather than a racemic mixture of the compound; a particular salt of a compound may be considered a different form from another salt of the compound; a preparation containing one conformational isomer of a double bond ((Z) or (E)) may be considered a different form from a preparation containing another conformational isomer of the double bond ((E) or (Z)); a preparation having one or more isotopes of atoms different from the isotopes present in a reference preparation may be considered to be in a different form. BRIEF DESCRIPTION OF THE DRAWINGS

[0090] Figure 1A The compound A of the present invention showed the effect of KRAS G13C Selective covalent modification.

[0091] Figure 1B The compound B of the present invention showed the effect of KRAS G13C Compound X is a KRAS from WO 2021 / 091982 G12C Inhibitor A647.

[0092] Figure 2 Compound A (compound of the present invention) was used to demonstrate the effect of compound A on KRAS G13C (NSCLC CDX KRAS G13C / WT Single-dose PK / PD in vivo inhibition of the PD model).

[0093] Figure 3 The use of Compound A (a compound of the present invention) in NSCLC CDX KRAS G13C / WT Tumor regression in the model.

[0094] Figure 4 The results showed that compound A (a compound of the present invention) can be used to detect KRAS in NSCLC PDX. G13C / WT Tumor regression in the model. DETAILED DESCRIPTION

[0095] Compound

[0096] Ras inhibitors are provided herein. The methods described herein require the formation of a high-affinity three-component complex between a synthetic ligand and two intracellular proteins that do not interact under normal physiological conditions: a target protein of interest (e.g., Ras), and a cytoplasmic chaperone (presenting protein) (e.g., cyclophilin A) widely expressed in cells. More specifically, in some embodiments, the Ras inhibitors described herein induce new binding pockets in Ras by driving the formation of a high-affinity triple complex between Ras protein and the widely expressed cytoplasmic chaperone cyclophilin A (CYPA). Without being bound by theory, the inventors believe that one way in which the compounds of the present invention and the complexes or conjugates formed therefrom exert an inhibitory effect on Ras is to spatially block the interaction sites between Ras and downstream effector molecules such as RAF required to propagate oncogenic signals.

[0097] Without being bound by theory, the inventors assume that the covalent and non-covalent interactions of the compounds of the present invention with Ras and chaperone proteins (e.g., cyclophilin A) can contribute to the inhibition of Ras activity. In some embodiments, the compounds of the present invention form covalent adducts with the side chains of Ras proteins (e.g., the sulfhydryl side chains of cysteine ​​at positions 12 or 13 of mutant Ras proteins). Covalent adducts can also be formed with other side chains of Ras. Additionally or alternatively, non-covalent interactions can work: for example, van der Waals interactions, hydrophobic interactions, hydrophilic interactions, and hydrogen bonding interactions and combinations thereof can contribute to the ability of the compounds of the present invention to form complexes and act as Ras inhibitors. Therefore, the compounds of the present invention can inhibit a variety of Ras proteins (e.g., K-Ras, N-Ras, H-Ras, and mutants thereof mutated at positions 12, 13, and 61, such as G12C, G12D, G12V, G12S, G13C, G13D, and Q61L, as well as other mutants described herein).

[0098] Methods of determining covalent adduct formation are known in the art. One method of determining covalent adduct formation is to perform a "cross-linking" assay, such as that performed under these conditions.

[0099] Note: The following protocol describes a procedure for monitoring the cross-linking of K-Ras G12C (GMP-PNP) with compounds of the invention. This protocol can also be implemented substituting other Ras proteins or nucleotides such as G13C.

[0100] The purpose of this biochemical assay is to measure the ability of test compounds to covalently label nucleotide-loaded K-Ras isoforms. 2A 5 μM stock solution of K-Ras(1-169)G12C loaded with GMP-PNP was diluted 10-fold to achieve a final concentration of 0.5 μM in an assay buffer containing 1 mM BME, 5 μM cyclophilin A, and 2 μM test compound; wherein the final sample volume was 100 μL.

[0101] The samples were incubated at 25°C for a period of up to 24 hours, after which they were quenched by adding 10 μL of 5% formic acid. The quenched samples were centrifuged at 15000 rpm for 15 minutes in a benchtop centrifuge, after which 10 μL aliquots were injected onto a reverse phase C4 column and eluted into a mass spectrometer with an increasing acetonitrile gradient in the mobile phase. Analysis of the raw data can be performed using Waters MassLynx MS software, where the binding % is calculated from the deconvoluted protein peaks of labeled and unlabeled K-Ras.

[0102] Therefore, the present invention provides a compound having a structure of Formula I or a pharmaceutically acceptable salt thereof:

[0103]

[0104] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0105] L 1 Not present or a joint;

[0106] W is a crosslinking group comprising vinyl ketone, vinyl sulfone, alkynyl ketone or alkynyl sulfone;

[0107] R 1 is hydrogen, optionally substituted 3 to 10 membered heterocycloalkyl or optionally substituted C 1 -C 6 heteroalkyl;

[0108] R 2 is optionally substituted C 1 -C 6 Alkyl; and

[0109] R 3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 Heteroalkyl.

[0110] In some embodiments, W is a crosslinking group comprising a vinyl ketone, a vinyl sulfone, or an alkynyl ketone.

[0111] In some embodiments, provided herein is a compound having a structure of Formula Ia or a pharmaceutically acceptable salt thereof:

[0112]

[0113] In some embodiments of the compounds of the invention, A is optionally substituted thiazole-diyl, optionally substituted oxazole-diyl, optionally substituted morpholine-diyl, optionally substituted pyrrolidine-diyl, optionally substituted pyridine-diyl, optionally substituted azetidine-diyl, optionally substituted pyrazine-diyl, optionally substituted pyrimidine-diyl, optionally substituted piperidine-diyl, optionally substituted oxadiazole-diyl, optionally substituted thiadiazole-diyl, optionally substituted triazole-diyl, optionally substituted thiomorpholine-diyl, or optionally substituted phenylene.

[0114] In some embodiments, the present disclosure provides a compound of structural formula II-1 or a pharmaceutically acceptable salt thereof:

[0115]

[0116] In some embodiments, a compound having a structure of Formula II-2 or a pharmaceutically acceptable salt thereof is provided:

[0117]

[0118] Where R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0119] R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0120] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0121] In some embodiments, the compounds of the present invention have the structure of Formula II-3, or a pharmaceutically acceptable salt thereof:

[0122]

[0123] In some embodiments, the compounds of the present invention have the structure of Formula II-4, or a pharmaceutically acceptable salt thereof:

[0124]

[0125]

[0126] In some embodiments, the compounds of the present invention have the structure of Formula II-4b, or a pharmaceutically acceptable salt thereof:

[0127]

[0128] In some embodiments of the compounds of the present invention, R 2 yes:

[0129] In some embodiments of the compounds of the present invention, R 3 is optionally substituted C 1 -C 6 In some embodiments, R 3 yes:

[0130] In some embodiments of the compounds of the present invention, R 3 is optionally substituted C 1 -C 3 In some embodiments, R 3 yes:

[0131] In some embodiments of the compounds of the invention, A is an optionally substituted 5- to 10-membered heteroarylene. In some embodiments, A is:

[0132] In some embodiments of the compounds of the invention, A is an optionally substituted phenylene. In some embodiments, A is:

[0133] In some embodiments of the compounds of the present invention, A is an optionally substituted 3-6 membered heterocycloalkylene. In some embodiments, A is selected from the following or a stereoisomer thereof:

[0134]

[0135] In some embodiments, A is selected from the following or stereoisomers thereof:

[0136] In some embodiments of the compounds of the invention, the linker is a structure of Formula III:

[0137] A 1 -(B 1 ) f -(C 1 ) g -(B 2 ) h -(D 1 )-(B 3 ) i -(C 2 ) j -(B 4 ) k –A 2

[0138]

[0139] Among them A 1 Is the connector and CH(R 3 ) between the keys; A 2 is the bond between W and the joint; B 1 , B 2 , B 3 and B 4 are each independently selected from optionally substituted C 1 -C 2 Alkylene, optionally substituted C 1 -C 3 Heteroalkylene, O, S and NR N ; Each R N are independently hydrogen, optionally substituted C 1 -C 4 Alkyl, optionally substituted C 2 -C 4 Alkenyl, optionally substituted C 2 -C 4 alkynyl, optionally substituted 3 to 14 membered heterocycloalkyl, optionally substituted 6 to 10 membered aryl, or optionally substituted C 1 -C 7 Heteroalkyl; C 1 and C 2 are each independently selected from carbonyl, thiocarbonyl, sulfonyl or phosphoryl; f, g, h, i, j and k are each independently 0 or 1; and D 1 is optionally substituted C 1 -C 10 Alkylene, optionally substituted C 2 -C 10Alkenylene, optionally substituted C 2 -C 10 alkylene, optionally substituted 3 to 14 membered heterocycloalkylene, optionally substituted 5 to 10 membered heteroarylene, optionally substituted 3 to 8 membered cycloalkylene, optionally substituted 6 to 10 membered arylene, optionally substituted C 2 -C 10 Polyethylene glycol or optionally substituted C 1 -C 10 Heteroalkylene, or connected to A 1 -(B 1 ) f -(C 1 ) g -(B 2 ) h -with-(B 3 ) i -(C 2 ) j -(B 4 ) k –A 2 chemical bonds.

[0140] In some embodiments of the compounds of the invention, the linker is or comprises a cyclic moiety. In some embodiments, the linker has a structure of formula IIIa:

[0141]

[0142] Where o is 0 or 1;

[0143] R 7 is hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted 3- to 8-membered cycloalkylene, or optionally substituted 3- to 8-membered heterocycloalkylene;

[0144] X 1 Absent, optionally substituted C 1 -C 4 Alkylene, O, NCH 3 or optionally substituted C 1 -C 4 heteroalkylene;

[0145] Cy is optionally substituted 3 to 8 membered cycloalkylene, optionally substituted 3 to 12 membered heterocycloalkylene, optionally substituted 6-10 membered arylene, or optionally substituted 5 to 10 membered heteroarylene; and

[0146] L 2 Does not exist, is -SO 2 -, -NH-, optionally substituted C1 -C 4 Alkylene, optionally substituted C 1 -C 4 heteroalkylene or an optionally substituted 3- to 6-membered heterocycloalkylene.

[0147] In some embodiments, the linker is selected from the following or stereoisomers thereof:

[0148]

[0149]

[0150]

[0151] In some embodiments, the linker is selected from the following or stereoisomers thereof:

[0152]

[0153]

[0154] In some embodiments, the compounds of the present invention have the structure of Formula II-5, or a pharmaceutically acceptable salt thereof:

[0155]

[0156] Among them, Cy 1 is optionally substituted spirocyclic 8 to 11 membered heterocycloalkylene or optionally substituted bicyclic 7 to 9 membered heterocycloalkylene; and

[0157] wherein W comprises vinyl ketone or vinyl sulfone.

[0158] In some embodiments, Cy 1 is an optionally substituted spirocyclic 10- to 11-membered heterocycloalkylene.

[0159] In some embodiments, the compounds of the present invention have the structure of Formula II-5a:

[0160]

[0161] Where X 2 is O, C(R 11 ) 2 NR 12 , S or SO 2 .

[0162] r is 1 or 2;

[0163] Each t is independently 0, 1, or 2;

[0164] R11 and R 12 are each independently hydrogen, optionally substituted C 1 -C 4 Alkyl, optionally substituted C 2 -C 4 heteroalkyl or optionally substituted 3 to 5 membered cycloalkyl; and

[0165] Each R 13 Independently -CH 3 .

[0166] In some embodiments, the compounds of the present invention have the structure of Formula II-5b:

[0167]

[0168] Where X 2 is O, C(R 11 ) 2 NR 12 , S or SO 2 .

[0169] r is 1 or 2;

[0170] s and t are each independently 0, 1 or 2;

[0171] R 11 and R 12 are each independently hydrogen, optionally substituted C 1 -C 4 Alkyl, optionally substituted C 2 -C 4 heteroalkyl, optionally substituted 3 to 6 membered heterocycloalkyl, or optionally substituted 3 to 5 membered cycloalkyl; and

[0172] Each R 13 Independently -CH 3 , F, or two R attached to the same atom 13 Together with the atoms to which it is attached, it forms an optionally substituted C 3 -C 6 Cycloalkyl, or two R attached to the same atom 13 Together with the atoms to which it is attached it forms an optionally substituted 3- to 6-membered heterocycloalkyl.

[0173] In some embodiments, R 13 Yes-CH 3 .

[0174] In some embodiments, the sum of s and t is 1. In some embodiments, the sum of s and t is 2. In some embodiments, s is 0 and t is 1. In some embodiments, the sum of s and t is 0.

[0175] In some embodiments, the compounds of the present invention have the structure of Formula II-5c:

[0176]

[0177] In some embodiments, the compounds of the present invention have the structure of Formula II-5d:

[0178]

[0179] In some embodiments, the compounds of the present invention have the structure of Formula II-5e:

[0180]

[0181] In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, X 2 is O. In some embodiments, X 2 is S. In some embodiments, X 2 Yes SO 2 .

[0182] In some embodiments, X 2 YesNR 12 In some embodiments, R 12 Selected from the following or their stereoisomers:

[0183] -CH 3 , In some embodiments, R 12 Selected from the following or their stereoisomers:

[0184] In some embodiments, X 2 is C(R 11 ) 2 In some embodiments, each R 11 It's hydrogen.

[0185] In some embodiments of the compounds of the present invention, W is a crosslinking group comprising a vinyl ketone. In some embodiments, W has a structure of Formula IVa:

[0186]

[0187] Where R 8a , R 8b and R8c are independently hydrogen, -CN, halogen, or optionally one or more independently selected from -OH, -OC 1 -C 3 Alkyl substituents substituted -C 1 -C 3 Alkyl, -NH 2 , -NH(C 1 -C 3 Alkyl), -N(C 1 -C 3 alkyl) 2 , or a 4 to 7 membered saturated heterocycloalkyl. In some embodiments, W is selected from the following or a stereoisomer thereof:

[0188] In some embodiments, W is selected from the following or stereoisomers thereof:

[0189]

[0190] In some embodiments of the compounds of the present invention, W is a crosslinking group comprising a vinyl sulfone. In some embodiments, W has a structure of Formula IVc:

[0191]

[0192] Where R 10a , R 10b and R 10c are independently hydrogen, -CN, or are optionally substituted by one or more independently selected from -OH, -OC 1 -C 3 Alkyl substituents substituted -C 1 -C 3 Alkyl, -NH 2 , -NH(C 1 -C 3 Alkyl), -N(C 1 -C 3 alkyl) 2 , or a 4 to 7 membered saturated heterocycloalkyl. In some embodiments, W is:

[0193]

[0194] In some embodiments of the compounds of the invention, W is a crosslinking group comprising an alkynone. In some embodiments, W has a structure of Formula IVb:

[0195]

[0196] Where R 9is hydrogen, optionally substituted by one or more independently selected from -OH, -OC 1 -C 3 Alkyl substituents substituted -C 1 -C 3 Alkyl, -NH 2 , -NH(C 1 -C 3 Alkyl), -N(C 1 -C 3 alkyl) 2 , or a 4- to 7-membered saturated cycloalkyl, or a 4- to 7-membered saturated heterocycloalkyl. In some embodiments, W is selected from:

[0197]

[0198] In some embodiments, the compounds of the present invention have the structure of Formula II-6:

[0199]

[0200] Where Q 1 Yes CH 2 NR N or O;

[0201] Q 2 CO、NR N or O; and

[0202] Z is optionally substituted 3- to 6-membered heterocycloalkylene or optionally substituted 5- to 10-membered heteroarylene; or

[0203] Where Q 1 -Q 2 -Z is optionally substituted 9- to 10-membered spirocyclic heterocycloalkylene.

[0204] In some embodiments, the compounds of the present invention have the structure of Formula II-6a:

[0205]

[0206] Where R 14 is fluorine, hydrogen or C 1 -C 3 Alkyl; and

[0207] u is either 0 or 1.

[0208] In some embodiments, R 14 is fluorine and u is 1. In some embodiments, R 14 is hydrogen and u is 0.

[0209] In some embodiments, the compounds of the present invention have the structure of Formula II-6b:

[0210]

[0211] In some embodiments, the compounds of the present invention have the structure of Formula II-6c:

[0212]

[0213] In some embodiments, the compound of the present invention is selected from Table 1 or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound of the present invention is selected from Table 1 or a pharmaceutically acceptable salt or atropisomer thereof. In some embodiments, the compound is a compound selected from A1 to A209 of Table 1. In some embodiments, the compound is a compound selected from A210 to A368 of Table 1.

[0214] Table 1: Certain compounds of the present invention

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225]

[0226]

[0227]

[0228]

[0229]

[0230]

[0231]

[0232]

[0233]

[0234]

[0235]

[0236]

[0237]

[0238]

[0239]

[0240]

[0241]

[0242]

[0243]

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250]

[0251]

[0252]

[0253]

[0254]

[0255]

[0256]

[0257]

[0258]

[0259]

[0260]

[0261]

[0262]

[0263]

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270]

[0271]

[0272]

[0273]

[0274]

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283]

[0284]

[0285]

[0286]

[0287] In some embodiments, the compound of the present invention is a compound selected from Table 2, or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound of the present invention is a compound selected from Table 2, or a pharmaceutically acceptable salt or atropisomer thereof.

[0288] In some embodiments, the compound of the present invention is not a compound selected from Table 2. In some embodiments, the compound of the present invention is not a compound selected from Table 2, or a pharmaceutically acceptable salt or stereoisomer thereof. In some embodiments, the compound of the present invention is not a compound selected from Table 2, or a pharmaceutically acceptable salt or atropisomer thereof.

[0289] Table 2: Some compounds

[0290]

[0291]

[0292]

[0293]

[0294]

[0295]

[0296]

[0297]

[0298]

[0299]

[0300]

[0301]

[0302]

[0303]

[0304]

[0305]

[0306]

[0307]

[0308]

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320]

[0321]

[0322]

[0323]

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330]

[0331]

[0332]

[0333]

[0334]

[0335]

[0336]

[0337]

[0338]

[0339]

[0340]

[0341]

[0342]

[0343]

[0344]

[0345]

[0346]

[0347]

[0348]

[0349]

[0350]

[0351]

[0352]

[0353]

[0354]

[0355]

[0356]

[0357]

[0358]

[0359]

[0360]

[0361]

[0362]

[0363]

[0364]

[0365]

[0366]

[0367]

[0368]

[0369]

[0370]

[0371]

[0372]

[0373]

[0374]

[0375]

[0376]

[0377]

[0378]

[0379]

[0380]

[0381]

[0382]

[0383]

[0384]

[0385]

[0386]

[0387]

[0388]

[0389]

[0390]

[0391]

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400]

[0401]

[0402]

[0403]

[0404]

[0405]

[0406]

[0407]

[0408]

[0409]

[0410]

[0411]

[0412]

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422]

[0423]

[0424]

[0425]

[0426]

[0427]

[0428]

[0429]

[0430]

[0431]

[0432]

[0433]

[0434]

[0435]

[0436]

[0437]

[0438]

[0439]

[0440]

[0441]

[0442]

[0443]

[0444]

[0445]

[0446]

[0447]

[0448]

[0449]

[0450]

[0451]

[0452]

[0453]

[0454]

[0455]

[0456]

[0457]

[0458]

[0459]

[0460]

[0461]

[0462]

[0463]

[0464]

[0465]

[0466]

[0467]

[0468]

[0469]

[0470]

[0471]

[0472]

[0473]

[0474]

[0475]

[0476]

[0477]

[0478]

[0479]

[0480]

[0481]

[0482]

[0483]

[0484]

[0485]

[0486]

[0487]

[0488]

[0489]

[0490]

[0491]

[0492] It should be noted that some compounds show bonds that are flat or wedged. In some cases, the relative stereochemistry of stereoisomers has been determined; in some cases, the absolute stereochemistry has been determined. In some cases, a single example number corresponds to a mixture of stereoisomers. The present invention encompasses all stereoisomers of the compounds of the above table. In certain embodiments, atropisomers of the compounds of the above table are encompassed. Brackets should be ignored.

[0493] Also provided is a pharmaceutical composition comprising the compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[0494] Further provided is a conjugate or a salt thereof, which comprises a structure of Formula V:

[0495] MLP

[0496] Formula V,

[0497] Where L is the connector;

[0498] P is a monovalent organic moiety; and

[0499] M has the structure of Formula VIa:

[0500]

[0501] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0502] R 2 is optionally substituted C 1 -C 6 alkyl;

[0503] R3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 heteroalkyl;

[0504] X 2 is O, C(R 11 ) 2 NR 12 , S or SO 2 ;

[0505] r is 1 or 2;

[0506] Each t is independently 0, 1, or 2;

[0507] R 11 and R 12 are each independently hydrogen, optionally substituted C 1 -C 4 Alkyl, optionally substituted C 2 -C 4 heteroalkyl or optionally substituted 3- to 5-membered cycloalkyl;

[0508] Each R 13 Independently -CH 3 ;and

[0509] R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0510] R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0511] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0512] Further provided is a conjugate or a salt thereof, which comprises a structure of Formula V:

[0513] MLP

[0514] Formula V,

[0515] Where L is the connector;

[0516] P is a monovalent organic moiety; and

[0517] M has the structure of Formula VIb:

[0518]

[0519] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0520] R 2 is optionally substituted C 1 -C 6 alkyl;

[0521] R 3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 heteroalkyl;

[0522] R 14 is fluorine, hydrogen or C 1 -C 3 alkyl;

[0523] u is 0 or 1; and

[0524] R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0525] R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0526] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0527] Further provided is a conjugate or a salt thereof, which comprises a structure of Formula V:

[0528] MLP

[0529] Formula V,

[0530] Where L is the connector;

[0531] P is a monovalent organic moiety; and

[0532] M has the structure of Formula VIc:

[0533]

[0534] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0535] R 2 is optionally substituted C 1 -C 6 alkyl;

[0536] R 3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 heteroalkyl; and

[0537] R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0538] R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0539] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0540] Further provided is a conjugate or a salt thereof, which comprises a structure of Formula V:

[0541] MLP

[0542] Formula V,

[0543] Where L is the connector;

[0544] P is a monovalent organic moiety; and

[0545] M has the structure of Formula VId:

[0546]

[0547] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0548] R 2 is optionally substituted C 1 -C 6 alkyl;

[0549] R 3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 heteroalkyl; and

[0550] R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0551] R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0552] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0553] In some embodiments of the conjugates of the invention, the monovalent organic moiety is a protein. In some embodiments, the protein is a Ras protein. In some embodiments, the Ras protein is K-Ras G12C, K-Ras G13C, H-Ras G12C, H-Ras G13C, N-Ras G12C or N-Ras G13C. In some embodiments of the conjugates of the invention, the linker is bound to the monovalent organic moiety via a bond to a thiol group of an amino acid residue of the monovalent organic moiety.

[0554] The compounds of the present invention are also suitable for antibody-drug conjugate and degrader applications.

[0555] Further provided is a method for treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof. The cancer may be, for example, pancreatic cancer, colorectal cancer, non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, thyroid adenocarcinoma, myelodysplastic syndrome, or squamous cell lung cancer. In some embodiments, the cancer comprises a Ras mutation, such as K-Ras G12C, K-Ras G13C, H-Ras G12C, H-Ras G13C, N-Ras G12C, or N-Ras G13C. Other Ras mutations are described herein.

[0556] Further provided is a method of treating a Ras protein-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.

[0557] A method for inhibiting Ras protein in a cell is further provided, the method comprising contacting the cell with an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof. For example, the Ras protein is K-Ras G12C, K-Ras G13C, H-Ras G12C, H-Ras G13C, N-Ras G12C or N-Ras G13C. Other Ras proteins are described herein. The cell may be a cancer cell, such as a pancreatic cancer cell, a colorectal cancer cell, a non-small cell lung cancer cell, an acute myeloid leukemia cell, a multiple myeloma cell, a thyroid adenocarcinoma cell, a myelodysplastic syndrome cell or a squamous cell lung cancer cell. Other cancer types are described herein. The cell may be in vivo or in vitro.

[0558] Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula I. Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula Ia. Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula II-1. Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula II-2. Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula II-3. Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula II-4. Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula II-5. Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula II-5a. Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula II-6. Further provided is a method for treating K-Ras G13C mutant cancer with a compound of formula II-6a. Further provided is a method of treating K-Ras G13C mutant cancer using a compound of formula II-6b. Further provided is a method of treating K-Ras G13C mutant cancer using a compound of formula II-6c.

[0559] Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula I. Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula Ia. Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula II-1. Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula II-2. Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula II-3. Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula II-4. Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula II-5. Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula II-5a. Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula II-6. Further provided is a method for treating K-Ras G12C mutant cancer with a compound of formula II-6a. Further provided is a method of treating K-Ras G12C mutant cancer using a compound of formula II-6b. Further provided is a method of treating K-Ras G12C mutant cancer using a compound of formula II-6c.

[0560] For compounds of the invention, one stereoisomer may exhibit a superior inhibitory effect over another stereoisomer. For example, one atropisomer may exhibit an inhibitory effect, while another atropisomer may exhibit little or no inhibitory effect.

[0561] In some embodiments, the methods or uses described herein also include administering additional anticancer therapies. In some embodiments, the additional anticancer therapies are HER2 inhibitors, EGFR inhibitors, second Ras inhibitors, SHP2 inhibitors, SOS1 inhibitors, Raf inhibitors, MEK inhibitors, ERK inhibitors, PI3K inhibitors, PTEN inhibitors, AKT inhibitors, mTORC1 inhibitors, BRAF inhibitors, PD-L1 inhibitors, PD-1 inhibitors, CDK4 / 6 inhibitors, or combinations thereof. In some embodiments, the additional anticancer therapies are SHP2 inhibitors. Other additional anticancer therapies are described herein.

[0562] Synthesis method

[0563] The compounds described herein can be prepared from commercially available starting materials or synthesized using known organic, inorganic or enzymatic techniques.

[0564] The compounds of the present invention can be prepared in a variety of ways well known to those skilled in the art of organic synthesis. For example, the compounds of the present invention can be synthesized using the methods described in the following schemes, as well as synthetic methods known in the field of synthetic organic chemistry or modifications of the methods understood by those skilled in the art. These methods include, but are not limited to, the methods described in the following schemes.

[0565] Scheme 1. General synthesis of macrocyclic esters

[0566]

[0567] The general synthesis of macrocyclic esters is outlined in Scheme 1. Appropriately substituted aryl-3-(5-bromo-1-ethyl-1H-indol-3-yl)-2,2-dimethylpropan-1-ols (1) can be prepared starting from protected 3-(5-bromo-2-iodo-1H-indol-3-yl)-2,2-dimethylpropan-1-ol and an appropriately substituted boronic acid in three steps involving palladium-mediated coupling, alkylation, and deprotection reactions. Amino-hexahydropyridazine-3-carboxylic acid methyl ester-boronic acid esters (2) can be prepared in three steps involving protection, iridium catalyst-mediated borylation, and coupling with (S)-hexahydropyridazine-3-carboxylic acid methyl ester.

[0568] Appropriately substituted acetylpyrrolidine-3-carbonyl-N-methyl-L-valine (or alternative amino acid derivatives) (4) can be prepared by coupling methyl-L-valine ester with protected (S)-pyrrolidine-3-carboxylic acid, followed by deprotection, coupling with a carboxylic acid containing an appropriately substituted Michael acceptor, and hydrolysis steps.

[0569] The final macrocyclic ester can be prepared by coupling amino-hexahydropyridazine-3-carboxylic acid methyl ester-boronate (2) with aryl-3-(5-bromo-1-ethyl-1H-indol-3-yl)-2,2-dimethylpropan-1-ol (1) in the presence of Pd catalyst, followed by hydrolysis and macrolactonization steps to give the appropriately protected macrocyclic intermediate (5). Deprotection and coupling with the appropriately substituted intermediate 4 yields the macrocyclic product. Additional deprotection and / or functionalization steps may be required to prepare the final compound.

[0570] Scheme 2. Alternative general synthesis of macrocyclic esters

[0571]

[0572] Alternatively, macrocyclic esters can be prepared as described in Scheme 2. Appropriately protected bromo-indolyl (6) is coupled with boronate (3) in the presence of a Pd catalyst, followed by iodination, deprotection, and ester hydrolysis. Subsequent coupling with (S)-hexahydropyridazine-3-methyl carboxylate, followed by hydrolysis and macrolactonization can produce the iodine intermediate (7). Coupling and alkylation with an appropriately substituted boronate in the presence of a Pd catalyst can yield a fully protected macrocycle (5). Additional deprotection or functionalization steps are required to prepare the final compound.

[0573] In addition, it will be appreciated by those skilled in the art that the compounds of the present disclosure can be synthesized using the methods described in the following examples, as well as synthetic methods known in the field of synthetic organic chemistry or variations thereof. These methods include, but are not limited to, the methods described in the following examples. For example, one skilled in the art will be able to install the -BLW group required for compounds of formula (I) in a macrocyclic ester, wherein B, L and W are as defined herein, including by using the methods exemplified in the Examples section herein.

[0574] The compounds of Table 1 herein are prepared using the methods disclosed herein, or using the methods disclosed herein in combination with the knowledge of those skilled in the art. The compounds of Table 2 can be prepared using the methods disclosed herein, or can be prepared using the methods disclosed herein in combination with the knowledge of those skilled in the art.

[0575] Scheme 3. General synthesis of macrocyclic esters

[0576]

[0577] An alternative general synthesis of macrocyclic esters is outlined in Scheme 3. Appropriately substituted indolyl boronates (8) can be prepared starting from protected 3-(5-bromo-2-iodo-1H-indol-3-yl)-2,2-dimethylpropan-1-ol and an appropriately substituted boronic acid in four steps involving palladium-mediated coupling, alkylation, deprotection, and palladium-mediated borylation.

[0578] Methyl (S)-2-amino-3-(4-bromothiazol-2-yl)propanoyl)hexahydropyridazine-3-carboxylate (10) can be prepared via coupling of (S)-2-amino-3-(4-bromothiazol-2-yl)propanoic acid (9) with methyl (S)-hexahydropyridazine-3-carboxylate.

[0579] The final macrocyclic ester can be prepared by coupling amino-3-(4-bromothiazol-2-yl)propionyl)hexahydropyridazine-3-carboxylic acid methyl ester (10) with an appropriately substituted indolyl boronate (8) in the presence of a Pd catalyst, followed by a hydrolysis and macrolactonization step to afford the appropriately protected macrocyclic intermediate (11). Deprotection and coupling with an appropriately substituted intermediate 4 can yield the macrocyclic product. Additional deprotection or functionalization steps may be required to prepare the final compounds 13 or 14.

[0580] Scheme 4. General synthesis of macrocyclic esters

[0581]

[0582] An alternative general synthesis of macrocyclic esters is outlined in Scheme 4. Appropriately substituted morpholine or alternative heterocyclic intermediates (15) can be coupled via palladium-mediated coupling with appropriately protected intermediates 1. Subsequent ester hydrolysis and coupling with piperazoic esters afford intermediates 16.

[0583] Macrocyclic esters can be prepared by hydrolysis, deprotection and macrocyclization procedures. Subsequent deprotection and coupling with intermediate 4 (or analogs) produces the appropriately substituted final macrocyclic product. Additional deprotection or functionalization steps may be required to prepare the final compound 17.

[0584] Scheme 5. General synthesis of macrocyclic esters

[0585]

[0586] An alternative general synthesis of macrocyclic esters is outlined in Scheme 5. Appropriately substituted macrocycles (20) can be prepared starting from appropriately protected boronate esters 18 and bromoindolyl intermediates (19) by palladium-mediated coupling, hydrolysis, coupling with piperazole esters, hydrolysis, deprotection, and macrocyclization steps. Subsequent coupling with appropriately substituted protected amino acids followed by palladium-mediated coupling affords intermediates 21. Additional deprotection and derivatization steps, including alkylation, may be required at this point.

[0587] The final macrocyclic ester can be prepared by coupling intermediate (22) with an appropriately substituted carboxylic acid intermediate (23). Additional deprotection or functionalization steps may be required to prepare the final compound (24).

[0588] In addition, the compounds of the present disclosure can be synthesized using the methods described in the following examples, as well as synthetic methods known in the field of synthetic organic chemistry, or modifications of the methods as understood by those skilled in the art. These methods include, but are not limited to, the methods described in the following examples. For example, one skilled in the art will be able to install the -BLW group required for compounds of formula (I) in a macrocyclic ester, wherein B, L and W are as defined herein, including by using the methods exemplified in the Examples section herein.

[0589] Pharmaceutical compositions and methods of use

[0590] Pharmaceutical compositions and methods of administration

[0591] The compounds involved in the present invention are Ras inhibitors and can be used to treat cancer. Therefore, one embodiment of the present invention provides a pharmaceutical composition containing a compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, and a method for preparing such a composition using the compound of the present invention.

[0592] As used herein, the term "pharmaceutical composition" refers to a compound, such as a compound of the present invention, or a pharmaceutically acceptable salt thereof, formulated together with a pharmaceutically acceptable excipient.

[0593] In some embodiments, the compound is present in the pharmaceutical composition in an amount of a unit dose suitable for administration in a treatment regimen, and the compound shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, the pharmaceutical composition can be specifically formulated for administration in solid or liquid form, including those suitable for administration in the following ways: oral administration, such as liquids (aqueous or non-aqueous solutions or suspensions), tablets (e.g., tablets targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, pastes for application to the tongue; parenteral administration, such as by subcutaneous, intramuscular, intravenous, or epidural injection, such as, for example, sterile solutions or suspensions, or sustained release formulations; topical administration, such as creams, ointments, or controlled release patches or sprays applied to the skin, lungs, or oral cavity; intravaginal or intrarectal administration, such as pessaries, creams, or foams; sublingual administration; ocular administration; transdermal administration; or nasal, pulmonary, and other mucosal surfaces.

[0594] As used herein, "pharmaceutically acceptable excipient" refers to any inactive ingredient (e.g., a vehicle capable of suspending or dissolving an active compound) that is non-toxic and non-inflammatory in a subject. Typical excipients include, for example, antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (pigments), softeners, emulsifiers, fillers (diluents), film formers or coatings, flavorings, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, or water for hydration. Excipients include, but are not limited to, optionally substituted butylated hydroxytoluene (BHT), calcium carbonate, calcium hydrogen phosphate, calcium stearate, cross-linked carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, citric acid, cross-linked polyvinylpyrrolidone, cysteine, ethylcellulose, gelatin, optionally substituted hydroxypropylcellulose, optionally substituted hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol. Those skilled in the art are familiar with a variety of agents and materials that can be used as excipients. See, e.g., Ansel et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro et al., Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. In some embodiments, the composition includes at least two different pharmaceutically acceptable excipients.

[0595] Unless expressly stated to the contrary, the compounds described herein, whether or not expressly stated, can be provided or utilized in the form of salts, such as pharmaceutically acceptable salts. As used herein, the term "pharmaceutically acceptable salt" refers to salts of compounds described herein that are suitable for use in contact with human tissues without excessive toxicity, irritation, allergic reactions, etc., and are commensurate with a reasonable benefit / risk ratio, within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66: 1-19, 1977 and Pharmaceutical Salts: Properties, Selection, and Use, (P. H. Stahl and C. G. Wermuth, ed.), Wiley-VCH, 2008. The salts can be prepared in situ during the final separation and purification of the compounds described herein, or separated by reacting the free base group with a suitable organic acid.

[0596] The compounds of the present invention may have ionizable groups so that they can be prepared into pharmaceutically acceptable salt forms. These salts may be acid addition salts involving inorganic or organic acids, or in the case where the compounds of the present invention are in acid form, the salts may be prepared from inorganic or organic bases. In some embodiments, the compound is prepared into a pharmaceutically acceptable salt form or used in a pharmaceutically acceptable salt form, and the pharmaceutically acceptable salt form is prepared as an addition product of a pharmaceutically acceptable acid or base. Suitable pharmaceutically acceptable acids and bases are well known in the art, such as hydrochloric acid, sulfuric acid, hydrobromic acid, acetic acid, lactic acid, citric acid or tartaric acid, for forming acid addition salts; and potassium hydroxide, sodium hydroxide, ammonium hydroxide, caffeine, various amines, etc., for forming basic salts. Methods for preparing appropriate salts are well-known in the art.

[0597] Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-optionally substituted hydroxy-ethyl Alkanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, etc. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc., and non-toxic ammonium, quaternary ammonium and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc.

[0598] As used herein, the term "subject" refers to any member of the animal kingdom. In some embodiments, a "subject" refers to a human being at any stage of development. In some embodiments, a "subject" refers to a human patient. In some embodiments, a "subject" refers to a non-human animal. In some embodiments, a non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, a cow, a primate, or a pig). In some embodiments, subjects include, but are not limited to, mammals, birds, reptiles, amphibians, fish, or insects. In some embodiments, a subject may be a transgenic animal, a genetically engineered animal, or a clone.

[0599] As used herein, the term "dosage form" refers to a physical discrete unit of a compound (e.g., a compound of the present invention) for administration to a subject. Each unit contains a predetermined amount of compound. In some embodiments, this amount is the amount (or an integral part thereof) of a unit dose suitable for administration according to a dosing regimen, which is determined to be associated with a desired or beneficial result when administered to a relevant population (i.e., according to a therapeutic dosing regimen). It will be appreciated by those skilled in the art that the total amount of the therapeutic composition or compound administered to a particular subject is determined by one or more attending physicians and may involve administration of a variety of dosage forms.

[0600] As used herein, the term "dosage regimen" refers to a group of unit doses (usually more than one unit dose) administered individually to a subject, the unit doses typically being spaced apart for a certain period of time. In some embodiments, a given therapeutic compound (e.g., a compound of the present invention) has a recommended dosing regimen, which may involve one or more doses. In some embodiments, the dosing regimen comprises multiple doses, each of which is spaced apart from each other by a period of the same length; in some embodiments, the dosing regimen comprises multiple doses and at least two different time periods separating individual doses. In some embodiments, all doses within the dosing regimen are the same unit dose amount. In some embodiments, the different doses within the dosing regimen are different amounts. In some embodiments, the dosing regimen comprises a first dose of the amount of the first dose, followed by one or more additional doses of the amount of the second dose different from the amount of the first dose. In some embodiments, the dosing regimen comprises a first dose of the amount of the first dose, followed by one or more additional doses of the amount of the second dose identical to the amount of the first dose. In some embodiments, the dosing regimen is associated with desired or beneficial results when applied to a relevant population (i.e., a therapeutic dosing regimen).

[0601] A "therapeutic regimen" refers to a regimen of dosages whose administration is associated with desired or beneficial therapeutic results in the relevant population.

[0602] The term "treatment" ("treatment / treat / treating") in its broadest sense refers to any administration of a substance (e.g., a compound of the present invention) that partially or completely alleviates, ameliorates, alleviates, inhibits one or more symptoms, features, or causes of a particular disease, disorder, or condition; delays its onset; reduces its severity; or reduces its occurrence. In some embodiments, this treatment may be applied to subjects who do not show signs of the relevant disease, disorder, or condition or to subjects who only show early signs of the disease, disorder, or condition. Alternatively or additionally, in some embodiments, treatment may be applied to subjects who show one or more determined signs of the relevant disease, disorder, or condition. In some embodiments, treatment can be used for subjects diagnosed with a relevant disease, disorder, or condition. In some embodiments, treatment can be used for subjects known to have one or more susceptibility factors that are statistically associated with an increased risk of developing a relevant disease, disorder, or condition.

[0603] The term "therapeutically effective amount" means an amount sufficient to treat a disease, disorder or illness when applied to a population suffering from or susceptible to a disease, disorder or illness according to a therapeutic dosing regimen. In some embodiments, a therapeutically effective amount is an amount that reduces the incidence or severity of one or more symptoms of the disease, disorder or illness or delays its onset. It will be understood by those skilled in the art that the term "therapeutically effective amount" does not actually require the desired successful treatment to be achieved in a particular individual. In fact, a therapeutically effective amount may be an amount that provides a specific desired pharmacological response in a considerable number of subjects when applied to a patient in need of such treatment. It is particularly important to understand that a particular subject may actually be "refractory" to a "therapeutically effective amount". In some embodiments, the therapeutically effective amount mentioned may refer to an amount measured in one or more specific tissues (e.g., tissues affected by a disease, disorder or illness) or fluids (e.g., blood, saliva, serum, sweat, tears, urine). It will be understood by those skilled in the art that in some embodiments, a therapeutically effective amount may be formulated as a single dose or administered in a single dose. In some embodiments, a therapeutically effective amount may be formulated as multiple doses, for example, formulated as part of a dosing regimen, or administered in multiple doses.

[0604] For use as a treatment for a subject, the compound of the present invention or a pharmaceutically acceptable salt thereof can be formulated as a pharmaceutical composition or a veterinary composition. Depending on the subject to be treated, the mode of administration, and the desired type of treatment, such as prevention, control, or treatment, the compound or a pharmaceutically acceptable salt thereof is formulated in a manner consistent with these parameters. An overview of such techniques can be found in Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott Williams & Wilkins, (2005); and Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New York, each of which is incorporated herein by reference.

[0605] The composition can be prepared according to conventional mixing, granulation or coating methods, respectively, and the pharmaceutical composition of the present invention can contain about 0.1% to about 99%, about 5% to about 90%, or about 1% to about 20% of the compound of the present invention or its pharmaceutically acceptable salt by weight or volume. In some embodiments, the compound described herein or its pharmaceutically acceptable salt is present in an amount by weight that can account for 1-95% of the total amount of the composition such as the pharmaceutical composition.

[0606] The composition can be provided in a dosage form suitable for the following administration: intra-articular, oral, parenteral (e.g., intravenous, intramuscular), rectal, skin, subcutaneous, surface, transdermal, sublingual, nasal, vaginal, intracapsular, intraurethral, ​​intrathecal, epidural, ear or eye administration, or by injection, inhalation or direct contact with the nose, urogenital, genital or oral mucosa. Therefore, the pharmaceutical composition can be in the form of, for example, tablets, capsules, pills, powders, granules, suspensions, emulsions, solutions, gels (including hydrogels), pastes, ointments, creams, plasters, medicinal solutions, osmotic delivery devices, suppositories, enemas, injections, implants, sprays, preparations suitable for iontophoresis delivery or aerosols. The composition can be prepared according to conventional medical practice.

[0607] As used herein, the term "administering" refers to administering a composition (e.g., a compound or a formulation comprising a compound as described herein) to a subject or system. Administration to an animal subject (e.g., to a human) can be performed by any appropriate route. For example, in some embodiments, administration can be bronchial (including by bronchial instillation), buccal, enteral, interdermal, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intracapsular, transmucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal, or vitreous administration.

[0608] The preparation can be prepared in a manner suitable for systemic administration or surface or topical administration. Systemic preparations include preparations designed for injection (e.g., intramuscular, intravenous or subcutaneous injection) or can be prepared for transdermal, transmucosal or oral administration. The preparation will generally include a diluent, and in some cases, adjuvants, buffers, preservatives, etc. The compound or its pharmaceutically acceptable salt can also be administered in liposome compositions or in microemulsion form.

[0609] For injection, the preparation can be prepared in conventional forms, such as liquid solutions or suspensions, or solid forms suitable for preparation as solutions or suspensions in liquids prior to injection, or in the form of emulsions. Suitable excipients include, for example, water, saline, dextrose, glycerol, etc. Such compositions may also contain a certain amount of non-toxic auxiliary substances, such as wetting agents or emulsifiers, pH buffers, etc., such as sodium acetate, sorbitan monolaurate, etc.

[0610] Various sustained-release drug systems have also been designed. See, for example, U.S. Pat. No. 5,624,677.

[0611] Systemic administration may also include relatively non-invasive methods, such as the use of suppositories, transdermal patches, transmucosal delivery, and intranasal administration. Oral administration is also suitable for the compounds of the present invention or their pharmaceutically acceptable salts. It will be appreciated in the art that suitable forms include syrups, capsules, and tablets.

[0612] Each compound or pharmaceutically acceptable salt thereof as described herein can be formulated in a variety of ways known in the art. For example, the first agent and the second agent in the combination therapy can be formulated together or separately. Other modalities of combination therapy are also described herein.

[0613] Individual or separately formulated medicaments can be packaged together in a kit form. Non-limiting examples include, but are not limited to, kits containing, for example, two pills, one pill and powder, suppositories or liquids in vials, two surface creams, etc. The kit may include optional components that help to apply a unit dose to a subject, such as vials, syringes for injection, custom IV delivery systems, inhalers, etc., for reconstitution of powder forms. In addition, the unit dose kit may contain instructions for the preparation and administration of the composition. The kit may be manufactured as a disposable unit dose for a subject, for multiple uses for a specific subject (at a constant dose, or wherein the efficacy of an individual compound or its pharmaceutically acceptable salt may vary with treatment progress); or the kit may contain multiple doses suitable for application to multiple subjects ("overall packaging"). The kit components may be assembled in cartons, blister packs, bottles, tubes, etc.

[0614] Formulations for oral use include tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients. These excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starch including potato starch, calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate or sodium phosphate); granulating agents and disintegrants (e.g., cellulose derivatives including microcrystalline cellulose, starch including potato starch, cross-linked sodium carboxymethyl cellulose, alginates or alginic acid); binders (e.g., sucrose, glucose, sorbitol, gum arabic, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, sodium carboxymethyl cellulose, methyl cellulose, optionally substituted hydroxypropyl methyl cellulose, ethyl cellulose, polyvinyl pyrrolidone or polyethylene glycol); and lubricants, glidants and anti-adherents (e.g., magnesium stearate, zinc stearate, stearic acid, silicon dioxide, hydrogenated vegetable oil or talc). Other pharmaceutically acceptable excipients may be colorants, flavoring agents, plasticizers, humectants, buffers, and the like.

[0615] Two or more compounds can be mixed together in tablets, capsules or other vehicles, or can be separated. In one example, the first compound is contained on the inside of the tablet, and the second compound is on the outside, so that the vast majority of the second compound is released before the first compound is released.

[0616] Formulations for oral use may also be provided in the form of chewable tablets, or in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g. potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin); or in the form of soft gelatin capsules in which the active ingredient is mixed with water or an oil medium, e.g. peanut oil, liquid paraffin or olive oil. Powders, granules and granules may be prepared using the ingredients mentioned above for tablets and capsules in a conventional manner, using, for example, a mixer, a fluid bed apparatus or a spray drying device.

[0617] Dissolution or diffusion controlled release can be achieved by appropriately coating tablets, capsules, granules or granular preparations of the compound, or by incorporating the compound or its pharmaceutically acceptable salt into a suitable matrix. The controlled release coating may include one or more of the above-mentioned coating materials, such as shellac, beeswax, glycowax, castor wax, carnauba wax, stearyl alcohol, glyceryl monostearate, glyceryl distearate, glyceryl palmitostearate, ethylcellulose, acrylic resin, dl-polylactic acid, cellulose acetate butyrate, polyvinyl chloride, polyvinyl acetate, vinyl pyrrolidone, polyethylene, polymethacrylate, methyl methacrylate, 2-optionally substituted hydroxymethylacrylate, methacrylate hydrogel, 1,3-butylene glycol, ethylene glycol methacrylate or polyethylene glycol. In controlled release matrix formulations, the matrix material may also include, for example, hydrated methylcellulose, carnauba wax and stearyl alcohol, carbopol 934, silicone, tristearin, methyl acrylate-methyl methacrylate, polyvinyl chloride, polyethylene or halogenated fluorocarbons.

[0618] Liquid forms for oral administration that may incorporate the compounds of the invention or pharmaceutically acceptable salts thereof and compositions include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions and emulsions flavored with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

[0619] In general, when administered to humans, the oral dosage of any compound of the present invention or its pharmaceutically acceptable salt will depend on the properties of the compound and can be easily determined by those skilled in the art. The dosage can be, for example, from about 0.001 mg to about 2000 mg per day, from about 1 mg to about 1000 mg per day, from about 5 mg to about 500 mg per day, from about 100 mg to about 1500 mg per day, from about 500 mg to about 1500 mg per day, from about 500 mg to about 2000 mg per day, or any range derived therefrom.

[0620] In some embodiments, the pharmaceutical composition may also include an additional compound with antiproliferative activity. Depending on the mode of administration, the compound or its pharmaceutically acceptable salt will be formulated into a suitable composition for delivery. Each compound or its pharmaceutically acceptable salt in the combination therapy can be formulated in a variety of ways known in the art. For example, the first agent and the second agent in the combination therapy can be formulated together or separately. Ideally, the first agent and the second agent are formulated together so that the agents are administered simultaneously or nearly simultaneously.

[0621] It should be understood that the compounds and pharmaceutical compositions of the present invention can be formulated and used in combination therapy, that is, the compounds and pharmaceutical compositions can be formulated with one or more other desired therapeutic agents or medical procedures or administered at the same time, before or after the administration of the one or more other desired therapeutic agents or medical procedures. The specific combination of each therapy (therapeutic agent or procedure) used in the combination regimen should take into account the compatibility of the desired therapeutic agent or procedure with the desired therapeutic effect to be achieved. It should also be understood that the therapies employed can achieve the desired effect for the same condition, or they can achieve different effects (e.g., control any adverse effects).

[0622] As described herein, administration of each drug in the combination therapy may independently be once to four times daily for a period of one day to one year, and may even be continued for the life of the subject. Chronic, long-term administration may be required.

[0623] How to use

[0624] In some embodiments, the present invention discloses a method of treating a disease or condition characterized by aberrant Ras activity caused by a Ras mutant. In some embodiments, the disease or condition is cancer.

[0625] Therefore, a method for treating cancer in a subject in need is also provided, the method comprising administering to the subject a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound or salt. In some embodiments, the cancer is colorectal cancer, non-small cell lung cancer, small cell lung cancer, pancreatic cancer, appendix cancer, melanoma, acute myeloid leukemia, small intestine cancer, ampullary cancer, germ cell cancer, cervical cancer, cancer of unknown primary site, endometrial cancer, esophagogastric cancer, GI neuroendocrine cancer, ovarian cancer, sex cord stromal tumor cancer, hepatobiliary cancer, or bladder cancer. In some embodiments, the cancer is appendix cancer, endometrial cancer, or melanoma. A method for treating a Ras protein-related disorder in a subject in need is also provided, the method comprising administering to the subject a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound or salt.

[0626] In some embodiments, the compounds of the present invention or their pharmaceutically acceptable salts, pharmaceutical compositions comprising such compounds or salts, and methods provided herein can be used to treat a variety of cancers, including tumors, such as lung cancer, prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, testicular cancer, etc. More specifically, cancers that can be treated by the compounds of the present invention or their salts, pharmaceutical compositions comprising such compounds or salts, and methods include, but are not limited to, for example, the following tumor types: astrocytes, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatocellular, laryngeal, lung, oral, ovarian, prostate, and thyroid carcinomas and sarcomas. Other cancers include, for example:

[0627] Heart, for example: sarcomas (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma;

[0628] Lung, for example: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, enchondromatous hamartoma, mesothelioma;

[0629] Gastrointestinal, for example: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vipoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma);

[0630] Urogenital tract, for example: kidney (adenocarcinoma, Wilm's tumor (Nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, lipoma);

[0631] Liver, for example: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;

[0632] Biliary tract, such as gallbladder cancer, ampullary cancer, and bile duct cancer;

[0633] Bone, for example: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor;

[0634] Nervous system, for example: skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meninges (meningiomas, meningosarcomas, gliomatosis), brain (astrocytomas, medulloblastomas, gliomas, ependymomas, germ cell tumors (pinealomas), glioblastoma multiforme, oligodendrogliomas, schwannomas, retinoblastomas, congenital tumors), spinal neurofibromas, neurofibromatosis type 1, meningiomas, gliomas, sarcomas);

[0635] Gynecology, for example: uterus (endometrial cancer, uterine cancer, endometrial cancer), cervix (cervical cancer, cervical precancerous atypical hyperplasia), ovary (ovarian cancer (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube (carcinoma);

[0636] Hematopoietic system, for example: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders (e.g., myelofibrosis and myeloproliferative neoplasms), multiple myeloma, myelodysplastic syndromes), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma);

[0637] Skin, such as: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, nevus dysplasia, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and

[0638] Adrenal glands, e.g. neuroblastoma.

[0639] In some embodiments, the Ras protein is wild-type (Ras WT ). Thus, in some embodiments, the compounds of the invention are used to treat a patient suffering from a disease comprising Ras WT (e.g. K-Ras WT 、H-Ras WT N-Ras WT) of a patient with cancer. In some embodiments, the Ras protein is a Ras amplified (eg, K-Ras amp ). Thus, in some embodiments, the compounds of the invention are used to treat a patient suffering from a disease comprising Ras amp (K-Ras amp 、H-Ras amp N-Ras amp ) in a method of treating a patient with a cancer. In some embodiments, the cancer comprises a Ras mutation, such as a Ras mutation described herein. In some embodiments, the mutation is selected from:

[0640] (a) the following K-Ras mutants: G12D, G12V, G12C, G13D, G12R, G12A, Q61H, G12S, A146T, G13C, Q61L, Q61R, K117N, A146V, G12F, Q61K, L19F, Q22K, V14I, A59T, A146P, G13R, G12L or G13V, and combinations thereof;

[0641] (b) the following H-Ras mutants: Q61R, G13R, Q61K, G12S, Q61L, G12D, G13V, G13D, G12C, K117N, A59T, G12V, G13C, Q61H, G13S, A18V, D119N, G13N, A146T, A66T, G12A, A146V, G12N or G12R, and combinations thereof; and

[0642] (c) the following N-Ras mutants: Q61R, Q61K, G12D, Q61L, Q61H, G13R, G13D, G12S, G12C, G12V, G12A, G13V, G12R, P185S, G13C, A146T, G60E, Q61P, A59D, E132K, E49K, T50I, A146V or A59T, and combinations thereof;

[0643] Or a combination of any of the foregoing. In some embodiments, the cancer comprises a K-Ras mutation selected from the group consisting of: G12C, G12D, G13C, G12V, G13D, G12R, G12S, Q61H, Q61K, and Q61L. In some embodiments, the cancer comprises an N-Ras mutation selected from the group consisting of: G12C, Q61H, Q61K, Q61L, Q61P, and Q61R. In some embodiments, the cancer comprises an H-Ras mutation selected from the group consisting of Q61H and Q61L. In some embodiments, the cancer comprises a Ras mutation selected from the group consisting of: G12C, G13C, G12A, G12D, G13D, G12S, G13S, G12V, and G13V. In some embodiments, the cancer comprises at least two Ras mutations selected from the group consisting of: G12C, G13C, G12A, G12D, G13D, G12S, G13S, G12V, and G13V. In some embodiments, the compounds of the present invention inhibit more than one Ras mutant. For example, the compound may inhibit both K-Ras G12C and K-Ras G13C. The compound may inhibit both N-Ras G12C and K-Ras G12C. In some embodiments, the compound may inhibit both K-Ras G12C and K-Ras G12D. In some embodiments, the compound may inhibit both K-Ras G12V and K-Ras G12C. In some embodiments, the compound may inhibit both K-Ras G12V and K-Ras G12S. In some embodiments, the compounds of the present invention inhibit Ras WT and one or more additional Ras mutations (e.g., K-, H-, or N-Ras WT and K-Ras G12D, G12V, G12C, G13D, G12R, G12A, Q61H, G12S, A146T, G13C, Q61L, Q61R, K117N, A146V, G12F, Q61K, L19F, Q22K, V14I, A59T, A146P, G13R, G12L, or G13V; K, H, or N-Ras WT and H-Ras Q61R, G13R, Q61K, G12S, Q61L, G12D, G13V, G13D, G12C, K117N, A59T, G12V, G13C, Q61H, G13S, A18V, D119N, G13N, A146T, A66T, G12A, A146V, G12N, or G12R; or K, H, or N-Ras WTand N-Ras Q61R, Q61K, G12D, Q61L, Q61H, G13R, G13D, G12S, G12C, G12V, G12A, G13V, G12R, P185S, G13C, A146T, G60E, Q61P, A59D, E132K, E49K, T50I, A146V or A59T). In some embodiments, the compounds of the invention inhibit Ras amp and one or more additional Ras mutations (e.g., K-, H-, or N-Ras amp and K-Ras G12D, G12V, G12C, G13D, G12R, G12A, Q61H, G12S, A146T, G13C, Q61L, Q61R, K117N, A146V, G12F, Q61K, L19F, Q22K, V14I, A59T, A146P, G13R, G12L, or G13V; K, H, or N-Ras amp and H-Ras Q61R, G13R, Q61K, G12S, Q61L, G12D, G13V, G13D, G12C, K117N, A59T, G12V, G13C, Q61H, G13S, A18V, D119N, G13N, A146T, A66T, G12A, A146V, G12N, or G12R; or K, H, or N-Ras amp and N-Ras Q61R, Q61K, G12D, Q61L, Q61H, G13R, G13D, G12S, G12C, G12V, G12A, G13V, G12R, P185S, G13C, A146T, G60E, Q61P, A59D, E132K, E49K, T50I, A146V, or A59T).

[0644] Methods for detecting Ras mutations are known in the art. Such methods include, but are not limited to, direct sequencing and using highly sensitive diagnostic assays (using CE-IVD marking), such as Domagala et al., Pol J Pathol 3: 145-164 (2012), which are incorporated herein by reference in their entirety, including TheraScreen PCR; AmoyDx; PNAClamp; RealQuality; EntroGen; LightMix; StripAssay; Hybcell plexA; Devyser; Surveyor; Cobas; and TheraScreenPyro. See also, for example, WO 2020 / 106640.

[0645] In some embodiments, the cancer is non-small cell lung cancer and the Ras mutation comprises a K-Ras mutation, such as K-Ras G12C, K-Ras G12V, or K-Ras G12D. In some embodiments, the cancer is colorectal cancer and the Ras mutation comprises a K-Ras mutation, such as K-Ras G12C, K-Ras G12V, or K-Ras G12D. In some embodiments, the cancer is pancreatic cancer and the Ras mutation comprises a K-Ras mutation, such as K-Ras G12D or K-Ras G12V. In some embodiments, the cancer is pancreatic cancer and the Ras mutation comprises an N-Ras mutation, such as N-Ras G12D. In some embodiments, the cancer is melanoma and the Ras mutation comprises an N-Ras mutation, such as N-Ras Q61R or N-Ras Q61K. In some embodiments, the cancer is non-small cell lung cancer and the Ras protein is K-Ras. amp In any of the foregoing, if not specifically stated, the compound may also inhibit Ras WT (e.g. K-, H- or N-Ras WT ) or Ras amp (e.g. K-, H- or N-Ras amp ).

[0646] In some embodiments, the cancer comprises a Ras mutation and STK11 LOF , KEAP1, EPHA5 or NF1 mutations. In some embodiments, the cancer is non-small cell lung cancer and comprises a K-Ras G12C mutation. In some embodiments, the cancer is non-small cell lung cancer and comprises a K-Ras G12C mutation and STK11 LOF In some embodiments, the cancer is non-small cell lung cancer and comprises a K-Ras G12C mutation and a STK11 LOF Mutation. In some embodiments, the cancer comprises a K-Ras G13C Ras mutation and a STK11 LOF, KEAP1, EPHA5 or NF1 mutations. In some embodiments, the cancer is non-small cell lung cancer and comprises a K-Ras G12D mutation. In some embodiments, the cancer is non-small cell lung cancer and comprises a K-Ras G12V mutation. In some embodiments, the cancer is colorectal cancer and comprises a K-Ras G12C mutation. In some embodiments, the cancer is pancreatic cancer and comprises a K-Ras G12C or K-Ras G12D mutation. In some embodiments, the cancer is pancreatic cancer and comprises a K-Ras G12V mutation. In some embodiments, the cancer is endometrial cancer, ovarian cancer, bile duct cancer, or mucinous appendix cancer and comprises a K-Ras G12C mutation. In some embodiments, the cancer is gastric cancer and comprises a K-Ras G12C mutation. In any of the foregoing, the compound may also inhibit Ras WT (e.g. K-, H- or N-Ras WT ) or Ras amp (e.g. K-, H- or N-Ras amp ).

[0647] Also provided is a method for inhibiting Ras protein in a cell, the method comprising contacting the cell with an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof. Also provided is a method for inhibiting RAF-Ras binding, the method comprising contacting the cell with an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof. The cell may be a cancer cell. The cancer cell may belong to any type of cancer described herein. The cell may be in vivo or in vitro.

[0648] Combination therapy

[0649] The methods of the invention may include the compounds of the invention used alone or in combination with one or more additional therapies (e.g., non-drug treatments or therapeutic agents). When administered alone, the dosage of one or more of the additional therapies (e.g., non-drug treatments or therapeutic agents) may be reduced relative to the standard dosage. For example, the dosage may be determined empirically based on drug combinations and permutations or may be inferred by isoradiometric analysis (e.g., Black et al., Neurology 65: S3-S6 (2005)).

[0650] The compounds of the present invention may be administered before, after, or simultaneously with the administration of one or more of such additional therapies. When combined, the dose of the compounds of the present invention and the dose of the one or more additional therapies (e.g., non-drug therapies or therapeutic agents) provide a therapeutic effect (e.g., a synergistic or additive therapeutic effect). The compounds of the present invention and additional therapies, such as anticancer agents, may be administered together, such as in the form of a single pharmaceutical composition, or separately, and when administered separately, this may occur simultaneously or sequentially. This sequential administration may be close or distant in time.

[0651] In some embodiments, the additional therapy is the administration of a side effect limiting agent (e.g., an agent intended to reduce the occurrence or severity of a therapeutic side effect). For example, in some embodiments, the compounds of the invention may also be used in combination with a therapeutic agent for treating nausea. Examples of agents that can be used to treat nausea include: dronabinol, granisetron, metoclopramide, ondansetron, and prochlorperazine, or a pharmaceutically acceptable salt thereof.

[0652] In some embodiments, the one or more additional therapies include non-drug therapy (e.g., surgery or radiotherapy). In some embodiments, the one or more additional therapies include therapeutic agents (e.g., compounds or biological agents as anti-angiogenic agents, signal transduction inhibitors, anti-proliferative agents, glycolysis inhibitors, or autophagy inhibitors). In some embodiments, the one or more additional therapies include non-drug therapy (e.g., surgery or radiotherapy) and therapeutic agents (e.g., compounds or biological agents as anti-angiogenic agents, signal transduction inhibitors, anti-proliferative agents, glycolysis inhibitors, or autophagy inhibitors). In other embodiments, the one or more additional therapies include two therapeutic agents. In yet other embodiments, the one or more additional therapies include three therapeutic agents. In some embodiments, the one or more additional therapies include four or more therapeutic agents.

[0653] In this Combination Therapies section, all references are incorporated by reference with respect to the agents described, whether or not expressly stated as such.

[0654] Non-drug treatments

[0655] Examples of non-drug treatments include, but are not limited to, radiation therapy, cryotherapy, hyperthermia, surgery (eg, surgical removal of tumor tissue), and T-cell acceptor transfer (ACT) therapy.

[0656] In some embodiments, the compounds of the present invention can be used as postoperative adjuvant therapy. In some embodiments, the compounds of the present invention can be used as preoperative neoadjuvant therapy.

[0657] Radiotherapy can be used to inhibit abnormal cell growth or treat hyperproliferative disorders, such as cancer, in a subject, such as a mammal (e.g., a human being). Techniques for administering radiotherapy are known in the art. Radiotherapy can be administered via one of several methods or a combination of methods, including but not limited to external beam therapy, internal radiotherapy, implant radiation, stereotactic radiosurgery, systemic radiation therapy, radiotherapy, and persistent or transient interstitial brachytherapy. The term "brachytherapy" as used herein refers to radiotherapy delivered by spatially confined radioactive materials inserted into or near a tumor or other proliferative tissue disease site in the body. The term is intended to include, but is not limited to, exposure to radioisotopes (e.g., At-211, I-131, I-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, and Lu radioisotopes). Suitable radiation sources for use as cell conditioning agents of the present invention include solids and liquids. As non-limiting examples, the radiation source can be a radionuclide, such as I-125, I-131, Yb-169, Ir-192 as a solid source, I-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma radiation or other therapeutic rays. The radioactive material can also be a fluid made from any radionuclide solution, such as a solution of I-125 or I-131, or the radioactive fluid can be prepared using a slurry of a suitable fluid containing small particles of solid radionuclides such as Au-198 or Y-90. In addition, the radionuclides can be embedded in a gel or radioactive microspheres.

[0658] In some embodiments, the compounds of the present invention can make abnormal cells more sensitive to radiotherapy to achieve the purpose of killing or inhibiting the growth of such cells. Therefore, the present invention also relates to a method for sensitizing abnormal cells in a mammal to radiotherapy, the method comprising administering to the mammal an amount of the compound of the present invention, the amount effectively sensitizing abnormal cells to radiotherapy. The amount of the compound in this method can be determined according to the method for determining the effective amount of such compounds described herein. In some embodiments, the compounds of the present invention can be used as an adjuvant therapy after radiotherapy or as a neoadjuvant therapy before radiotherapy.

[0659] In some embodiments, the non-drug treatment is T cell acceptor transfer (ACT) therapy. In some embodiments, the T cell is an activated T cell. The T cell can be modified to express a chimeric antigen receptor (CAR). CAR-modified T (CAR-T) cells can be produced by any method known in the art. For example, CAR-T cells can be produced by introducing a suitable expression vector encoding CAR into T cells. Before T cells are amplified and genetically modified, the source of T cells is obtained from the subject. T cells can be obtained from a variety of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from the site of infection, ascites, pleural effusion, spleen tissue and tumor. In certain embodiments of the present invention, a variety of T cell lines available in the art can be used. In some embodiments, the T cell is an autologous T cell. Before or after the T cells are genetically modified to express a desired protein (e.g., CAR), the T cells can be activated and expanded, typically using methods as described, for example, in the following U.S. Patents: 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 7,572,631; 5,883,223; 6,905,874; 6,797,514; and 6,867,041.

[0660] Therapeutic agents

[0661] The therapeutic agent may be a compound used to treat cancer or its associated symptoms. The compounds of the present invention may be combined with a second, third or fourth therapeutic agent or more therapeutic agents. The compounds of the present invention may be combined with one or more therapeutic agents and one or more non-drug therapies.

[0662] For example, the therapeutic agent may be a steroid. Steroids are known in the art. Therefore, in some embodiments, the one or more additional therapies include steroids. Suitable steroids may include, but are not limited to, 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clocortolone, cloprednol, corticosterone, cortisone, isone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difuprednate, enoxolone, fluazacort, fiucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, fluprednidene acetate, fluprednisolone, flurandrenolide, fluticasone propionate, formocortal, halcinonide, halobetasol propionate, halometasone, hydrocortisone, loteprednol etabonate

[00136] The invention relates to cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane, cyclopentane

[0663] Other examples of therapeutic agents that can be used in combination therapy with the compounds of the invention include compounds described in U.S. Pat. Nos. 6,258,812, 6,630,500, 6,515,004, 6,713,485, 5,521,184, 5,770,599, 5,747,498, 5,990,141, 6,235,764, and 8,623,885, as well as U.S. Pat. International patent applications WO01 / 37820, WO01 / 32651, WO02 / 68406, WO02 / 66470, WO02 / 55501, WO04 / 05279, WO04 / 07481, WO04 / 07458, WO04 / 09784, WO02 / 59110, WO99 / 45009, WO00 / 59509, WO99 / 61422, WO00 / 12089 and WO00 / 02871.

[0664] The therapeutic agent may be a biological agent (e.g., a cytokine (e.g., interferon or interleukin, such as IL-2)) for treating cancer or its associated symptoms. Biological agents are known in the art. In some embodiments, the biological agent is an immunoglobulin-based biological agent, such as a monoclonal antibody (e.g., a humanized antibody, a fully human antibody, an Fc fusion protein, or a functional fragment thereof) that excites the target to stimulate an anti-cancer response or antagonizes an antigen that is important for cancer. Antibody-drug conjugates are also included.

[0665] The therapeutic agent may be a T cell checkpoint inhibitor. Such checkpoint inhibitors are known in the art. In one embodiment, the checkpoint inhibitor is an inhibitory antibody (e.g., a monospecific antibody, such as a monoclonal antibody). The antibody may be, for example, a humanized or fully human antibody. In some embodiments, the checkpoint inhibitor is a fusion protein, such as an Fc-receptor fusion protein. In some embodiments, the checkpoint inhibitor is an agent that interacts with a checkpoint protein, such as an antibody. In some embodiments, the checkpoint inhibitor is an agent that interacts with a ligand of a checkpoint protein, such as an antibody. In some embodiments, the checkpoint inhibitor is an inhibitor (e.g., an inhibitory antibody or a small molecule inhibitor) of CTLA-4 (e.g., an anti-CTLA-4 antibody or a fusion protein). In some embodiments, the checkpoint inhibitor is an inhibitor or antagonist (e.g., an inhibitory antibody or a small molecule inhibitor) of PD-1. In some embodiments, the checkpoint inhibitor is an inhibitor or antagonist (e.g., an inhibitory antibody or a small molecule inhibitor) of PD-L1. In some embodiments, the checkpoint inhibitor is an inhibitor or antagonist (e.g., an inhibitory antibody or Fc fusion or small molecule inhibitor) of PD-L2 (e.g., a PD-L2 / Ig fusion protein). In some embodiments, the checkpoint inhibitor is an inhibitor or antagonist (e.g., an inhibitory antibody or small molecule inhibitor) of B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligand, or a combination thereof.In some embodiments, the checkpoint inhibitor is pembrolizumab, nivolumab, PDR001 (NVS), REGN2810 (Sanofi / Regeneron), a PD-L1 antibody such as avelumab, durvalumab, atezolizumab, pidilizumab, JNJ-63723283 (JNJ), BGB-A317 (BeiGene & Celgene) Or the checkpoint inhibitors disclosed in Preusser, M. et al. (2015) Nat. Rev. Neurol., including but not limited to ipilimumab, tremelimumab, nivolumab, pembrolizumab, AMP224, AMP514 / MEDI0680, BMS936559, MED14736, MPDL3280A, MSB0010718C, BMS986016, IMP321, lirilumab, IPH2101, 1-7F9 and KW-6002.

[0666] The therapeutic agent may be an anti-TIGIT antibody, such as MBSA43, BMS-986207, MK-7684, COM902, AB154, MTIG7192A, or OMP-313M32 (etigilimab). Other anti-TIGIT antibodies are known in the art.

[0667] The therapeutic agent may be an agent for treating cancer or its associated symptoms (e.g., a cytotoxic agent, a non-peptide small molecule, or other compounds useful for treating cancer or its associated symptoms, collectively referred to as "anti-cancer agents"). Anti-cancer agents may be, for example, chemotherapeutic agents or targeted therapeutic agents. Such agents are known in the art.

[0668] Anticancer agents include mitotic inhibitors, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, alkylating agents, antimetabolites, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodophyllotoxins, antibiotics, L-asparaginase, topoisomerase inhibitors, interferons, platinum coordination complexes, anthracenedione substituted urea, methylhydrazine derivatives, adrenocortical inhibitors, adrenocortical steroids, progesterone, estrogen, antiestrogens, androgens, antiandrogens and gonadotropin-releasing hormone analogs. Other anticancer agents include leucovorin (LV), irinotecan, oxaliplatin, capecitabine, paclitaxel and docetaxel. In some embodiments, the one or more additional therapies include two or more anticancer agents. The two or more anticancer agents can be used in a mixture for combined administration or separate administration. Suitable dosing regimens for combined anticancer agents are known in the art and described in, for example, Saltz et al., Proc. Am. Soc. Clin. Oncol. 18: 233a (1999), and Douillard et al., Lancet 355 (9209): 1041-1047 (2000).

[0669] Other non-limiting examples of anticancer agents include (Imatinib Mesylate); (carfilzomib); (bortezomib); Casodex (bicalutamide); (gefitinib); alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa and uredopa; ethyleneimines and methylmelamines including altretamine, triethylenemelamine, triethylenephosphamide, triethylenethiophosphamide and trimethylolmelamine; polyacetyl groups (especially bullatacin and bullatacinone); camptothecins (including the synthetic analog topotecan); bryostatin; callystatin; CC-1065 (including its adolesin derivatives); the cyclohexane and cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; the cyclohexane derivatives thereof; oxide hydrochloride), melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine;Antibiotics, such as enediyne antibiotics (e.g., calicheamicins, such as calicheamicin γll and calicheamicin ωll (see, e.g., Agnew, Chem. Intl. Ed Engl. 33:183-186 (1994)); dynemicins, such as dynemicin A; bisphosphonates, such as clodronate; esperamicin; neocarzinostatin chromophores; chromophore and related chromophores, enediyne antibiotic chromophores, aclacinomysin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, calicheamicin, carabicin, caminomycin, carminomycin, carzinophilin, chromomycin s), dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, adriamycin (doxorubicin), morpholinodoxorubicin, cyanomorpholinodoxorubicin, 2-pyrrolinyl-doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid (mycophenolic acid), acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites, such as methotrexate and 5-fluorouracil (5-FU);Folic acid analogs, such as denopterin, pteropterin, trimetrexate; purine analogs, such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens, such as calusterone, dromostanolone propionate, propionate, epitiostanol, mepitiostane, testolactone; antiadreners, such as aminoglutethimide, mitotane, trilostane; folic acid supplements, such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; acetate; epothilones, such as epothilone B; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; maytansinoids, such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin;losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes, such as T-2 toxin, verracurin A, roridin A, A) and anguidine; urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, such as (paclitaxel), (Nanoparticulate formulation of albumin-engineered paclitaxel without polyoxyethylene hydrogenated castor oil) and (docetaxel); chloranbucil; tamoxifen (Nolvadex TM );raloxifene;aromatase inhibiting 4(5)-imidazole;4-hydroxytamoxifen;trioxifene;keoxifene;LY 117018;onapristone;toremifene Flutamide, nilutamide, bicalutamide, leuprolide, goserelin; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; platinum coordination complexes, such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; (vinorelbine); novantrone; teniposide; edatrexate; daunomycin; aminopterin; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; esperamicins; capecitabine (e.g., ); and a pharmaceutically acceptable salt of any one of the foregoing.

[0670] Additional non-limiting examples of anticancer agents include trastuzumab Bevacizumab Cetuximab (cetuximabv) Rituximab ABVD, avicine, abagovomab, acridine carboxamide, adecatumumab, 17-N-allylamino-17-demethoxygeldanamycin, alpharadin, alvocidib, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, amonafide, anthracenedione, anti-CD22 immunotoxin, anti-tumor agents (e.g., cell cycle non-specific anti-tumor agents and other anti-tumor agents described herein), anti-tumorigenic herbal medicine, apaziquone, atiprimod, azathioprine, belotecan, bendamustine, BIBW 2992, biricodar, brostallicin, bryostatin, buthionine sulfoximinesulfoximine), CBV (chemotherapy), calyculin, dichloroacetic acid, discormolide, elsamitrucin, enocitabine, eribulin, exatecan, exisulind, ferruginol, forodesine, fosfestrol, ICE chemotherapy regimen, IT-101, imexon, imiquimod, indolocarbazole, irofulven, laminoguida aniquidar, larotaxel, lenalidomide, lucanthone, lurtotecan, mafosfamide, mitozolomide, nafoxidine, nedaplatin, olaparib, ortataxel, PAC-1, papaya, pixantrone, proteasome inhibitors, rebeccamycin, resiquimod, rubitecan, SN-38, salinosporamide A), sapacitabine, Stanford V, swainsonine, talaporfin, tariquidar, tegafur-uracil, temodar, tesetaxel, triplatin tetranitrate, tris(2-chloroethyl)amine, troxacitabine, uramustine, vadimezan, vinflunine, ZD6126, and zosuquidar.

[0671] Other non-limiting examples of anticancer agents include natural products such as vinca alkaloids (e.g., vinblastine, vincristine, and vinorelbine), epipodophyllotoxins (e.g., etoposide and teniposide), antibiotics (e.g., dactinomycin / actinomycin D), daunomycin, and idarubicin), anthracyclines, mitoxantrone, bleomycin, plicamycin (mithramycin), mitomycins, enzymes (e.g., L-asparaginase, which systemically metabolizes L-asparagine and removes cells that cannot synthesize asparagine themselves), antiplatelet agents, antiproliferative / antimitotic alkylating agents such as nitrogen mustards (e.g., methyl mustard, cyclophosphamide and analogs, melphalan, and chlorambucil), ethyleneimine and methylmelamines (e.g., hexamethylmelamine and thiotepa), CDK inhibitors (e.g., CDK4 / 6 inhibitors, such as abemaciclib, ribociclib, palbociclib, seliciclib, UCN-01, P1446A-05, PD-0332991, dinaciclib, P27-00, AT-7519, RGB286638, and SCH727965), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine (BCNU) and the like,and streptozocin), trazenes-dacarbazinine (DTIC), antiproliferative / antimitotic antimetabolites (e.g., folic acid analogs), pyrimidine analogs (e.g., fluorouracil, azathiouracil, and cytarabine), purine analogs and related inhibitors (e.g., mercaptopurine, thioguanine, pentostatin, and 2-chlorodeoxyadenosine), aromatase inhibitors (e.g., anastrozole, exemestane, and letrozole), and platinum coordination complexes (e.g., cisplatin and carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide, histone deacetylase (HDAC) inhibitors (e.g., trichostatin, sodium butyrate, apicidan, suberoyl anilide hydroamic acid, acid, vorinostat, belinostat, LBH 589, romidepsin, ACY-1215, and panobinostat), mTOR inhibitors (e.g., vistusertib, temsirolimus, everolimus, ridaforolimus, and sirolimus), KSP (Eg5) inhibitors (e.g., Array 520), DNA binding agents (e.g., ), PI3K inhibitors such as PI3Kδ inhibitors (e.g., GS-1101 and TGR-1202), (PI3Kδ and γ inhibitors (e.g., CAL-130), copanlisib, alpelisib, and idelalisib; multikinase inhibitors (e.g., TG02 and sorafenib), hormones (e.g., estrogens), and hormone agonists, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., goserelin, leuprorelin, olide and triptorelin), BAFF neutralizing antibodies (e.g., LY2127399), IKK inhibitors, p38 MAPK inhibitors, anti-IL-6 (e.g., CNT0328), telomerase inhibitors (e.g., GRN163L), Aurora kinase inhibitors (e.g., MLN8237), cell surface monoclonal antibodies (e.g., anti-CD38 (HUMAX-CD38)), anti-CS1 (e.g., elotuzumab), HSP90 inhibitors (e.g., 17AAG and KOS 953), P13K / Akt inhibitors (e.g., perifosine), Akt inhibitors (e.g., GSK-2141795), PKC inhibitors (e.g., enzastaurin), FTIs (e.g., Zarnestra TM ), anti-CD138 (e.g. BT062), Torcl / 2 specific kinase inhibitors (e.g. INK128), ER / UPR targeting agents (e.g. MKC-3946), cFMS inhibitors (e.g. ARRY-382), JAK1 / 2 inhibitors (e.g. CYT387), PARP inhibitors (e.g. olaparib and veliparib (ABT-888)), and BCL-2 antagonists.

[0672] In some embodiments, the anticancer agent is selected from the group consisting of mechlorethamine, camptothecin, ifosfamide, tamoxifen, raloxifene, gemcitabine, Sorafenib or any analog or derivative variant thereof.

[0673] In some embodiments, the anticancer agent is a HER2 inhibitor. HER2 inhibitors are known in the art. Non-limiting examples of HER2 inhibitors include monoclonal antibodies, such as trastuzumab and pertuzumab Small molecule tyrosine kinase inhibitors, such as gefitinib Erlotinib Pilitinib, CP-654577, CP-724714, canertinib (CI1033), HKI-272, lapatinib (GW-572016; ), PKI-166, AEE788, BMS-599626, HKI-357, BIBW 2992, ARRY-334543, and JNJ-26483327.

[0674] In some embodiments, the anticancer agent is an ALK inhibitor. ALK inhibitors are known in the art. Non-limiting examples of ALK inhibitors include ceritinib, TAE-684 (NVP-TAE694), PF02341066 (crizotinib or 1066), alectinib; brigatinib; entrectinib; ensartinib (X-396); lorlatinib; ASP3026; CEP-37440; 4SC-203; TL-398; PLB1003; TSR-011; CT-707; TPX-0005; and AP26113. Additional examples of ALK kinase inhibitors are described in Examples 3-39 of WO05016894.

[0675] In some embodiments, the anticancer agent is an inhibitor of a receptor tyrosine kinase (RTK) / growth factor receptor downstream member (e.g., a SHP2 inhibitor (e.g., SHP099, TNO155, RMC-4550, RMC-4630, JAB-3068, JAB-3312, RLY-1971, ERAS-601, SH3809, PF-07284892, or BBP-398) or a pharmaceutically acceptable salt, solvate, isomer (e.g., stereoisomer ), prodrugs or tautomers), SOS1 inhibitors (e.g., BI-1701963, BI-3406, SDR5, BAY-293 or RMC-5845 or pharmaceutically acceptable salts, solvates, isomers (e.g., stereoisomers), prodrugs or tautomers thereof), Raf inhibitors, MEK inhibitors, ERK inhibitors, PI3K inhibitors, PTEN inhibitors, AKT inhibitors or mTOR inhibitors (e.g., mTORC1 inhibitors or mTORC2 inhibitors). In some embodiments, the anticancer agent is JAB-3312.

[0676] In some embodiments, the anticancer agent is a SOS1 inhibitor. SOS1 inhibitors are known in the art. In some embodiments, the SOS1 inhibitor is selected from WO 2022146698, WO 2022081912, WO 2022058344, WO2022026465, WO 2022017519, WO 2021173524, WO 2021130731, WO 2021127429, WO2021092115, WO 2021105960, WO 2021074227, WO 2020180768, WO 2020180770, WO2020173935, WO 2020146470, WO 2019201848, WO 2019122129, WO 2018172250 and WO2018115380, or a pharmaceutically acceptable salt, solvate, isomer (eg, stereoisomer), prodrug or tautomer thereof. In some embodiments, the compounds of the present invention are used in combination with SOS1 inhibitors to treat K-Ras G13C cancer.

[0677] In some embodiments, the anticancer agent is an additional Ras inhibitor or a Ras vaccine or another therapeutic modality designed to directly or indirectly reduce the oncogenic activity of Ras. Such agents are known in the art. In some embodiments, the anticancer agent is an additional Ras inhibitor. In some embodiments, the Ras inhibitor targets Ras in its active state or GTP-bound state. In some embodiments, the Ras inhibitor targets Ras in an inactive state or GDP-bound state. In some embodiments, the Ras inhibitor is, for example, an inhibitor of K-Ras G12C, such as AMG 510, MRTX1257, MRTX849, JNJ-74699157, LY3499446, or ARS-1620, ARS-853, BPI-421286, LY3537982, JDQ443, JAB-21822, JAB-21000, IBI351, ERAS-3490, RMC-6291, or GDC-6036. In some embodiments, the Ras inhibitor is an inhibitor of K-Ras G12D, such as MRTX1133 or JAB-22000. In some embodiments, the Ras inhibitor is a K-Ras G12V inhibitor, such as JAB-23000. In some embodiments, the Ras inhibitor is RMC-6236. In some embodiments, the Ras inhibitor is selected from the Ras (ON) inhibitors (i.e., Ras in its GTP-bound state) disclosed in the following documents, which are incorporated herein by reference in their entirety, or pharmaceutically acceptable salts, solvates, isomers (e.g., stereoisomers), prodrugs, or tautomers thereof: WO 2021091982, WO 2021091967, WO 2021091956, and WO2020132597. Other examples of Ras inhibitors are known in the art, for example in the following documents, which are incorporated herein by reference in their entirety: WO 2022271658, WO 2022269508, WO 2022266167, WO 2022266069, WO 2022266015, WO 2022265974, WO 2022261154, WO 2022261154, WO 2022251576, WO2022251296, WO 2022237815, WO 2022232332, WO 2022232331, WO 2022232320, WO 2022232318, WO 2022223037, WO 2022221739, WO 2022221528、WO 2022221386、WO2022216762、WO 2022192794、WO 2022192790、WO 2022188729、WO2022187411、WO2022184178、WO 2022173870、WO 2022173678、WO 2022135346、WO 2022133731、WO2022133038、WO 2022133345、WO 2022132200、WO 2022119748、WO 2022109485、WO2022109487、WO 2022066805、WO 2022002102、WO 2022002018、WO 2021259331、WO2021257828、WO 2021252339、WO 2021248095、WO 2021248090, WO 2021248083, WO2021248082, WO 2021248079, WO 2021248055, WO 2021245051, WO 2021244603, WO2021239058, WO 2021231526, WO 2021228161, WO 2021219090, WO 2021219090, WO2021219072, WO 2021218939, WO 2021217019, WO 2021216770, WO 2021215545, WO2021215544, WO 2021211864, WO 2021190467、WO 2021185233、WO 2021180181、WO2021175199、2021173923、WO 2021169990、WO 2021169963、WO 2021168193、WO2021158071、WO 2021155716、WO 2021152149、WO 2021150613、WO 2021147967、WO2021147965、WO 2021143693、WO 2021142252、WO 2021141628、WO 2021139748、WO2021139678、WO 2021129824, WO 2021129820, WO 2021127404, WO 2021126816, WO2021126799, WO 2021124222, WO 2021121371, WO 2021121367, WO 2021121330, WO2020050890, WO 2020047192, WO 2020035031, WO 2020028706, WO 2019241157, WO2019232419, WO2019217691, WO 2019217307, WO 2019215203, WO 2019213526, WO2019213516, WO 2019155399, WO 2019150305, WO 2019110751, WO 2019099524, WO2019051291, WO 2018218070, WO 2018217651, WO 2018218071, WO 2018218069, WO2018206539, WO 2018143315, WO 2018140600, WO 2018140599, WO 2018140598, WO2018140514, WO 2018140513, WO 2018140512, WO 2018119183, WO 2018112420, WO2018068017, WO 2018064510, WO 2017201161, WO 2017172979, WO 2017100546, WO2017087528, WO 2017058807, WO 2017058805, WO 2017058728, WO 2017058902, WO2017058792, WO 2017058768, WO 2017058915, WO 2017015562, WO 2016168540, WO2016164675, WO 2016049568, WO 2016049524, WO 2015054572, WO 2014152588, WO2014143659 and WO 2013155223.

[0678] In some embodiments, the therapeutic agent that can be combined with the compounds of the invention is a MAP kinase (MAPK) pathway inhibitor (or "MAPK inhibitor"). Such agents are known in the art. MAPK inhibitors include, but are not limited to, one or more of the MAPK inhibitors described in Cancers (Basel) 2015 Sep; 7(3): 1758–1784. For example, the MAPK inhibitor can be selected from one or more of the following: trametinib, binimetinib, selumetinib, cobimetinib, LErafAON (NeoPharm), ISIS 5132; vemurafenib, pimasertib, TAK733, RO4987655 (CH4987655); CI-1040; PD-0325901; CH5126766; MAP855; AZD6244; refametinib (RDEA 119 / BAY 86-9766); GDC-0973 / XL581; AZD8330 (ARRY-424704 / ARRY-704); RO5126766 (Roche, described in PLoS One. 2014 Nov 25;9(11)); and GSK1120212 (or JTP-74057, described in Clin Cancer Res. 2011 Mar 1;17(5):989-1000). The MAPK inhibitor may be PLX8394, LXH254, GDC-5573 or LY3009120.

[0679] In some embodiments, the anticancer agent is a disruptor or inhibitor of the RAS-RAF-ERK or PI3K-AKT-TOR or PI3K-AKT signaling pathway. Such agents are known in the art. PI3K / AKT inhibitors may include, but are not limited to, one or more PI3K / AKT inhibitors described in Cancers (Basel) September 2015; 7(3): 1758–1784. For example, the PI3K / AKT inhibitor may be selected from one or more of the following: NVP-BEZ235; BGT226; XL765 / SAR245409; SF1126; GDC-0980; PI-103; PF-04691502; PKI-587; GSK2126458.

[0680] In some embodiments, the anticancer agent is a PD-1 or PD-L1 antagonist. Such agents are known in the art.

[0681] In some embodiments, additional therapeutic agents include ALK inhibitors, HER2 inhibitors, EGFR inhibitors, IGF-1R inhibitors, MEK inhibitors, PI3K inhibitors, AKT inhibitors, TOR inhibitors, MCL-1 inhibitors, BCL-2 inhibitors, SHP2 inhibitors, proteasome inhibitors and immunotherapy. In some embodiments, additional therapeutic agents include FGFR inhibitors, PARP inhibitors, BET inhibitors, PRMT5i inhibitors, MAT2A inhibitors, VEGF inhibitors and HDAC inhibitors. In some embodiments, the therapeutic agent may be a pan-RTK inhibitor, such as afatinib.

[0682] IGF-1R inhibitors are known in the art and include linsitinib or a pharmaceutically acceptable salt thereof.

[0683] EGFR inhibitors are known in the art and include, but are not limited to, small molecule antagonists, antibody inhibitors, or specific antisense nucleotides or siRNA. Useful antibody inhibitors of EGFR include cetuximab Panitumumab Zalutumumab, nimotuzumab and matuzumab. Other antibody-based EGFR inhibitors include any anti-EGFR antibody or antibody fragment that can partially or completely block the activation of EGFR by the natural ligand. Non-limiting examples of antibody-based EGFR inhibitors include Modjtahedi et al., Br. J. Cancer 1993, 67: 247-253; Teramoto et al., Cancer 1996, 77: 639-645; Goldstein et al., Clin. Cancer Res. 1995, 1: 1311-1318; Huang et al., 1999, Cancer Res. 15: 59 (8): 1935-40; and Yang et al., Cancer Res. 1999, 59: 1236-1243. The EGFR inhibitor may be the monoclonal antibody Mab E7.6.3 (Yang, 1999, supra) or MabC225 (ATCC Accession No. HB-8508), or an antibody or antibody fragment having binding specificity thereto.

[0684] Small molecule EGFR antagonists include gefitinib Erlotinib and lapatinib See, for example, Yan et al., Pharmacogenetics and Pharmacogenomics in Oncology Therapeutic Antibody Development, BioTechniques 2005, 39(4):565-8; and Paez et al., EGFR Mutations in Lung Cancer Correlation with Clinical Response to Gefitinib Therapy, Science 2004, 304(5676):1497-500. In some embodiments, the EGFR inhibitor is osimertinib. Other non-limiting examples of small molecule EGFR inhibitors include any of the EGFR inhibitors described in the following patent publications, and all pharmaceutically acceptable salts of such EGFR inhibitors: EP 0520722; EP 0566226; WO96 / 33980; U.S. Pat. No. 5,747,498; WO96 / 30347; EP 0787772; WO97 / 30034; WO97 / 30044; WO97 / 38994; WO97 / 49688; EP 837063; WO98 / 02434; WO97 / 38983; WO95 / 19774; WO95 / 19970; WO97 / 13771; WO98 / 02437; WO98 / 02438; WO97 / 32881; DE 19629652; WO98 / 33798; WO97 / 32880; WO97 / 32880; EP 682027; WO97 / 02266; WO97 / 27199; WO98 / 07726; WO97 / 34895; WO96 / 31510; WO98 / 14449; WO98 / 14450; WO98 / 14451; WO95 / 09847; WO97 / 19065; WO98 / 17662; U.S. Patent No. 5,789,427; U.S. Patent No. 5,650,415; U.S. Patent No. 5,656,643; WO99 / 35146; WO99 / 35132; WO99 / 07701; and WO92 / 20642. Other non-limiting examples of small molecule EGFR inhibitors include any EGFR inhibitor described in Traxler et al., Exp. Opin. Ther. Patents 1998, 8(12): 1599-1625. In some embodiments, the EGFR inhibitor is an ERBB inhibitor. In humans, the ERBB family contains HER1 (EGFR, ERBB1), HER2 (NEU, ERBB2), HER3 (ERBB3) and HER (ERBB4).

[0685] MEK inhibitors are known in the art and include, but are not limited to, pimasetinib, selumetinib, cobimetinib trametinib and bimetinib In some embodiments, the MEK inhibitor targets a MEK mutation that is a class I MEK1 mutation selected from the group consisting of D67N, P124L, P124S, and L177V. In some embodiments, the MEK mutation is a class II MEK1 mutation selected from the group consisting of ΔE51-Q58, ΔF53-Q58, E203K, L177M, C121S, F53L, K57E, Q56P, and K57N.

[0686] PI3K inhibitors are known in the art and include, but are not limited to, wortmannin; 17-hydroxywortmannin analogs described in WO06 / 044453; 4-[2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine (also known as pictilisib or GDC-0941 and described in WO09 / 036082 and WO09 / 055730); 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile (also known as BEZ 235 or NVP-BEZ235, and described in WO06 / 122806); (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one (described in WO08 / 070740); LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (available from Axon Medchem); PI 103 hydrochloride (3-[4-(4-morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol hydrochloride (available from Axon Medchem); PIK 75 (2-methyl-5-nitro-2-[(6-bromoimidazo[1,2-a]pyridin-3-yl)methylene]-1-methylhydrazide-benzenesulfonic acid monohydrochloride) (available from Axon Medchem); PIK 90 (N-(7,8-dimethoxy-2,3-dihydro-imidazo[1,2-c]quinazolin-5-yl)-nicotinamide (available from Axon Medchem); AS-252424 (5-[1-[5-(4-fluoro-2-hydroxy-phenyl)-furan-2-yl]-methyl-(Z)-ylidene]-thiazolidine-2,4-dione (available from Axon Medchem); Medchem); TGX-221 (7-methyl-2-(4-morpholinyl)-9-[1-(phenylamino)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one (available from Axon Medchem); XL-765; and XL-147.Other PI3K inhibitors include demethoxyviridin, perifosine, CAL101, PX-866, BEZ235, SF1126, INK1117, IPI-145, BKM120, XL147, XL765, Palomid 529, GSK1059615, ZSTK474, PWT33597, IC87114, TGI 00-115, CAL263, PI-103, GNE-477, CUDC-907, and AEZS-136.

[0687] AKT inhibitors are known in the art and include, but are not limited to, Akt-1-1 (inhibits Akt1) (Barnett et al., Biochem. J. 2005, 385(Pt. 2):399-408); Akt-1-1,2 (inhibits Ak1 and 2) (Barnett et al., Biochem. J. 2005, 385(Pt. 2):399-408); API-59CJ-Ome (e.g., Jin et al., Br. J. Cancer 2004, 91:1808-12); 1-H-imidazo[4,5-c]pyridinyl compounds (e.g., WO 05 / 011700); indole-3-methanol and its derivatives (e.g., U.S. Pat. No. 6,656,963; Sarkar and Li J et al., 2003); Nutr. 2004, 134(12 Suppl):3493S-3498S); perifosine (e.g., interferes with Akt membrane localization; Dasmahapatra et al., Clin. Cancer Res. 2004, 10(15):5242-52); phosphatidylinositol ether lipid analogs (e.g., Gills and Dennis Expert. Opin. Investig. Drugs 2004, 13:787-97); and triciribine (TCN or API-2 or NCI identifier: NSC 154020; Yang et al., Cancer Res. 2004, 64:4394-9).

[0688] mTOR inhibitors are known in the art and include, but are not limited to, ATP-competitive mTORC1 / mTORC2 inhibitors, such as PI-103, PP242, PP30; Torin 1; FKBP12 enhancers; 4H-1-benzopyran-4-one derivatives; and rapamycin (also known as sirolimus) and its derivatives, including: temsirolimus Everolimus ( WO94 / 09010); deforolimus (also known as deforolimus or AP23573); rapamycin analogs (rapalogs), such as those disclosed in WO98 / 02441 and WO01 / 14387, such as AP23464 and AP23841; 40-(2-hydroxyethyl)rapamycin; 40-[3-hydroxy(hydroxymethyl)methylpropionate]-rapamycin (also known as CC1779); 40-epi-(tetrazolyl)-rapamycin (also known as ABT578); 32-deoxyrapamycin; 16-pentynyloxy-32(S)-dihydrorapamycin; derivatives disclosed in WO05 / 005434; U.S. Pat. No. 5,614,877; No. 5,258,389, No. 5,118,677, No. 5,118,678, No. 5,100,883, No. 5,151,413, No. 5,120,842 and No. 5,256,790, as well as derivatives disclosed in WO94 / 090101, WO92 / 05179, WO93 / 111130, WO94 / 02136, WO94 / 02485, WO95 / 14023, WO94 / 02136, WO95 / 16691, WO96 / 41807, WO96 / 41807 and WO2018204416; and phosphorus-containing rapamycin derivatives (e.g., WO05 / 016252). In some embodiments, the mTOR inhibitor is a bisteric inhibitor (see, e.g., WO2018204416, WO2019212990, and WO2019212991), such as RMC-5552, which has the structure:

[0689]

[0690] BRAF inhibitors that can be used in combination with the compounds of the present invention are known in the art and include, for example, vemurafenib, dabrafenib, and encorafenib. BRAF may include a Class 3 BRAF mutation. In some embodiments, a Class 3 BRAF mutation is selected from one or more of the following amino acid substitutions in human BRAF: D287H; P367R; V459L; G466V; G466E; G466A; S467L; G469E; N581S; N581I; D594N; D594G; D594A; D594H; F595L; G596D; G596R; and A762E.

[0691] MCL-1 inhibitors are known in the art and include, but are not limited to, AMG-176, MIK665, and S63845. Myeloid cell leukemia-1 (MCL-1) protein is one of the key anti-apoptotic members of the B-cell lymphoma-2 (BCL-2) protein family. Overexpression of MCL-1 is closely associated with tumor progression and resistance to not only traditional chemotherapy but also targeted therapeutics including BCL-2 inhibitors such as ABT-263.

[0692] In some embodiments, the additional therapeutic agent is a SHP2 inhibitor. SHP2 is known in the art. SHP2 is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that contributes to a variety of cellular functions, including proliferation, differentiation, cell cycle maintenance and migration. SHP2 has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP) and a C-terminal tail. The two SH2 domains control the subcellular localization and functional regulation of SHP2. The molecule exists in an inactive, self-inhibitory conformation stabilized by a binding network involving residues from the N-SH2 and PTP domains. Stimulation with, for example, cytokines or growth factors that act through receptor tyrosine kinases (RTKs) can cause exposure of the catalytic site, leading to enzyme activation of SHP2.

[0693] SHP2 is involved in signal transduction via RAS-mitogen-activated protein kinase (MAPK), i.e., JAK-STAT or phosphoinositide 3-kinase-AKT pathways. Mutations in the PTPN11 gene and subsequently in SHP2 have been identified in several human developmental diseases, such as Noonan Syndrome and Leopard Syndrome, and human cancers, such as juvenile myelomonocytic leukemia, neuroblastoma, melanoma, acute myeloid leukemia, and breast, lung and colon cancers. Some of these mutations destabilize the autoinhibitory conformation of SHP2 and promote self-activation or enhanced growth factor-driven activation of SHP2. Therefore, SHP2 represents a particularly noteworthy target for the development of novel therapies for the treatment of various diseases including cancer. It has been shown that the combination of SHP2 inhibitors (e.g., RMC-4550 or SHP099) and RAS pathway inhibitors (e.g., MEK inhibitors) can inhibit the proliferation of multiple cancer cell lines (e.g., pancreatic cancer, lung cancer, ovarian cancer and breast cancer) in vitro. Therefore, combination therapy involving SHP2 inhibitors and RAS pathway inhibitors may be a general strategy for preventing tumor resistance in a variety of malignancies.

[0694] Comprehensive practical examples of SHP2 suppression in this area: Chen et al., MolPharmacol.2006, 70, 562; Sarver et al., J.Med.Chem.2017, 62, 179 3; 20222084008, WO 2022135568, WO 2021176072, WO 2021171261, WO2021149817, WO 2021148010, WO 2021147879, WO 2021143823, WO 2021143701, WO2021143680, WO 2021121397, WO 2021119525, WO 2021115286, WO 2021110796, WO2021088945, WO 2021073439, WO 2021061706, WO 2021061515, WO 2021043077, WO2021033153, WO 2021028362, WO 2021033153, WO 2021028362, WO 2021018287, WO2020259679, WO 2020249079, WO 2020210384, WO 2020201991, WO 2020181283, WO2020177653, WO 2020165734, WO 2020165733, WO 2020165732, WO 2020156243, WO2020156242, WO 2020108590, WO 2020104635, WO 2020094104, WO 2020094018, WO2020081848, WO 2020073949, WO 2020073945, WO 2020072656, WO 2020065453, WO2020065452, WO 2020063760, WO 2020061103, WO 2020061101, WO 2020033828, WO2020033286, WO 2020022323, WO 2019233810, WO 2019213318, WO 2019183367, WO2019183364, WO 2019182960, WO 2019167000, WO 2019165073, WO2019158019、WO2019152454、WO 2019051469、WO 2019051084、WO 2018218133、WO 2018172984、WO2018160731、WO 2018136265、WO 2018136264、WO 2018130928、WO 2018129402、WO2018081091、WO 2018057884、WO 2018013597、WO 2017216706、WO 2017211303、WO2017210134、WO 2017156397、WO 2017100279、WO 2017079723、WO 2017078499、WO2016203406、WO 2016203405、WO 2016203404、WO 2016196591、WO 2016191328、WO2015107495、WO 2015107494、WO 2015107493、WO 2014176488、WO 2014113584, US20210085677, US10858359, US10934302, US10954243, US10988466, US11001561, US11033547, US11034705 or US11044675, or a pharmaceutically acceptable salt, solvate, isomer (e.g., stereoisomer), prodrug or tautomer thereof, each of which is incorporated herein by reference.

[0695] In some embodiments, the SHP2 inhibitor binds to the active site. In some embodiments, the SHP2 inhibitor is a mixed irreversible inhibitor. In some embodiments, the SHP2 inhibitor binds to an allosteric site, such as a non-covalent allosteric inhibitor. In some embodiments, the SHP2 inhibitor is a covalent SHP2 inhibitor, such as an inhibitor targeting a cysteine ​​residue (C333) located outside the phosphatase active site. In some embodiments, the SHP2 inhibitor is a reversible inhibitor. In some embodiments, the SHP2 inhibitor is an irreversible inhibitor. In some embodiments, the SHP2 inhibitor is SHP099. In some embodiments, the SHP2 inhibitor is TNO155, which has the structure:

[0696] or a pharmaceutically acceptable salt, solvate, isomer (e.g., stereoisomer), prodrug, or tautomer thereof. In some embodiments, the SHP2 inhibitor is RMC-4550. In some embodiments, the SHP2 inhibitor is RMC-4630, which has the structure:

[0697] or a pharmaceutically acceptable salt, solvate, isomer (e.g., stereoisomer), prodrug, or tautomer thereof. In some embodiments, the SHP2 inhibitor is JAB-3068, which has the structure:

[0698]

[0699] or a pharmaceutically acceptable salt, solvate, isomer (e.g., stereoisomer), prodrug, or tautomer thereof. In some embodiments, the SHP2 inhibitor is JAB-3312. In some embodiments, the SHP2 inhibitor is the following compound,

[0700]

[0701] or a pharmaceutically acceptable salt, solvate, isomer (e.g., stereoisomer), prodrug, or tautomer thereof. In some embodiments, the SHP2 inhibitor is RLY-1971, which has the structure

[0702]

[0703] or a pharmaceutically acceptable salt, solvate, isomer (e.g., stereoisomer), prodrug, or tautomer thereof. In some embodiments, the SHP2 inhibitor is ERAS-601. In some embodiments, the SHP2 inhibitor is BBP-398.

[0704] In some embodiments, the additional therapeutic agent is selected from the group consisting of: MEK inhibitors, HER2 inhibitors, SHP2 inhibitors, CDK4 / 6 inhibitors, mTOR inhibitors, SOS1 inhibitors, and PD-L1 inhibitors. In some embodiments, the additional therapeutic agent is selected from the group consisting of: MEK inhibitors, SHP2 inhibitors, and PD-L1 inhibitors. See, for example, Hallin et al., Cancer Discovery, DOI: 10.1158 / 2159-8290 (October 28, 2019) and Canon et al., Nature, 575: 217 (2019). In some embodiments, the Ras inhibitor of the present invention is used in combination with a MEK inhibitor and a SOS1 inhibitor. In some embodiments, the Ras inhibitor of the present invention is used in combination with a PD-L1 inhibitor and a SOS1 inhibitor. In some embodiments, the Ras inhibitor of the present invention is used in combination with a PD-L1 inhibitor and a SHP2 inhibitor. In some embodiments, the Ras inhibitor of the present invention is used in combination with a MEK inhibitor and a SHP2 inhibitor. In some embodiments, the Ras inhibitors of the present invention are used in combination with a SHP2 inhibitor and a Ras inhibitor that inhibits multiple Ras isoforms and / or mutants (e.g., RMC-6236). In some embodiments, the cancer is lung cancer, and the treatment comprises administering a Ras inhibitor of the present invention in combination with a second or third therapeutic agent, such as a SHP2 inhibitor, and a Ras inhibitor that inhibits multiple Ras isoforms and / or mutants. In some embodiments, the cancer is colorectal cancer, and the treatment comprises administering a Ras inhibitor of the present invention in combination with a second or third therapeutic agent, such as a SHP2 inhibitor, and a Ras inhibitor that inhibits multiple Ras isoforms and / or mutants. In some embodiments, the Ras inhibitors of the present invention are used in combination with immunotherapy, optionally in combination with chemotherapeutic agents.

[0705] Proteasome inhibitors are known in the art and include, but are not limited to, carfilzomib. Bortezomib and oprozomib.

[0706] Immunotherapies include, but are not limited to, monoclonal antibodies, immunomodulatory imides (IMiDs), GITR agonists, genetically engineered T cells (e.g., CAR-T cells), bispecific antibodies (e.g., BiTEs), and anti-PD-1 agents, anti-PD-L1 agents, anti-CTLA4 agents, anti-LAG1 agents, and anti-OX40 agents). Other immunotherapies are known in the art.

[0707] Immunomodulators (IMiDs) are a class of immunomodulatory drugs (drugs that modulate immune responses) that contain an imide group. IMiDs include thalidomide and its analogs (lenalidomide, pomalidomide, and apremilast).

[0708] Exemplary anti-PD-1 antibodies and methods of use thereof are described in Goldberg et al., Blood 2007, 110(1):186-192; Thompson et al., Clin. Cancer Res. 2007, 13(6):1757-1761; and WO06 / 121168A1), and are also described elsewhere herein.

[0709] FGFR inhibitors are known in the art, such as pemigatinib and erdafitinib, including FGFR2 inhibitors and FGFR4 inhibitors. See, for example, Cancers (Basel), June 2021; 13(12):2968.

[0710] BET inhibitors are known in the art, such as romidepsin, panobinostat and belinostat. See, for example, British J. Cancer 124: 1478 (2021).

[0711] PRMT5i inhibitors are known in the art, such as PF-0693999, PJ-68, and MRTX1719. See, e.g., Biomed. Pharmacotherapy 144: 112252 (2021).

[0712] MAT2A inhibitors are known in the art, such as AG-270 and IDE397. See, for example, Exp Opin Ther Patents (2022) DOI: 10.1080 / 13543776.2022.2119127.

[0713] GITR agonists include, but are not limited to, GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies), such as the GITR fusion proteins described in U.S. Pat. No. 6,111,090, U.S. Pat. No. 8,586,023, WO2010 / 003118, and WO2011 / 090754; or such as U.S. Pat. No. 7,025,962, EP 1947183, U.S. Pat. No. 7,812,135; U.S. Pat. No. 8,388,967; U.S. Pat. No. 8,591,886; U.S. Pat. No. 7,618,632, EP1866339 and anti-GITR antibodies described in WO2011 / 028683, WO2013 / 039954, WO05 / 007190, WO07 / 133822, WO05 / 055808, WO99 / 40196, WO01 / 03720, WO99 / 20758, WO06 / 083289, WO05 / 115451 and WO2011 / 051726.

[0714] Another example of a therapeutic agent that can be used in combination with the compounds of the present invention is an anti-angiogenic agent. Anti-angiogenic agents are known in the art and include, but are not limited to, chemical compositions, antibodies, antigen binding regions, radionuclides, and combinations and conjugates thereof prepared by in vitro synthesis. Anti-angiogenic agents can be agonists, antagonists, allosteric modulators, toxins, or more generally can be used to inhibit or stimulate their targets (e.g., receptor or enzyme activation or inhibition), and thereby promote cell death or cell growth arrest. In some embodiments, the one or more additional therapies include anti-angiogenic agents.

[0715] Anti-angiogenic agents can be MMP-2 (matrix metalloproteinase 2) inhibitors, MMP-9 (matrix metalloproteinase 9) inhibitors and COX-II (cyclooxygenase 11) inhibitors. Non-limiting examples of anti-angiogenic agents include rapamycin, temsirolimus (CCI-779), everolimus (RAD001), sorafenib, sunitinib and bevacizumab. Examples of useful COX-II inhibitors include alecoxib, valdecoxib and rofecoxib. Examples of useful matrix metalloproteinase inhibitors are described in WO96 / 33172, WO96 / 27583, WO98 / 07697, WO98 / 03516, WO98 / 34918, WO98 / 34915, WO98 / 33768, WO98 / 30566, WO90 / 05719, WO99 / 52910, WO99 / 52889, WO99 / 29667, WO99007675, EP0606046, EP0780386, EP1786785, EP1181017, EP0818442, EP1004578 and US20090012085, and U.S. Pat. Nos. 5,863,949 and 5,861,510. Preferred MMP-2 and MMP-9 inhibitors are those with little or no MMP-1 inhibitory activity. More preferred are inhibitors that selectively inhibit MMP-2 or AMP-9 relative to other matrix metalloproteinases (i.e., MAP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13). Some specific examples of MMP inhibitors are AG-3340, RO 32-3555, and RS13-0830.

[0716] Other exemplary anti-angiogenic agents include KDR (kinase domain receptor) inhibitors (e.g., antibodies and antigen binding regions that specifically bind to kinase domain receptors), anti-VEGF agents (e.g., antibodies or antigen binding regions that specifically bind to VEGF (e.g., bevacizumab) or soluble VEGF receptors or their ligand binding regions), such as VEGF-TRAP TM , and anti-VEGF receptor agents (e.g., antibodies or antigen binding regions that specifically bind to VEGF receptors), VEGF inhibitors, EGFR inhibitors (e.g., antibodies or antigen binding regions that specifically bind to EGFR), e.g. (panitumumab), erlotinib Anti-Ang1 agents and anti-Ang2 agents (e.g., antibodies or antigen binding regions that specifically bind to Angl and Ang2 or their receptors, such as Tie2 / Tek), and anti-Tie2 kinase inhibitors (e.g., antibodies or antigen binding regions that specifically bind to Tie2 kinase). Other anti-angiogenic agents include Campath, IL-8, B-FGF, Tek antagonists (US2003 / 0162712; US6,413,932), anti-TWEAK agents (e.g., antibodies or antigen binding regions that specifically bind, or soluble TWEAK receptor antagonists; see US6,727,225), ADAM disintegrin domains that antagonize the binding of integrins to their ligands (US2002 / 0042368), anti-eph receptor or anti-dactyl antibodies or anti-peptide receptors that specifically bind. The invention relates to a PDGF-BB antagonist (e.g., an antibody or antigen binding region that specifically binds to a PDGF-BB ligand) and a PDGFR kinase inhibitor (e.g., an antibody or antigen binding region that specifically binds to a PDGFR kinase). Additional anti-angiogenic agents include: SD-7784 (Pfizer, USA); cilengitide (Merck KGaA, Germany, EPO 0770622); pegaptaniboctasodium (Gilead Sciences, USA); Alphastatin (BioActa, UK); M-PGA (Celgene, USA, US 5712291); ilomastat (Arriva, USA, US 5892112); emaxanib (Pfizer, USA, US 5792783); vatalanib (Novartis, Switzerland); 2-methoxyestradiol (EntreMed, USA); TLC ELL-12 (Elan, Ireland); anecortave acetate (Alcon, USA); α-D148 Mab (Amgen, USA); CEP-7055 (Cephalon, USA); anti-Vn Mab (Crucell, Netherlands), DAC anti-angiogenic agent (ConjuChem, Canada); Angiocidin (InKine Pharmaceutical, USA);KM-2550 (Kyowa Hakko, Japan); SU-0879 (Pfizer, USA); CGP-79787 (Novartis, Switzerland, EP 0970070); ARGENT technology (Ariad, USA); YIGSR-Stealth (Johnson & Johnson, USA); fibrinogen-E fragment (BioActa, UK); angiogenesis inhibitor (Trigen, UK); TBC-1635 (Encysive Pharmaceuticals, USA); SC-236 (Pfizer, USA); ABT-567 (Abbott, USA); Metastatin (EntreMed, USA); maspin (Sosei, Japan); 2-methoxyestradiol (Oncology Sciences Corporation, USA); ER-68203-00 (IV AX, USA); BeneFin (Lane Labs, USA); Tz-93 (Tsumura, Japan); TAN-1120 (Takeda, Japan); FR-111142 (Fujisawa, Japan, JP 02233610); platelet factor 4 (RepliGen, USA, EP 407122); vascular endothelial growth factor antagonist (Borean, Denmark); bevacizumab (pINN) (Genentech, USA); angiogenesis inhibitor (SUGEN, USA); XL 784 (Exelixis, USA); XL 647 (Exelixis, USA); second-generation α5β3 integrin MAb (Applied Molecular Evolution, USA and Medlmmune, USA); enzastaurin hydrochloride (Lilly, USA); CEP 7055 (Cephalon, USA and Sanofi-Synthelabo, France); BC1 (Genoa Institute of Cancer Research, Italy); rBPI 21 and BPI-derived antiangiogenic agents (XOMA, USA); PI 88 (Progen, Australia); Cilengitide (Merck KGaA, Germany; Munich Technical University, Germany, Scripps Clinic and Research Foundation, USA);AVE8062 (Ajinomoto, Japan); AS1404 (Cancer Research Laboratory, New Zealand); SG 292, (Telios, USA); endostatin (Endostatin) (Boston Childrens Hospital, USA); ATN 161 (Attenuon, USA); 2-methoxyestradiol (Boston Childrens Hospital, USA); ZD 6474 (AstraZeneca, UK); ZD 6126 (Angiogene Pharmaceuticals, UK); PPI 2458 (Praecis, USA); AZD 9935 (AstraZeneca, UK); AZD 2171, (AstraZeneca, UK); vatalanib (pINN) (Novartis, Switzerland and Schering AG, Germany); tissue factor pathway inhibitor (EntreMed, USA); pegaptanib (Pinn) (Gilead Sciences, USA); xanthorrhizol (Yonsei University, South Korea); gene-based VEGF-2 vaccine (Scripps Clinic and Research Foundation, USA); SPV5.2, (Supratek, Canada); SDX 103 (University of California, San Diego, USA); PX478 (ProlX, USA); METASTATIN (EntreMed, USA); troponin I (Harvard University, USA); SU6668 (SUGEN, USA); OXI 4503 (OXiGENE, USA); o-guanidine (Dimensional Pharmaceuticals, USA); motuporamine C (British Columbia University, Canada); CDP 791 (Celltech Group, UK); atiprimod (pINN) (GlaxoSmithKline, UK); E 7820 (Eisai, Japan); CYC 381 (Harvard University, USA); AE 941 (Aeterna, Canada); angiogenesis vaccine (EntreMed, USA);Urokinase plasminogen activator inhibitor (Dendreon, USA); oglufanide (pINN) (Melmotte, USA); HIF-1α inhibitor (Xenova, UK); CEP 5214 (Cephalon, USA); BAY RES2622 (Bayer, Germany); angustin (InKine, USA); A6 (Angstrom, USA); KR31372 (Korea Research Institute of Chemical Technology, South Korea); GW 2286 (GlaxoSmithKline, UK); EHT 0101 (ExonHit, France); CP 868596 (Pfizer, USA); CP 564959 (OSI, USA); CP 547632 (Pfizer, USA); 786034 (GlaxoSmithKline, UK); KRN 633 (Kirin Brewery, Japan); drug delivery system, intraocular 2-methoxyestradiol; anginex (Maastricht University, Netherlands, and Minnesota University, USA); ABT 510 (Abbott, USA); AAL993 (Novartis, Switzerland); VEGI (ProteomTech, USA); tumor necrosis factor-α inhibitor; SU 11248 (Pfizer, USA and SUGEN USA); ABT 518 (Abbott, USA); YH16 (Yantai Rongchang, China); S-3APG (Boston Childrens Hospital, USA and EntreMed, USA); MAb, KDR (ImClone Systems, USA); MAb, α5β (Protein Design, USA); KDR kinase inhibitor (Celltech Group, UK and Johnson & Johnson, USA); GFB 116 (South Florida University, USA and Yale University, USA); CS706 (Sankyo, Japan); combretastatin A4 prodrug (Arizona State University, USA); chondroitinase AC (IBEX, Canada);BAY RES 2690 (Bayer, Germany); AGM 1470 (Harvard University, USA, Takeda, Japan, and TAP, USA); AG 13925 (Agouron, USA); tetrathiomolybdate (University of Michigan, USA); GCS 100 (Wayne State University, USA); CV 247 (Ivy Medical, UK); CKD 732 (Chong Kun Dang, South Korea); irsogladine (Nippon Shinyaku, Japan); RG 13577 (Aventis, France); WX 360 (Wilex, Germany); squalamine (Genaera, USA); RPI 4610 (Sirna, USA); heparinase inhibitor (InSight, Israel); KL 3106 (Kolon, South Korea); Honokiol (Emory University, USA); ZK CDK (Schering AG, Germany); ZK Angio (Schering AG, Germany); ZK 229561 (Novartis, Switzerland, and Schering AG, Germany); XMP 300 (XOMA, USA); VGA 1102 (Taisho, Japan); VE-cadherin-2 antagonist (ImClone Systems, USA); Vasostatin (National Institutes of Health, USA); Flk-1 (ImClone Systems, USA); TZ 93 (Tsumura, Japan); TumStatin (Beth Israel Hospital, USA); truncated soluble FLT1 (vascular endothelial growth factor receptor 1) (Merck & Co, USA); Tie-2 ligand (Regeneron, USA); and thrombin 1 inhibitor (Allegheny Health, Education and Research Foundation, USA). ;

[0717] Other examples of therapeutic agents that can be used in combination with the compounds of the invention include agents (e.g., antibodies, antigen binding regions, or soluble receptors) that specifically bind to and inhibit the activity of growth factors, such as antagonists of hepatocyte growth factor (HGF, also known as Scatter Factor), and antibodies or antigen binding regions that specifically bind to the receptor c-Met. Such agents are known in the art.

[0718] Another example of a therapeutic agent that can be used in combination with the compounds of the present invention is an autophagy inhibitor. Autophagy inhibitors are known in the art and include, but are not limited to, chloroquine, 3-methyladenine, hydroxychloroquine (Plaquenil TM ), bafilomycin A1, 5-amino-4-imidazolecarboxamide riboside (AICAR), soft sponge acid, autophagy inhibitory algae toxins that inhibit type 2A or type 1 protein phosphatases, cAMP analogs, and drugs that increase cAMP levels, such as adenosine, LY204002, N6-mercaptopurine riboside, and vincristine. In addition, antisense or siRNA that inhibits the expression of proteins including but not limited to ATG5 (involved in autophagy) can also be used. In some embodiments, the one or more additional therapies include autophagy inhibitors.

[0719] Another example of a therapeutic agent that can be used in combination with the compounds of the present invention is an anti-neoplastic agent, which is known in the art. In some embodiments, the one or more additional therapies include an anti-neoplastic agent. Non-limiting examples of anti-tumor agents include acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, hexamethylmelamine, amifostine, amrubicin, amsacrine, anagrelide, anastrozole, ancer, ancestim, arglabin, arsenic trioxide, BAM-002 (Novelos), bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabineocfosfate, DA 3030 (Dong-A), daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docosanol, doxercalciferol, doxifluridine, doxorubicin, bromocriptine, carmustine, cytarabine, fluorouracil, HIT diclofenac, interferon α, daunorubicin, doxorubicin, tretinoin, edelfosine, edrecolomab, eflornithine, emitefur, epirubicin, epoetin beta), etoposide phosphate, exemestane, exisulind, fadrozole, filgrastim, finasteride, fludarabine phosphatephosphate), formestane, fotemustine, gallium nitrate, gemcitabine, gemtuzumab zogamicin, gimeracil / oteracil / tegafur combination, glycopine, goserelin, heptaplatin, human chorionic gonadotropin, human fetal alpha-fetoprotein, ibandronic acid acid), idarubicin, imiquimod, interferon alpha, natural interferon alpha, interferon alpha-2, interferon alpha-2a, interferon alpha-2b, interferon alpha-Nl, interferon alpha-n3, composite interferon-1, natural interferon alpha, interferon beta, interferon beta-la, interferon beta-lb, interferon gamma, natural interferon gamma-la, interferon gamma-lb, interleukin-1β, iobenguane, irinotecan, irsogladine, lanreotide, LC 9018 (Yakult), leflunomide, lenograstim, lentinan sulfate, letrozole, interferon alpha, leuprolide, levamisole + fluorouracil, liarozole, lobaplatin, lonidamine, lovastatin, masoprocol, melarsoprol, metoclopramide metoclopramide), mifepristone, miltefosine, mirimostim, mismatched double-stranded RNA, mitoguanidine, dibromodulanol, mitoxantrone, molgramostim, nafarelin, naloxone + pentazocine, nartograstim, nedaplatin, nilutamide, noscapine, new erythropoiesis stimulating protein, NSC 631570, octreotide, oprelvekin, osaterone, oxaliplatin, paclitaxel, pamidronate, pegaspargase, peginterferon α-2b, pentosan polysulfate sodiumsodium), pentostatin, picibanil, birubicin, rabbit anti-thymocyte polyclonal antibody, peginterferon alpha-2a, porfimer sodium, raloxifene, raltitrexed, rasburiembodiment, etidronate rhenium Re 186, RII retinamide, rituximab, romurtide, samarium 153Sm lexidronam, sargramostim, sizofiran, sobuzoxane, sonermin, strontium chloride-89, suramin, tasonermin, tazarotene, tegafur, temoporfin, temozolomide, teniposide, tetrachlorodecaoxide, thalidomide, thymalfasin, thyrotropin alfa, topotecan, toremifene, tositumomab-iodine 131 131), trastuzumab, treosulfan, tretinoin, trilostane, trimetrexate, triptorelin, native tumor necrosis factor alpha, ubenimex, bladder cancer vaccine, Maruyama vaccine, melanoma lysate vaccine, valrubicin, verteporfin, vinorelbine, virulizin, zinostatin stimalamer, or zoledronic acid; abarelix; AE 941 (Aeterna), ambamustine, antisense oligonucleotides, bcl-2 (Genta), APC 8015 (Dendreon), decitabine, dexaminoglutethimide, diaziquone, EL 532 (Elan), EM800 (Endorecherche), eniluracil, etanidazole, fenretinide, filgrastim SD01 (Amgen), fulvestrant, galocitabine, gastrin 17 immunogen, HLA-B7 gene therapy (Vical), granulocyte macrophage colony stimulating factor, histamine dihydrochloride, ibritumomab tiuxetan, ilomastat, IM 862 (Cytran), interleukin-2, iproxifene, LDI 200 (Milkhaus), leridistim, lintuzumab, CA 125 MAb (Biomira), cancer MAb (Japan Pharmaceutical Development), HER-2 and Fc MAb (Medarex), idiotype 105AD7 MAb (CRC Technology), idiotype CEA MAb (Trilex), LYM-1-iodine 131 MAb (Techni clone), polymorphic epithelial mucin-yttrium 90 MAb (Antisoma), marimastat, menogaril, mitumomab, motexafin gadolinium, MX 6 (Galderma), nelarabine, nolatrexed, P 30 protein, pegvisomant, pemetrexed, porfiromycin, prinomastat, RL 0903 (Shire), rubitecan, satraplatin, sodium phenylacetate, spalfosic acid, SRL172 (SR Pharma), SU 5416 (SUGEN), TA 077 (Tanabe), tetrathiomolybdate, thaliblastine, thrombopoietin, tin ethyl etiopurpurin, tirapazamine, cancer vaccine (Biomira), melanoma vaccine (New YorkUniversity), melanoma vaccine (Sloan Kettering Institute), melanoma tumor lysate vaccine (New York Medical College), viral melanoma cell lysate vaccine (Royal Newcastle Hospital), or valspodar.

[0720] Additional examples of therapeutic agents that can be used in combination with the compounds of the invention include ipilimumab Tremelimumab; galiximab; nivolumab, also known as BMS-936558 Pembrolizumab Avelumab AMP224; BMS-936559; MPDL3280A, also known as RG7446; MEDI-570; AMG557; MGA271; IMP321; BMS-663513; PF-05082566; CDX-1127; anti-OX40 (Providence Health Services); huMAbOX40L; atacicept; CP-870893; lucatumumab; dacetuzumab; muromonab-CD3; ipilumumab; MEDI4736 MSB0010718C; AMP 224; adalimumab ado-trastuzumab emtansine Aflibercept Alemtuzumab Basiliximab Belimumab Basiliximab Belimumab Brentuximab vedotin Canakinumab Certolizumab pegol Daclizumab Daratumumab Denosumab Eculizumab Efalizumab Gemtuzumab ozogamicin Golimumab Ibritumomab tiuxetan infliximab Motavizumab Natalizumab Obinutuzumab Ofatumumab Omalizumab Palivizumab Pertuzumab Pertuzumab Ranibizumab Raxibacumab Tocilizumab Tositumomab; Tositumomab-i-131; Tositumomab and Tositumomab-i-131 Ustekinumab AMG 102; AMG 386; AMG 479; AMG 655; AMG 706; AMG 745; and AMG 951.

[0721] Depending on the illness being treated, the compounds described herein may be used in combination with the agents disclosed herein or other suitable agents. Therefore, in some embodiments, one or more compounds of the present disclosure will be co-administered with other therapies described herein. When used in combination therapy, the compounds described herein may be administered simultaneously or separately with the second agent. This combination may include administering two agents simultaneously in the same dosage form, administering simultaneously in independent dosage forms, and administering separately. That is, the compounds described herein and any agent described herein may be formulated into the same dosage form together and administered simultaneously. Alternatively, the compounds of the present invention and any therapy described herein may be administered simultaneously, wherein the two agents are present in independent preparations. In another alternative, the compounds of the present disclosure may be administered first and then any therapy described herein, or vice versa. In some embodiments of the separate administration scheme, the compounds of the present invention and any therapy described herein are administered a few minutes apart or a few hours apart or a few days apart.

[0722] In some embodiments of any of the methods described herein, the first therapy (e.g., a compound of the invention) and one or more additional therapies are administered simultaneously or sequentially in any order. The first therapeutic agent may be administered immediately, at most 1 hour, at most 2 hours, at most 3 hours, at most 4 hours, at most 5 hours, at most 6 hours, at most 7 hours, at most 8 hours, at most 9 hours, at most 10 hours, at most 11 hours, at most 12 hours, at most 13 hours, 14 hours, at most 16 hours, at most 17 hours, at most 18 hours, at most 19 hours, at most 20 hours, at most 21 hours, at most 22 hours, at most 23 hours, at most 24 hours, or at most 1-7 days, 1-14 days, 1-21 days, or 1-30 days before or after the administration of the one or more additional therapies.

[0723] The present invention also provides a kit comprising (a) a pharmaceutical composition comprising an agent described herein (e.g., a compound of the present invention) and (b) a package insert with instructions for performing any of the methods described herein. In some embodiments, the kit comprises (a) a pharmaceutical composition comprising an agent described herein (e.g., a compound of the present invention), (b) one or more additional therapies (e.g., non-drug therapies or therapeutic agents), and (c) a package insert with instructions for performing any of the methods described herein.

[0724] Since one aspect of the present invention encompasses treating a disease or its associated symptoms with a combination of pharmaceutically active compounds that can be administered separately, the present invention also relates to combining independent pharmaceutical compositions in the form of a kit. The kit may include two independent pharmaceutical compositions: a compound of the present invention and one or more additional therapies. The kit may include a container for accommodating the independent compositions, such as a sub-bottle or a sub-foil package. Additional examples of containers include syringes, boxes, and bags. In some embodiments, the kit may include instructions for use of the independent components. The kit form is particularly advantageous when the independent components are preferably administered in different dosage forms (e.g., oral and parenteral), when administered at different dosing intervals, or when the prescribing health care provider wishes to adjust the individual components in the combination.

[0725] Numbered implementation plan

[0726] 1. A compound having a structure of Formula I, or a pharmaceutically acceptable salt thereof:

[0727]

[0728] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0729] L 1 Not present or a joint;

[0730] W is a crosslinking group comprising vinyl ketone, vinyl sulfone, alkynyl ketone or alkynyl sulfone;

[0731] R 1 is hydrogen, optionally substituted 3 to 10 membered heterocycloalkyl or optionally substituted C 1 -C 6 heteroalkyl;

[0732] R 2 is optionally substituted C 1 -C 6 Alkyl; and

[0733] R 3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 Heteroalkyl.

[0734] 2. A compound as described in embodiment 1, or a pharmaceutically acceptable salt thereof, wherein A is optionally substituted thiazole-diyl, optionally substituted oxazole-diyl, optionally substituted morpholine-diyl, optionally substituted pyrrolidine-diyl, optionally substituted pyridine-diyl, optionally substituted azetidine-diyl, optionally substituted pyrazine-diyl, optionally substituted pyrimidine-diyl, optionally substituted piperidine-diyl, optionally substituted oxadiazole-diyl, optionally substituted thiadiazole-diyl, optionally substituted triazole-diyl, optionally substituted thiomorpholine-diyl, or optionally substituted phenylene.

[0735] 3. The compound as described in Embodiment 1 or 2, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-1:

[0736]

[0737] 4. The compound as described in Embodiment 1 or 2, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-2:

[0738]

[0739] Where R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0740] R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0741] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0742] 5. The compound as described in Embodiment 4, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-3:

[0743]

[0744] 6. The compound as described in Embodiment 4, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-4:

[0745]

[0746]

[0747] 7. The compound as described in Embodiment 4, or a pharmaceutically acceptable salt thereof, has the structure of Formula II-4b:

[0748]

[0749] 8. A compound as described in any one of embodiments 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 2 yes:

[0750] 9. A compound as described in any one of embodiments 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R 3 is optionally substituted C 1 -C 6 alkyl.

[0751] 10. The compound according to embodiment 9, or a pharmaceutically acceptable salt thereof, wherein R 3 yes:

[0752] 11. A compound as described in any one of embodiments 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R 3 is optionally substituted C 1 -C 3 Heteroalkyl.

[0753] 12. The compound according to embodiment 11, or a pharmaceutically acceptable salt thereof, wherein R 3 yes:

[0754] 13. The compound of any one of embodiments 1 to 12, or a pharmaceutically acceptable salt thereof, wherein A is an optionally substituted 5- to 10-membered heteroarylene.

[0755] 14. The compound of embodiment 13, or a pharmaceutically acceptable salt thereof, wherein A is:

[0756] 15. The compound of any one of embodiments 1 to 12, or a pharmaceutically acceptable salt thereof, wherein A is optionally substituted phenylene.

[0757] 16. The compound of embodiment 15, or a pharmaceutically acceptable salt thereof, wherein A is:

[0758] 17. The compound of any one of embodiments 1 to 12, or a pharmaceutically acceptable salt thereof, wherein A is an optionally substituted 3- to 6-membered heterocycloalkylene.

[0759] 18. The compound of embodiment 17, or a pharmaceutically acceptable salt thereof, wherein A is:

[0760]

[0761] 19. The compound according to embodiment 17 or a pharmaceutically acceptable salt thereof, wherein A is:

[0762]

[0763] 20. The compound of any one of embodiments 1 to 19, or a pharmaceutically acceptable salt thereof, wherein the linker is a structure of Formula III:

[0764] A 1 -(B 1 ) f -(C 1 ) g -(B 2 ) h -(D 1 )-(B 3 ) i -(C 2 ) j -(B 4 ) k –A 2

[0765] Formula III,

[0766] Among them A 1 The linker and CH(R 3 ) between the keys; A 2 is the bond between W and the linker; B 1 , B 2 , B 3 and B 4 are each independently selected from optionally substituted C 1 -C 2 Alkylene, optionally substituted C 1 -C 3 Heteroalkylene, O, S and NR N ; Each R N are independently hydrogen, optionally substituted C 1– C 4 Alkyl, optionally substituted C 2 -C 4 Alkenyl, optionally substituted C 2 -C4 alkynyl, optionally substituted 3 to 14 membered heterocycloalkyl, optionally substituted 6 to 10 membered aryl, or optionally substituted C 1 -C 7 Heteroalkyl; C 1 and C 2 are each independently selected from carbonyl, thiocarbonyl, sulfonyl or phosphoryl; f, g, h, i, j and k are each independently 0 or 1; and D 1 is optionally substituted C 1 -C 10 Alkylene, optionally substituted C 2 -C 10 Alkenylene, optionally substituted C 2 -C 10 alkylene, optionally substituted 3 to 14 membered heterocycloalkylene, optionally substituted 5 to 10 membered heteroarylene, optionally substituted 3 to 8 membered cycloalkylene, optionally substituted 6 to 10 membered arylene, optionally substituted C 2 -C 10 Polyethylene glycol or optionally substituted C 1 -C 10 Heteroalkylene, or connected to A 1 -(B 1 ) f -(C 1 ) g -(B 2 ) h -with-(B 3 ) i -(C 2 ) j -(B 4 ) k –A 2 chemical bonds.

[0767] 21. The compound of any one of embodiments 1 to 20, or a pharmaceutically acceptable salt thereof, wherein the linker is or comprises a cyclic moiety.

[0768] 22. The compound of embodiment 21, or a pharmaceutically acceptable salt thereof, wherein the linker has a structure of Formula IIIa:

[0769]

[0770] Where o is 0 or 1;

[0771] R 7 is hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted 3- to 8-membered cycloalkylene, or optionally substituted 3- to 8-membered heterocycloalkylene;

[0772] X 1 Absent, optionally substituted C 1 -C 4 Alkylene, O, NCH 3 or optionally substituted C 1 -C 4 heteroalkylene;

[0773] Cy is optionally substituted 3 to 8 membered cycloalkylene, optionally substituted 3 to 12 membered heterocycloalkylene, optionally substituted 6-10 membered arylene, or optionally substituted 5 to 10 membered heteroarylene; and

[0774] L 2 Does not exist, is -SO 2 -, -NH-, optionally substituted C 1 -C 4 Alkylene, optionally substituted C 1 -C 4 heteroalkylene or an optionally substituted 3- to 6-membered heterocycloalkylene.

[0775] 23. The compound of embodiment 22, or a pharmaceutically acceptable salt thereof, wherein the linker is selected from the following or a stereoisomer thereof:

[0776]

[0777]

[0778]

[0779] 24. The compound of embodiment 22, or a pharmaceutically acceptable salt thereof, wherein the linker is selected from the following or a stereoisomer thereof:

[0780]

[0781]

[0782] 25. A compound as described in any one of Embodiments 1 to 24, or a pharmaceutically acceptable salt thereof, wherein the compound is not a compound of Table 2.

[0783] 26. A compound as described in any one of embodiments 1 to 25, or a pharmaceutically acceptable salt thereof, having a structure of Formula II-5:

[0784]

[0785] Among them, Cy 1is optionally substituted spirocyclic 8 to 11 membered heterocycloalkylene or optionally substituted bicyclic 7 to 9 membered heterocycloalkylene; and

[0786] wherein W comprises vinyl ketone or vinyl sulfone.

[0787] 27. The compound as described in embodiment 26, or a pharmaceutically acceptable salt thereof, wherein Cy 1 is an optionally substituted spirocyclic 10- to 11-membered heterocycloalkylene.

[0788] 28. The compound of embodiment 27, or a pharmaceutically acceptable salt thereof, has the structure of Formula II-5a:

[0789]

[0790] Where X 2 is O, C(R 11 ) 2 NR 12 , S or SO 2 .

[0791] r is 1 or 2;

[0792] Each t is independently 0, 1, or 2;

[0793] R 11 and R 12 are each independently hydrogen, optionally substituted C 1 -C 4 Alkyl, optionally substituted C 2 -C 4 heteroalkyl or optionally substituted 3 to 5 membered cycloalkyl; and

[0794] Each R 13 Independently -CH 3 .

[0795] 29. The compound of embodiment 27, or a pharmaceutically acceptable salt thereof, has the structure of Formula II-5b:

[0796]

[0797] Where X 2 is O, C(R 11 ) 2 NR 12 , S or SO 2 .

[0798] r is 1 or 2;

[0799] s and t are each independently 0, 1 or 2;

[0800] R11 and R 12 are each independently hydrogen, optionally substituted C 1 -C 4 Alkyl, optionally substituted C 2 -C 4 heteroalkyl, optionally substituted 3 to 6 membered heterocycloalkyl, or optionally substituted 3 to 5 membered cycloalkyl; and

[0801] Each R 13 Independently -CH 3 , F, or two R attached to the same atom 13 Together with the atoms to which it is attached, it forms an optionally substituted C 3 -C 6 Cycloalkyl, or two R attached to the same atom 13 Together with the atoms to which it is attached it forms an optionally substituted 3- to 6-membered heterocycloalkyl.

[0802] 30. The compound as described in embodiment 29, wherein R 13 Yes-CH 3 .

[0803] 31. The compound of embodiment 29, wherein the sum of s and t is 1.

[0804] 32. A compound as described in embodiment 29, wherein the sum of s and t is 2.

[0805] 33. A compound as described in embodiment 29, wherein s is 0 and t is 1.

[0806] 34. A compound as described in embodiment 29, wherein the sum of s and t is 0.

[0807] 35. The compound of embodiment 28 or 29, or a pharmaceutically acceptable salt thereof, has the structure of formula II-5c:

[0808]

[0809] 36. The compound of embodiment 28 or 29, or a pharmaceutically acceptable salt thereof, has the structure of Formula II-5d:

[0810]

[0811] 37. The compound of embodiment 28 or 29, or a pharmaceutically acceptable salt thereof, has the structure of Formula II-5e:

[0812]

[0813] 38. The compound of embodiment 28 or 29, or a pharmaceutically acceptable salt thereof, wherein r is 1.

[0814] 39. The compound of embodiment 28 or 29, or a pharmaceutically acceptable salt thereof, wherein r is 2.

[0815] 40. A compound as described in any one of embodiments 28 to 39, or a pharmaceutically acceptable salt thereof, wherein X 2 It's O.

[0816] 41. A compound as described in any one of embodiments 28 to 39, or a pharmaceutically acceptable salt thereof, wherein X 2 It’s S.

[0817] 42. A compound as described in any one of embodiments 28 to 39, or a pharmaceutically acceptable salt thereof, wherein X 2 Yes SO 2 .

[0818] 43. A compound as described in any one of embodiments 28 to 39, or a pharmaceutically acceptable salt thereof, wherein X 2 YesNR 12 .

[0819] 44. The compound of embodiment 43, or a pharmaceutically acceptable salt thereof, wherein R 12 Selected from the following or their stereoisomers:

[0820] -CH 3 , or -H.

[0821] 45. The compound of embodiment 43, or a pharmaceutically acceptable salt thereof, wherein R 12 Selected from the following or their stereoisomers:

[0822]

[0823] 46. ​​A compound as described in any one of embodiments 28 to 39, or a pharmaceutically acceptable salt thereof, wherein X 2 is C(R 11 ) 2 .

[0824] 47. The compound of embodiment 46, or a pharmaceutically acceptable salt thereof, wherein each R 11 It's hydrogen.

[0825] 48. A compound as described in any one of embodiments 1 to 47, or a pharmaceutically acceptable salt thereof, wherein W is a cross-linking group comprising a vinyl ketone.

[0826] 49. A compound as described in Embodiment 48, or a pharmaceutically acceptable salt thereof, wherein W has a structure of Formula IVa:

[0827]

[0828] Where R 8a , R 8b and R 8c are independently hydrogen, -CN, halogen, or optionally one or more independently selected from -OH, -OC 1 -C 3 Alkyl substituents substituted -C 1 -C 3 alkyl,

[0829] -NH 2 , -NH(C 1 -C 3 Alkyl), -N(C 1 -C 3 alkyl) 2 , or a 4- to 7-membered saturated heterocycloalkyl group.

[0830] 50. A compound as described in embodiment 49, or a pharmaceutically acceptable salt thereof, wherein W is selected from the following or a stereoisomer thereof:

[0831]

[0832] 51. A compound as described in embodiment 49, or a pharmaceutically acceptable salt thereof, wherein W is selected from the following or its stereoisomers:

[0833]

[0834] 52. A compound as described in any one of embodiments 1 to 47, or a pharmaceutically acceptable salt thereof, wherein W is a cross-linking group comprising vinyl sulfone.

[0835] 53. A compound as described in embodiment 52, or a pharmaceutically acceptable salt thereof, wherein W has a structure of Formula IVc:

[0836]

[0837] Where R 10a , R 10b and R 10c are independently hydrogen, -CN, or are optionally substituted by one or more independently selected from -OH, -OC 1 -C 3 Alkyl substituents substituted -C 1 -C 3 alkyl,

[0838] -NH 2 , -NH(C 1 -C 3 Alkyl), -N(C 1 -C 3 alkyl) 2 , or a 4- to 7-membered saturated heterocycloalkyl group.

[0839] 54. The compound of embodiment 53, or a pharmaceutically acceptable salt thereof, wherein W is:

[0840]

[0841] 55. A compound as described in any one of embodiments 1 to 47, or a pharmaceutically acceptable salt thereof, wherein W is a cross-linking group comprising an alkynone.

[0842] 56. A compound as described in Embodiment 55, or a pharmaceutically acceptable salt thereof, wherein W has the structure of Formula IVb:

[0843]

[0844] Where R 9 is hydrogen, optionally substituted by one or more independently selected from -OH, -OC 1 -C 3 Alkyl substituents substituted -C 1 -C 3 Alkyl, -NH 2 , -NH(C 1 -C 3 Alkyl), -N(C 1 -C 3 alkyl) 2 , or a 4- to 7-membered saturated cycloalkyl group, or a 4- to 7-membered saturated heterocycloalkyl group.

[0845] 57. The compound of embodiment 56, or a pharmaceutically acceptable salt thereof, wherein W is selected from:

[0846]

[0847] 58. The compound of embodiment 56 or 57, or a pharmaceutically acceptable salt thereof, has the structure of formula II-6:

[0848]

[0849] Where Q 1 Yes CH 2 NR N or O;

[0850] Q 2 CO、NRN or O; and

[0851] Z is optionally substituted 3- to 6-membered heterocycloalkylene or optionally substituted 5- to 10-membered heteroarylene; or

[0852] Where Q 1 -Q 2 -Z is optionally substituted 9- to 10-membered spirocyclic heterocycloalkylene.

[0853] 59. A compound as described in any one of embodiments 56 to 58, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-6a:

[0854]

[0855] Where R 14 is fluorine, hydrogen or C 1 -C 3 Alkyl; and

[0856] u is either 0 or 1.

[0857] 60. The compound of embodiment 59, or a pharmaceutically acceptable salt thereof, wherein R 14 is fluorine and u is 1.

[0858] 61. The compound of embodiment 59, or a pharmaceutically acceptable salt thereof, wherein R 14 is hydrogen and u is 0.

[0859] 62. A compound as described in any one of embodiments 56 to 59, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-6b:

[0860]

[0861] 63. A compound as described in any one of embodiments 56 to 59, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-6c:

[0862]

[0863] 64. A compound or a pharmaceutically acceptable salt thereof selected from Table 1.

[0864] 65. A pharmaceutical composition comprising a compound according to any one of Embodiments 1 to 64, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0865] 66. A conjugate or a salt thereof comprising a structure of Formula V:

[0866] MLP

[0867] Formula V,

[0868] Where L is the connector;

[0869] P is a monovalent organic moiety; and

[0870] M has the structure of Formula VIa:

[0871]

[0872] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0873] R 2 is optionally substituted C 1 -C 6 alkyl;

[0874] R 3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 heteroalkyl;

[0875] X 2 is O, C(R 11 ) 2 NR 12 , S or SO 2 ;

[0876] r is 1 or 2;

[0877] Each t is independently 0, 1, or 2;

[0878] R 11 and R 12 are each independently hydrogen, optionally substituted C 1 -C 4 Alkyl, optionally substituted C 2 -C 4 heteroalkyl or optionally substituted 3- to 5-membered cycloalkyl;

[0879] Each R 13 Independently -CH 3 ;and

[0880] R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0881] R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0882] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0883] 67. A conjugate or a salt thereof comprising a structure of Formula V:

[0884] MLP

[0885] Formula V,

[0886] Where L is the connector;

[0887] P is a monovalent organic moiety; and

[0888] M has the structure of Formula VIb:

[0889]

[0890] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0891] R 2 is optionally substituted C 1 -C 6 alkyl;

[0892] R 3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 heteroalkyl;

[0893] R 14 is fluorine, hydrogen or C 1 -C 3 alkyl;

[0894] u is 0 or 1; and

[0895] R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1-C 6 Alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0896] R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0897] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0898] 68. A conjugate or a salt thereof comprising a structure of Formula V:

[0899] MLP

[0900] Formula V,

[0901] Where L is the connector;

[0902] P is a monovalent organic moiety; and

[0903] M has the structure of Formula VIc:

[0904]

[0905] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0906] R 2 is optionally substituted C 1 -C 6 alkyl;

[0907] R 3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 heteroalkyl; and

[0908] R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0909] R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0910] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0911] 69. A conjugate or a salt thereof comprising a structure of Formula V:

[0912] MLP

[0913] Formula V,

[0914] Where L is the connector;

[0915] P is a monovalent organic moiety; and

[0916] M has the structure of Formula VId:

[0917]

[0918] wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene;

[0919] R 2 is optionally substituted C 1 -C 6 alkyl;

[0920] R 3 is optionally substituted C 1 -C 6 Alkyl or optionally substituted C 1 -C 3 heteroalkyl; and

[0921] R 4 , R 5 and R 6 are each independently selected from hydrogen, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or

[0922] R4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or

[0923] R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

[0924] 70. The conjugate or salt thereof of any one of embodiments 66 to 69, wherein the monovalent organic moiety is a protein.

[0925] 71. The conjugate or salt thereof of embodiment 70, wherein the protein is Ras protein.

[0926] 72. The conjugate or salt thereof of embodiment 71, wherein the Ras protein is K-Ras G12C, K-Ras G13C, H-Ras G12C, H-Ras G13C, N-Ras G12C or N-Ras G13C.

[0927] 73. The conjugate of embodiment 72, wherein the Ras protein is K-Ras G13C.

[0928] 74. The conjugate or salt thereof of any one of embodiments 66 to 73, wherein the linker is bound to the monovalent organic moiety via a bond to a thiol group of an amino acid residue of the monovalent organic moiety.

[0929] 75. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of any one of Embodiments 1 to 64, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Embodiment 65.

[0930] 76. The method of embodiment 75, wherein the cancer is pancreatic cancer, colorectal cancer, non-small cell lung cancer, or endometrial cancer.

[0931] 77. The method of embodiment 75 or 76, wherein the cancer comprises a Ras mutation.

[0932] 78. The method of embodiment 77, wherein the Ras mutation is K-Ras G12C, K-Ras G13C, H-Ras G12C, H-Ras G13C, N-Ras G12C, or N-Ras G13C.

[0933] 79. The method of embodiment 78, wherein the Ras mutation is K-Ras G13C.

[0934] 80. A method of treating a Ras protein-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 64, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Embodiment 65.

[0935] 81. A method of inhibiting Ras protein in a cell, the method comprising contacting the cell with an effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of Embodiments 1 to 64 or a pharmaceutical composition according to Embodiment 65.

[0936] 82. The method of embodiment 80 or 81, wherein the Ras protein is K-Ras G12C, K-Ras G13C, H-Ras G12C, H-Ras G13C, N-Ras G12C or N-Ras G13C.

[0937] 83. A method as described in embodiment 82, wherein the Ras protein is K-Ras G13C.

[0938] 84. The method of any one of embodiments 81 to 83, wherein the cell is a cancer cell.

[0939] 85. The method of embodiment 84, wherein the cancer cell is a pancreatic cancer cell, a colorectal cancer cell, a non-small cell lung cancer cell, or an endometrial cancer cell.

[0940] 86. The method or use of any one of embodiments 75 to 85, wherein the method or use further comprises administering an additional anti-cancer therapy.

[0941] 87. The method of embodiment 86, wherein the additional anti-cancer therapy is an EGFR inhibitor, a second Ras inhibitor, a SHP2 inhibitor, a SOS1 inhibitor, a Raf inhibitor, a MEK inhibitor, an ERK inhibitor, a PI3K inhibitor, a PTEN inhibitor, an AKT inhibitor, an mTORC1 inhibitor, a BRAF inhibitor, a PD-L1 inhibitor, a PD-1 inhibitor, a CDK4 / 6 inhibitor, a HER2 inhibitor, or a combination thereof.

[0942] 88. The method of embodiment 86 or 87, wherein the additional anti-cancer therapy is a SHP2 inhibitor.

[0943] Example

[0944] The present disclosure will be further illustrated by the following examples and synthetic examples, which should not be construed as limiting the scope or spirit of the present disclosure to the specific procedures described herein. It should be understood that the examples provided are intended to illustrate certain embodiments and are not intended to limit the scope of the present disclosure. It should also be understood that various other embodiments, modifications thereof, and equivalents that may be conceivable to those skilled in the art may be resorted to without departing from the spirit of the present disclosure or the scope of the appended claims.

[0945] Chemical synthesis

[0946] The definitions used in the following examples and elsewhere herein are as follows:

[0947] CH 2 Cl 2 , DCM, methylene chloride, dichloromethane

[0948] CH 3 CN, MeCN, Acetonitrile

[0949] CuI Copper(I) iodide

[0950] DIPEA Diisopropylethylamine

[0951] DMF N,N-Dimethylformamide

[0952] EtOAc Ethyl acetate

[0953] h hour

[0954] H 2 O Water

[0955] HCl

[0956] K 3 PO 4 Tripotassium phosphate

[0957] MeOH Methanol

[0958] Na 2 SO 4 Sodium sulfate

[0959] NMP N-Methylpyrrolidone

[0960] Pd(dppf)Cl 2 [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)

[0961] instrument

[0962] Mass spectral data collection is carried out using Shimadzu LCMS-2020, Agilent 1260LC-6120 / 6125MSD, Shimadzu LCMS-2010EV or Waters Acquity UPLC with QDa detector or SQ detector 2. Sample is injected into C-18 reverse phase column with liquid phase. Compound is eluted from column using acetonitrile gradient and fed into mass analyzer. Initial data analysis is carried out using Agilent ChemStation, Shimadzu LabSolutions or Waters MassLynx. NMR data are collected using Bruker AVANCE III HD 400MHz, Bruker Ascend 500MHz or Varian 400MHz instruments and raw data is analyzed using TopSpin or Mestrelab Mnova.

[0963] Synthetic intermediates

[0964] Intermediate 1. Synthesis of 3-(5-bromo-1-ethyl-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]indol-3-yl)-2,2-dimethylpropan-1-ol

[0965]

[0966] Step 1. At 0°C in N 2 To a mixture of 3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropanoyl chloride (65 g, 137 mmol, crude) in DCM (120 mL) was slowly added 1 M SnCl 4 The mixture was stirred at 0°C for 30 minutes, and then a solution of 5-bromo-1H-indole (26.8 g, 137 mmol) in DCM (40 mL) was added dropwise. The mixture was stirred at 0°C for 45 minutes, then diluted with EtOAc (300 mL), washed with brine (100 mL×4), and washed with Na 2 SO 4 The mixture was dried and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give 1-(5-bromo-1H-indol-3-yl)-3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropan-1-one (55 g, 75% yield). LCMS (ESI): m / z [M+Na] C 29 H 32 BrNO 2 Calculated value for SiNa: 556.1; experimental value: 556.3.

[0967] Step 2: At 0°C in N 2 To a mixture of 1-(5-bromo-1H-indol-3-yl)-3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropan-1-one (50 g, 93.6 mmol) in THF (100 mL) was added LiBH 4 (6.1 g, 281 mmol). The mixture was heated to 60°C and stirred for 20 hours, then MeOH (10 mL) and EtOAc (100 mL) were added, and the mixture was washed with brine (50 mL), washed with Na 2 SO 4 Dry, filter, and concentrate the filtrate under reduced pressure. The residue was diluted with DCM (50 mL), cooled to 10 °C and dihydropyridine (9.5 g, 37.4 mmol) and TsOH. 2 O (890 mg, 4.7 mmol). The mixture was stirred at 10 ° C for 2 hours, filtered, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give 1-(5-bromo-1H-indol-3-yl)-3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropan-1-one (41 g, 84% yield). LCMS (ESI): m / z [M+H] C 29 H 34 Calculated value of BrNOSi: 519.2; experimental value: 520.1; 1 HNMR (400MHz, CDCl 3 )δ7.96(s,1H),7.75-7.68(m,5H),7.46-7.35(m,6H),7.23-7.19(m,2H),6 .87(d,J=2.1Hz,1H),3.40(s,2H),2.72(s,2H),1.14(s,9H),0.89(s,6H).

[0968] Step 3. To 1-(5-bromo-1H-indol-3-yl)-3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropan-1-one (1.5 g, 2.9 mmol) and I 2 (731 mg, 2.9 mmol) in THF (15 mL) was added with AgOTf (888 mg, 3.5 mmol). The mixture was stirred at room temperature for 2 h, then diluted with EtOAc (200 mL) and washed with saturated Na 2 S 2 O 3 (100 mL) and washed with anhydrous Na 2 SO 4The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give 5-bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-2-iodo-1H-indole (900 mg, 72% yield) as a solid. 1 H NMR (400 MHz, DMSO-d 6 )δ11.70(s,1H),7.68(d,J=1.3Hz,1H),7.64-7.62(m,4H),7.46-7.43(m,6H),7.24-7.22(d, 1H),7.14-7.12(dd,J=8.6,1.6Hz,1H),3.48(s,2H),2.63(s,2H),1.08(s,9H),0.88(s,6H).

[0969] Step 4. To a stirred mixture of HCOOH (66.3 g, 1.44 mol) in TEA (728 g, 7.2 mol) at 0°C under Ar atmosphere was added (4S, 5S)-2-chloro-2-methyl-1-(4-methylbenzenesulfonyl)-4,5-diphenyl-1,3-diaza-2-rutheniumcyclopentaneisopropyltoluene (3.9 g, 6.0 mmol) portionwise. The mixture was heated to 40°C and stirred for 15 minutes, then cooled to room temperature and 1-(3-bromopyridin-2-yl)ethanone (120 g, 600 mmol) was added in portions. The mixture was heated to 40°C and stirred for an additional 2 hours, then the solvent was concentrated under reduced pressure. Brine (2 L) was added to the residue, the mixture was extracted with EtOAc (4×700 mL), and the residue was purified by evaporation over anhydrous Na 2 SO 4 Dried and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give (1S)-1-(3-bromopyridin-2-yl)ethanol (100 g, 74% yield) as an oil. LCMS (ESI): m / z [M+H] C 7 H 8 Calculated for BrNO 201.1; found 201.9.

[0970] Step 5. To a stirred mixture of (1S)-1-(3-bromopyridin-2-yl)ethanol (100 g, 495 mmol) in DMF (1 L) was added a 60% dispersion of NaH in oil (14.25 g, 594 mmol) in portions at 0°C. The mixture was stirred at 0°C for 1 hour. MeI (140.5 g, 990 mmol) was added dropwise at 0°C and the mixture was allowed to warm to room temperature and stirred for 2 hours. The mixture was cooled to 0°C and saturated NH 4 The mixture was extracted with EtOAc (3×1.5 L) and washed with anhydrous Na2 SO 4 Dried and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give 3-bromo-2-[(1S)-1-methoxyethyl]pyridine (90 g, 75% yield) as an oil. LCMS (ESI): m / z [M+H] C 8 H 10 Calculated for BrNO 215.0; found 215.9.

[0971] Step 6. To 3-bromo-2-[(1S)-1-methoxyethyl]pyridine (90 g, 417 mmol) and Pd(dppf)Cl was added at room temperature under Ar atmosphere. 2 To a stirred mixture of bis(pinacolato)diboron (127 g, 500 mmol) (30.5 g, 41.7 mmol) in toluene (900 mL) was added bis(pinacolato)diboron (127 g, 500 mmol) and KOAc (81.8 g, 833 mmol) in portions. The mixture was heated to 100 °C and stirred for 3 hours. The filtrate was concentrated under reduced pressure and the residue was purified by Al 2 O 3 Column chromatography purification afforded 2-[(1S)-1-methoxyethyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (100 g, 63% yield) as a semi-solid. LCMS (ESI): m / z [M+H] C 14 H 22 BNO 3 Calculated value 263.2; experimental value 264.1.

[0972] Step 7. To a stirred mixture of 5-bromo-3-[3-[(tert-butyldiphenylsilyl)oxy]-2,2-dimethylpropyl]-2-iodo-1H-indole (140 g, 217 mmol) and 2-[(1S)-1-methoxyethyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (100 g, 380 mmol) in 1,4-dioxane (1.4 L) was added K in multiple portions at room temperature under Ar atmosphere. 2 CO 3 (74.8g, 541mmol), Pd(dppf)Cl 2 (15.9 g, 21.7 mmol) and H 2 O (280 mL). The mixture was heated to 85°C and stirred for 4 hours, then cooled and H 2 O (5 L), and the mixture was extracted with EtOAc (3×2 L). The combined organic layers were washed with brine (2×1 L), 2 SO 4Dried and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give 5-bromo-3-[3-[(tert-butyldiphenylsilyl)oxy]-2,2-dimethylpropyl]-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]-1H-indole (71 g, 45% yield) as a solid. LCMS (ESI): m / z [M+H] C 37 H 43 Bn 2 O 2 Calculated value of Si: 654.2; experimental value: 655.1.

[0973] Step 8. Heat the mixture at 0°C in N 2 To a stirred mixture of 5-bromo-3-[3-[(tert-butyldiphenylsilyl)oxy]-2,2-dimethylpropyl]-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]-1H-indole (71 g, 108 mmol) in DMF (0.8 L) was added Cs in portions under atmosphere. 2 CO 3 (70.6 g, 217 mmol) and EtI (33.8 g, 217 mmol). The mixture was warmed to room temperature and stirred for 16 hours, then H 2 O (4 L) and the mixture was extracted with EtOAc (3×1.5 L). The combined organic layers were washed with brine (2×1 L) and dried over anhydrous Na 2 SO 4 Dried and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give 5-bromo-3-[3-[(tert-butyldiphenylsilyl)oxy]-2,2-dimethylpropyl]-1-ethyl-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]indole (66 g, 80% yield) as an oil. LCMS (ESI): m / z [M+H] C 39 H 47 Bn 2 O 2 Calculated value of Si: 682.3; experimental value: 683.3.

[0974] Step 9. Heat the mixture at room temperature under N 2 To a stirred mixture of TBAF (172.6 g, 660 mmol) in THF (660 mL) was added 5-bromo-3-[3-[(tert-butyldiphenylsilyl)oxy]-2,2-dimethylpropyl]-1-ethyl-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]indole (66 g, 97 mmol) in portions under a 4% CO atmosphere. The mixture was heated to 50° C. and stirred for 16 h, cooled, and washed with H 2O (5 L) and extracted with EtOAc (3 x 1.5 L). The combined organic layers were washed with brine (2 x 1 L) and dried over anhydrous Na 2 SO 4 Dried and filtered. After filtration, the filtrate was concentrated under reduced pressure. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give 3-(5-bromo-1-ethyl-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]indol-3-yl)-2,2-dimethylpropan-1-ol (30 g, 62% yield) as a solid. LCMS (ESI): m / z[M+H]C 23 H 29 Bn 2 O 2 Calculated value: 444.1; experimental value: 445.1.

[0975] Intermediate 1. Alternative synthesis via the Fisher Indole Route.

[0976]

[0977] Step 1. Incubate at -10 °C under N 2 To a mixture of i-PrMgCl (2M in THF, 0.5 L) was added a 2.5M solution of n-BuLi in hexane (333 mL, 833 mmol) dropwise over 15 minutes under atmosphere. The mixture was stirred at -10°C for 30 minutes, then 3-bromo-2-[(1S)-1-methoxyethyl]pyridine (180 g, 833 mmol) in THF (0.5 L) was added dropwise over 30 minutes at -10°C. The resulting mixture was warmed to -5°C and stirred for 1 hour, then 3,3-dimethyloxane-2,6-dione (118 g, 833 mmol) in THF (1.2 L) was added dropwise over 30 minutes at -5°C. The mixture was warmed to 0°C and stirred for 1.5 hours, then quenched by adjusting the pH to about 5 by adding a pre-cooled 4M HCl solution in 1,4-dioxane (0.6 L) at 0°C. The mixture was diluted with ice water (3 L) and extracted with EtOAc (3 x 2.5 L). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter, concentrate the filtrate under reduced pressure, and purify the residue by silica gel column chromatography to give 5-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]-2,2-dimethyl-5-oxopentanoic acid (87 g, 34% yield) as a solid. LCMS (ESI): m / z [M+H] C 15 H 21 NO 4 Calculated value: 279.2; experimental value: 280.1.

[0978] Step 2. Heat the mixture at room temperature under N 2 To a mixture of 5-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]-2,2-dimethyl-5-oxopentanoic acid (78 g, 279 mmol) in EtOH (0.78 L) was added (4-bromophenyl)hydrazine hydrochloride (68.7 g, 307 mmol) in EtOH (0.78 L) under atmosphere in multiple portions. The mixture was heated to 85 ° C and stirred for 2 hours, cooled to room temperature, and then a 4M HCl solution in 1,4-dioxane (69.8 mL, 279 mmol) was added dropwise. The mixture was heated to 85 ° C and stirred for another 3 hours, then concentrated under reduced pressure, and the residue was dissolved in TFA (0.78 L). The mixture was heated to 60 ° C and stirred for 1.5 hours, concentrated under reduced pressure, and washed with saturated NaHCO 3 The residue was adjusted to about pH 5 and then extracted with EtOAc (3 x 1.5 L). The combined organic layers were washed with anhydrous Na 2 SO 4 The mixture was dried, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give 3-(5-bromo-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]-1H-indol-3-yl)-2,2-dimethylpropanoic acid and (S)-3-(5-bromo-2-(2-(1-methoxyethyl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropanoic acid ethyl ester (78 g, crude). LCMS (ESI): m / z [M+H] C 21 H 23 Bn 2 O 3 The calculated value is 430.1 and C 23 H 27 Bn 2 O 3 Calculated value 458.1; experimental values ​​431.1 and 459.1.

[0979] Step 3. Heat the mixture at 0°C in N 2 To a mixture of 3-(5-bromo-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]-1H-indol-3-yl)-2,2-dimethylpropanoic acid and (S)-ethyl 3-(5-bromo-2-(2-(1-methoxyethyl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropanoate (198 g, 459 mmol) in DMF (1.8 L) was added Cs in portions under atmosphere. 2 CO 3(449 g, 1.38 mol). Then, EtI (215 g, 1.38 mmol) in DMF (200 mL) was added dropwise at 0°C. The mixture was warmed to room temperature and stirred for 4 hours, then diluted with brine (5 L) and extracted with EtOAc (3×2.5 L). The combined organic layers were washed with brine (2×1.5 L) and washed with anhydrous Na 2 SO 4 The mixture was dried and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give ethyl 3-(5-bromo-1-ethyl-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]indol-3-yl)-2,2-dimethylpropanoate (160 g, 57% yield) as a solid. LCMS (ESI): m / z [M+H] C 25 H 31 Bn 2 O 3 Calculated value 486.2; experimental value 487.2.

[0980] Step 4. Heat the mixture at 0°C in N 2 To a mixture of ethyl 3-(5-bromo-1-ethyl-2-[2-[(1S)-1-methoxyethyl]pyridin-3-yl]indol-3-yl)-2,2-dimethylpropanoate (160 g, 328 mmol) in THF (1.6 L) was added LiBH 4 (28.6 g, 1.3 mol). The mixture was heated to 60°C for 16 h, cooled, and washed with pre-cooled (0°C) NH 4 The mixture was extracted with EtOAc (3×2 L) and the combined organic layers were washed with brine (2×1 L) and washed with anhydrous Na 2 SO 4 The mixture was dried and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give two atropisomers (as a single atropisomer) of 3-(5-bromo-1-ethyl-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropan-1-ol (60 g, 38% yield) and (40 g, 26% yield), both in the form of solids. LCMS (ESI): m / z [M+H] C 23 H 29 Bn 2 O 2 Calculated value 444.1; experimental value 445.2.

[0981] Intermediate 2. Synthesis ((6 3 S,4S,Z)-1 1 -Ethyl-1 2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-tert-butyl 8-oxa-2(4,2)-thiazol-1(5,3)-indol-6(1,3)-pyridazineheterocycleundecanoyl-4-yl)carbamate

[0982]

[0983] Step 1. To a solution of methyl (2S)-3-(4-bromo-1,3-thiazol-2-yl)-2-[(tert-butoxycarbonyl)amino]propanoate (110 g, 301.2 mmol) in THF (500 mL) and H 2 To the solution in 4% HCl (200 mL), LiOH (21.64 g, 903.6 mmol) was added. The resulting solution was stirred for 1 hour and then concentrated under reduced pressure. The resulting residue was adjusted to pH 6 with 1M HCl and then extracted with DCM (3 x 500 mL). The combined organic layers were purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure to obtain the desired product (108 g, crude). LCMS (ESI) m / z: [M+H]C 11 H 15 Bn 2 O 4 Calculated value of S: 351.00; experimental value: 351.0.

[0984] Step 2. To a solution of (S)-3-(4-bromothiazol-2-yl)-2-((tert-butoxycarbonyl)amino)propanoic acid (70 g, 199.3 mmol) in DCM (500 mL) was added (3S)-1,2-diazacyclohexane-3-carboxylic acid methyl ester bis(trifluoroacetate) salt (111.28 g, 298.96 mmol), NMM (219.12 mL, 1993.0 mmol), EDCI (76.41 g, 398.6 mmol) and HOBt (5.39 g, 39.89 mmol) at 0°C. The resulting solution was warmed to room temperature and stirred for 1 hour. The reactants were then treated with H 2 O (500 mL) and extracted with EtOAc (3 x 500 mL). The combined organic layers were purified by Na 2 SO 4Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel chromatography (0→50% EtOAc / petroleum ether) to give the desired product (88.1 g, 92.6% yield). LCMS (ESI) m / z: [M+H]C 17 H 25 Bn 4 O 5 Calculated value of S: 477.08; experimental value: 477.1.

[0985] Step 3. To a solution of 3-(5-bromo-1-ethyl-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropan-1-ol (60 g, 134.7 mmol) in toluene (500 mL) was added bis(pinacolato)diboron (51.31 g, 202.1 mmol), Pd(dppf)Cl 2 (9.86 g, 13.48 mmol) and KOAc (26.44 g, 269.4 mmol). The reaction mixture was then heated to 90 °C and stirred for 2 hours. The reaction solution was then cooled to room temperature and concentrated under reduced pressure. Purification by silica gel chromatography (0→50% EtOAc / petroleum ether) gave the desired product (60.6 g, 94.0% yield). LCMS (ESI) m / z: [M+H]C 29 H 41 BN 2 O 4 Calculated value: 493.32; experimental value: 493.3.

[0986] Step 4. To (S)-3-(1-ethyl-2-(2-(1-methoxyethyl)pyridin-3-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-3-yl)-2,2-dimethylpropan-1-ol (30 g, 60.9 mmol) in toluene (600 mL), dioxane (200 mL) and H2O was added at room temperature. 2 To the solution in O (200 mL) were added (S)-methyl 1-((S)-3-(4-bromothiazol-2-yl)-2-((tert-butoxycarbonyl)amino)propanoyl)hexahydropyridazine-3-carboxylate (43.62 g, 91.4 mmol), K 3 PO 4 (32.23 g, 152.3 mmol) and Pd(dppf)Cl 2 (8.91 g, 12.18 mmol). The resulting solution was heated to 70 °C and stirred overnight. The reaction mixture was then cooled to room temperature and H 2O (200 mL). The resulting mixture was extracted with EtOAc (3 x 1000 mL) and the combined organic layers were purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel chromatography (0→90% EtOAc / petroleum ether) to give the desired product (39.7 g, 85.4% yield). LCMS (ESI) m / z: [M+H]C 40 H 54 N 6 O 7 Calculated value of S: 763.39; experimental value: 763.3.

[0987] Step 5. To a solution of (S)-methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3-(4-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)thiazol-2-yl)propanoyl)hexahydropyridazine-3-carboxylate (39.7 g, 52.0 mmol) in THF (400 mL) and H 2 O (100 mL) was added with LiOH●H 2 O (3.74 g, 156.2 mmol). The resulting mixture was stirred for 1.5 hours and then concentrated under reduced pressure. The residue was acidified to pH 6 with 1M HCl and extracted with DCM (3 x 1000 mL). The combined organic layers were purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure to obtain the desired product (37.9 g, crude). LCMS (ESI) m / z: [M+H]C 39 H 52 N 6 O 7 Calculated value of S: 749.37; experimental value: 749.4.

[0988] Step 6. To a solution of (S)-1-((S)-2-((tert-butoxycarbonyl)amino)-3-(4-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)thiazol-2-yl)propanoyl)hexahydropyridazine-3-carboxylic acid (37.9 g, 50.6 mmol), HOBt (34.19 g, 253.0 mmol) and DIPEA (264.4 mL, 1518 mmol) in DCM (4 L) was added EDCI (271.63 g, 1416.9 mmol) at 0°C. The resulting mixture was warmed to room temperature and stirred overnight. The reaction mixture was then treated with H 2The mixture was quenched with 0 and washed with 1M HCl (4 x 1 L). The organic layer was separated and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0→70% EtOAc / petroleum ether) to give the desired product (30 g, 81.1% yield). LCMS (ESI) m / z: [M+H]C 39 H 50 N 6 O 6 Calculated value of S: 731.36; experimental value: 731.3.

[0989] Intermediate 3. Synthesis of (S)-3-bromo-5-iodo-2-(1-methoxyethyl)pyridine

[0990]

[0991] Step 1. To a stirred solution of 3-bromo-2-[(1S)-1-methoxyethyl]pyridine (80.00 g, 370.24 mmol, 1.00 equiv) and bis(pinacolato)diboron (141.03 g, 555.3 mmol, 1.50 equiv) in THF (320 mL) was added dtbpy (14.91 g, 55.5 mmol) and chloro(1,5-cyclooctadiene)iridium(I) dimer (7.46 g, 11.1 mmol) under an argon atmosphere. The resulting mixture was stirred at 75 °C for 16 hours under an argon atmosphere. The mixture was concentrated under reduced pressure. The resulting mixture was dissolved in EtOAc (200 mL) and the mixture was washed with water containing Na 2 CO 3 (40g) and NaOH (10g) (mass 4:1) water (600mL) adjusted to pH 10. The aqueous layer was extracted with EtOAc (800mL). The aqueous phase was acidified to pH=6 with HCl (6N) to precipitate the desired solid to give 5-bromo-6-[(1S)-1-methoxyethyl]pyridin-3-ylboronic acid (50g, 52.0% yield) as a light yellow solid. LCMS (ESI): m / z [M+H] C 8 H 11 BBr 3 Calculated value: 259.0; experimental value: 260.0.

[0992] Step 2. To a stirred solution of 5-bromo-6-[(1S)-1-methoxyethyl]pyridin-3-ylboronic acid (23.00 g, 88.5 mmol) in ACN (230 mL) was added NIS (49.78 g, 221.2 mmol) at room temperature under argon atmosphere. The resulting mixture was stirred at 80 °C under argon atmosphere overnight. The resulting mixture was concentrated under reduced pressure. The resulting mixture was dissolved in DCM (2.1 L) and treated with Na 2 S 2 O3 The mixture was washed with 4% paraformaldehyde (3x 500 mL). The organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give (S)-3-bromo-5-iodo-2-(1-methoxyethyl)pyridine (20 g, 66.0% yield). LCMS (ESI): m / z [M+H] C 8 H 9 Calculated for BrINO: 340.9; found: 341.7.

[0993] Intermediate 4. Synthesis ((6 3 S,4S,Z)-11-ethyl-1 2 -(2-((S)-1-methoxyethyl)-5-(4-methylpiperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-tert-butyl 8-oxa-2(4,2)-thiazol-1(5,3)-indol-6(1,3)-pyridazineheterocycleundecanoyl-4-yl)carbamate

[0994]

[0995] Step 1. Into a 3L three-necked round-bottom flask purged and maintained with an argon inert atmosphere, 3-bromo-5-iodo-2-[(1S)-1-methoxyethyl]pyridine (147 g, 429.8 mmol), benzyl piperazine-1-carboxylate (94.69 g, 429.8 mmol), Pd(OAc) were placed. 2 (4.83g, 21.4mmol), BINAP (5.35g, 8.6mmol), Cs 2 CO 3 (350.14g, 1074.6mmol), toluene (1L). The resulting solution was stirred in an oil bath at 100 ° C overnight. After the reaction was completed, the reaction mixture was cooled to 25 ° C. The resulting mixture was concentrated under reduced pressure. The residue was applied to a silica gel column using ethyl acetate / hexane (1: 1). The solvent was removed under reduced pressure to obtain (S)-4-(5-bromo-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylic acid benzyl ester (135g, 65.1% yield) as a dark yellow solid. LCMS (ESI): m / z[M+H]C 20 H 24 Bn 3 O 3 Calculated value: 433.1; experimental value: 434.1.

[0996] Step 2. Into a 3L three-necked round-bottom flask purged and maintained with an argon inert atmosphere, benzyl 4-[5-bromo-6-[(1S)-1-methoxyethyl]pyridin-3-yl]piperazine-1-carboxylate (135 g, 310.8 mmol), bis(pinacolato)diboron (86.82 g, 341.9 mmol), Pd(dppf)Cl 2 (22.74g, 31.0mmol), KOAc (76.26g, 777.5mmol), toluene (1L). The resulting solution was stirred at 90 ° C in an oil bath for 2 days. The reaction mixture was cooled to 25 ° C. The resulting mixture was concentrated under vacuum. The residue was applied to a neutral alumina column using ethyl acetate / hexane (1: 3). The solvent was removed under reduced pressure to obtain (S)-4-(6-(1-methoxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)piperazine-1-carboxylic acid benzyl ester (167g, crude) as a dark yellow solid. LCMS (ESI): m / z[M+H]C 26 H 36 BN 3 O 5 Calculated value 481.3; experimental value 482.1.

[0997] Step 3. Into a 3 L three-necked round-bottom flask purged and maintained with an argon inert atmosphere were placed (S)-4-(6-(1-methoxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)piperazine-1-carboxylate (167 g, 346.9 mmol), 5-bromo-3-[3-[(tert-butyldiphenylsilyl)oxy]-2,2-dimethylpropyl]-2-iodo-1H-indole (224.27 g, 346.9 mmol), Pd(dppf)Cl 2 (25.38 g, 34.6 mmol), dioxane (600 mL), H 2 O (200 mL), K 3 PO 4(184.09g, 867.2mmol), toluene (200mL). The resulting solution was stirred overnight at 70 ° C in an oil bath. After the reaction was completed, the reaction mixture was cooled to 25 ° C. The resulting mixture was concentrated under vacuum. The residue was applied to a silica gel column using ethyl acetate / hexane (1: 1). The solvent was removed under reduced pressure to obtain (S)-4-(5-(5-bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylic acid benzyl ester (146g, 48.1% yield) as a yellow solid. LCMS (ESI): m / z[M+H]C 49 H 57 Bn 4 O 4 Calculated value of Si: 872.3; experimental value: 873.3.

[0998] Step 4. Heat the mixture at 0°C in N 2 (S)-benzyl 4-(5-(5-bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylate (146 g, 167.0 mmol) and Cs 2 CO 3 To a stirred mixture of 4-nitropropene (163.28 g, 501.1 mmol) in DMF (1200 mL) was added C 2 H 5 I (52.11 g, 334.0 mmol). The final reaction mixture was stirred at 25 °C for 12 h. The desired product could be detected by LCMS. The resulting mixture was diluted with EA (1 L) and washed with brine (3 x 1.5 L). The organic layer was purified by anhydrous Na 2 SO 4 After filtration, the filtrate was concentrated under reduced pressure to obtain (S)-4-(5-(5-bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-1-ethyl-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylic acid benzyl ester (143 g, crude) as a yellow solid, which was directly used in the next step without further purification. LCMS (ESI): m / z [M+H] C 51 H 61 Bn 4 O 4 Calculated value of Si: 900.4; experimental value: 901.4.

[0999] Step 5. To a stirred mixture of (S)-benzyl 4-(5-(5-bromo-3-(3-((tert-butyldiphenylsilyl)oxy)-2,2-dimethylpropyl)-1-ethyl-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylate (143 g, 158.5 mmol) in DMF (1250 mL) was added CsF (72.24 g, 475.5 mmol). Then, N 2 The reaction mixture was stirred at 60 ° C for 2 days under atmosphere. The desired product can be detected by LCMS. The resulting mixture was diluted with EA (1 L) and washed with brine (3x 1 L). The organic phase was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (1 / 3) to give two atropisomers (S)-4-(5-(5-bromo-1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylic acid benzyl ester A (38 g, 36% yield, RT = 1.677 min, in 3 min LCMS (0.1% FA)) and B (34 g, 34% yield, RT = 1.578 min, in 3 min LCMS (0.1% FA)). LCMS (ESI): m / z [M+H] C 35 H 43 Bn 4 O 4 Calculated value 663.2; experimental value 662.2.

[1000] Step 6. Into a 500 mL three-necked round-bottom flask purged and maintained with a nitrogen inert atmosphere, were placed (S)-4-(5-(5-bromo-1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylic acid benzyl ester A (14 g, 21.1 mmol), bis(pinacolato)diboron (5.89 g, 23.21 mmol), Pd(dppf)Cl 2(1.54g, 2.1mmol), KOAc (5.18g, 52.7mmol), toluene (150mL). The resulting solution was stirred at 90 ° C in an oil bath for 5 hours. The reaction mixture was cooled to 25 ° C. The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography and eluted with PE / EA (1 / 3) to give (S)-4-(5-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylic acid benzyl ester (12g, 76.0% yield) as a yellow solid. LCMS (ESI): m / z[M+H]C 41 H 55 BN 4 O 6 Calculated value: 710.4; experimental value: 711.3.

[1001] Step 7. Into a 250 mL round-bottom flask purged and maintained with an argon inert atmosphere were placed (S)-benzyl 4-(5-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylate (10.8 g, 15.2 mmol), (3S)-methyl 1-[(2S)-3-(4-bromo-1,3-thiazol-2-yl)-2-[(tert-butoxycarbonyl)amino]propanoyl]-1,2-diazacyclohexane-3-carboxylate (7.98 g, 16.7 mmol), Pd(dtbpf)Cl 2 (0.99 g, 1.52 mmol), K 3 PO 4 (8.06 g, 37.9 mmol), toluene (60 mL), dioxane (20 mL), H 2The obtained solution was stirred at 70 ° C for 3 hours in an oil bath. The reaction mixture was cooled to 25 ° C. The obtained solution was extracted with EtOAc (2x 50mL) and concentrated under reduced pressure. The residue was applied to a silica gel column using ethyl acetate / hexane (10: 1). The solvent was removed to obtain (S)-1-((S)-3-(4-(2-(5-(4-((benzyloxy)carbonyl)piperazine-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-1H-indol-5-yl)thiazole-2-yl)-2-((tert-butoxycarbonyl)amino)propanoyl)hexahydropyridazine-3-methyl carboxylate (8g, 50.9% yield) as a yellow solid. LCMS (ESI): m / z[M+H]C 52 H 68 N 8 O 9 Calculated value of S: 980.5; experimental value: 980.9.

[1002] Step 8. In N 2 (S)-methyl 1-((S)-3-(4-(2-(5-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-1H-indol-5-yl)thiazol-2-yl)-2-((tert-butoxycarbonyl)amino)propanoyl)hexahydropyridazine-3-carboxylate (12 g, 12.23 mmol) was added to a solution of THF (100 mL) / H2O under atmosphere. 2 O (100mL) in the stirred mixture, add LiOH (2.45g, 61.1mmol) and the resulting mixture is stirred at 25 ° C for 2 hours. The desired product can be detected by LCMS. THF is concentrated under reduced pressure. The pH of the aqueous phase is acidified to 5 with HCL (1N) at 0 ° C. The aqueous layer is extracted with DCM (3x 100ml). The organic phase is concentrated under reduced pressure to obtain (S) -1- ((S) -3- (4- (2- (5- (4- ((benzyloxy) carbonyl) piperazine -1- base) -2- ((S) -1- methoxyethyl) pyridin-3-yl) -1- ethyl -3- (3- hydroxy -2,2- dimethylpropyl) -1H- indol-5-yl) thiazole -2- base) -2- ((tert-butoxycarbonyl) amino) propionyl) hexahydropyridazine -3- carboxylic acid (10g, 84.5% yield) in a light yellow solid. LCMS (ESI): m / z [M+H] C 51 H 66 N 8 O 9 Calculated value of S: 966.5; experimental value: 967.0.

[1003] Step 9. Into a 3 L round bottom flask purged and maintained with an inert atmosphere of nitrogen was placed (S)-1-((S)-3-(4-(2-(5-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-1H-indol-5-yl)thiazol-2-yl)-2-((tert-butoxycarbonyl)amino)propanoyl)hexahydropyridazine-3-carboxylic acid (18 g, 18.61 mmol), ACN (1.8 L), DIEA (96.21 g, 744.4 mmol), EDCI (107.03 g, 558.3 ​​mmol), HOBT (25.15 g, 186.1 mmol). The resulting solution was stirred at 25° C. overnight. After the reaction was completed, the resulting mixture was concentrated under vacuum. The resulting solution was diluted with DCM (1 L). The resulting mixture was washed with HCl (3 x 1 L, 1 N aqueous). The resulting mixture was washed with water (3 x 1 L). The organic layer was then concentrated and the residue was applied to a silica gel column using ethyl acetate / hexane (1: 1). The solvent was removed under reduced pressure to obtain 4-(5-(6 3 S,4S,Z)-4-((tert-butoxycarbonyl)amino)-1 1 -ethyl-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-8-Oxa-2(4,2)-thiazolyl-1(5,3)-indolyl-6(1,3)-pyridazine heterocyclic undecylidene-1 2 -yl)-benzyl 6-((S)-1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylate (10.4 g, 54.8% yield). LCMS (ESI): m / z [M+H] C 51 H 64 N 8 O 8 Calculated value of S: 948.5; experimental value: 949.3.

[1004] Step 10. Into a 250 mL round-bottom flask purged and maintained with a nitrogen inert atmosphere, 4-(5-((6 3 S,4S,Z)-4-((tert-butoxycarbonyl)amino)-1 1 -ethyl-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5,6 6 -Hexahydro-1 1 H-8-Oxa-2(4,2)-thiazolyl-1(5,3)-indolyl-6(1,3)-pyridazine heterocyclic undecylidene-1 2 -yl)-6-((S)-1-methoxyethyl)pyridin-3-yl)piperazine-1-carboxylic acid benzyl ester (10.40 g, 10.9 mmol), Pd(OH) 2 / C (5 g, 46.9 mmol), MeOH (100 mL). The resulting solution was stirred at 25 °C under 2 atm H 2 Stir under atmosphere for 3 hours. Filter out the solid and wash the filter cake with MeOH (3 x 100 mL). Then concentrate the combined organic phase under reduced pressure to obtain (6 3 S,4S,Z)-11-ethyl-1 2 -(2-((S)-1-methoxyethyl)-5-(piperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-tert-butyl 8-oxa-2(4,2)-thiazol-1(5,3)-indol-6(1,3)-pyridazinylheterocycloundecanoyl-4-yl)carbamate (8.5 g, 90.4% yield). LCMS (ESI): m / z [M+H] C 43 H 58 N 8 O 6 Calculated value of S: 814.4; experimental value: 815.3.

[1005] Step 11. Place (6 3 S,4S,Z)-11-ethyl-1 2 -(2-((S)-1-methoxyethyl)-5-(piperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1H-tert-butyl 8-oxa-2(4,2)-thiazol-1(5,3)-indol-6(1,3)-pyridazinyl)carbamate (8.5 g, 10.4 mmol), MeOH (100 mL), AcOH (1.88 g, 31.2 mmol) were added and stirred for 15 minutes. Then HCHO (1.88 g, 23.15 mmol, 37% aqueous solution) and NaBH were added at 25°C. 3 CN (788 mg, 12.5 mmol). The resulting solution was stirred at 25 ° C for 3 hours. The resulting mixture was quenched with 100 mL of water and concentrated under reduced pressure to remove MeOH. The resulting solution was diluted with 300 mL of DCM. The resulting mixture was washed with water (3 x 100 mL). The solvent was removed to obtain (6 3 S,4S,Z)-1 1 -Ethyl-1 2 -(2-((S)-1-methoxyethyl)-5-(4-methylpiperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-tert-butyl 8-oxa-2(4,2)-thiazol-1(5,3)-indol-6(1,3)-pyridazinylheterocycloundecanoyl-4-yl)carbamate (8.2 g, 90.1% yield). LCMS (ESI): m / z [M+H] C 44 H 60 N 8 O 6 Calculated value of S: 828.4; experimental value: 829.3.

[1006] Intermediate 5. Synthesis (6 3 S,4S)-4-amino-1 1 -Ethyl-1 2 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-8-Oxa-1(5,3)-indol-6(1,3)-pyridazin-2(1,3)-benzene heterocycle undecanoic acid-5,7-dione

[1007]

[1008] Step 1. To a solution of (2S)-3-(3-bromophenyl)-2-[(tert-butoxycarbonyl)amino]propanoic acid (100 g, 290 mmol) in DMF (1 L) was added NaHCO 3 (48.8 g, 581.1 mmol) and MeI (61.9 g, 435.8 mmol). The reaction mixture was stirred for 16 h and then heated to 40 °C. 2 O (1 L) and extracted with EtOAc (3 x 1 L). The combined organic layers were washed with brine (3 x 500 mL) and purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel column chromatography (13% EtOAc / petroleum ether) to give the final product (109 g, crude). LCMS (ESI) m / z [M+Na] C 15 H 20 BrNO 4 Calculated value: 380.05; experimental value: 380.0.

[1009] Step 2. To a stirred solution of methyl (2S)-3-(3-bromophenyl)-2-[(tert-butoxycarbonyl)amino]propanoate (108 g, 301.5 mmol) and bis(pinacolato)diboron (99.53 g, 391.93 mmol) in dioxane (3.2 L) was added KOAc (73.97 g, 753.70 mmol) and Pd(dppf)Cl 2 (22.06 g, 30.15 mmol). The reaction mixture was heated to 90 °C for 3 hours and then cooled to room temperature and extracted with EtOAc (2 x 3 L). The combined organic layers were washed with brine (3 x 800 mL), purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel column chromatography (5% EtOAc / petroleum ether) to give the product (96 g, 78.6% yield). LCMS (ESI) m / z [M+Na] C 21 H 32 BNO 6 Calculated value: 428.22; experimental value: 428.1.

[1010] Step 3. To a solution of methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoate (94 g, 231.9 mmol) and 3-(5-bromo-1H-indol-3-yl)-2,2-dimethylpropyl acetate (75.19 g, 231.93 mmol) in dioxane (1.5 L) and H2O was added. 2O (300 mL) was added to the mixture 2 CO 3 (64.11 g, 463.85 mmol) and Pd(DtBPF)Cl 2 (15.12 g, 23.19 mmol). The reaction mixture was heated to 70°C and stirred for 4 hours. The reaction mixture was extracted with EtOAc (2 x 2 L) and the combined organic layers were washed with brine (3 x 600 mL), washed with Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel column chromatography (20% EtOAc / petroleum ether) to give the product (130 g, crude). LCMS (ESI) m / z [M+H] C 30 H 38 N 2 O 6 Calculated value: 523.28; experimental value: 523.1.

[1011] Step 4. To a solution of methyl (2S)-3-(3-[3-[3-(acetyloxy)-2,2-dimethylpropyl]-1H-indol-5-yl]phenyl)-2-[(tert-butoxycarbonyl)amino]propanoate (95.0 g, 181.8 mmol) and iodine (36.91 g, 145.41 mmol) in THF (1 L) was added AgOTf (70.0 g, 272.7 mmol) and NaHCO at -10 °C. 3 (22.9 g, 272.65 mmol). The reaction mixture was stirred at 0°C for 30 min and then reacted with saturated Na 2 S 2 O 3 The resulting mixture was extracted with EtOAc (3 x 1 L) and the combined organic layers were washed with brine (3 x 500 mL) and purified by Na 2 SO 4 The mixture was dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50% EtOAc / petroleum ether) to give (S)-methyl 3-(3-(3-(3-acetoxy-2,2-dimethylpropyl)-2-iodo-1H-indol-5-yl)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate (49.3 g, 41.8% yield). LCMS (ESI) m / z [M+H] C 30 H 37 IN 2 O 6 Calculated value: 649.18; experimental value: 649.1.

[1012] Step 5. To a solution of methyl (2S)-3-(3-[3-[3-(acetyloxy)-2,2-dimethylpropyl]-2-iodo-1H-indol-5-yl]phenyl)-2-[(tert-butoxycarbonyl)amino]propanoate (60 g, 92.5 mmol) in THF (600 mL) was added LiOH·H 2 O (19.41 g, 462.5 mmol) in H 2 O (460 mL). The resulting solution was stirred overnight and then the pH was adjusted to 6 with HCl (1 M). The resulting solution was extracted with EtOAc (2 x 500 mL) and the combined organic layers were washed with brine (2 x 500 mL), washed with Na 2 SO 4 Dry, filter and concentrate under reduced pressure to obtain the product (45 g, 82.1% yield). LCMS (ESI) m / z [M+Na] C 27 H 33 IN 2 O 6 Calculated value: 615.13; experimental value: 615.1.

[1013] Step 6. To a solution of (2S)-2-[(tert-butoxycarbonyl)amino]-3-[3-[3-(3-hydroxy-2,2-dimethylpropyl)-2-iodo-1H-indol-5-yl]phenyl]propanoic acid (30 g, 50.6 mmol) and (3S)-methyl 1,2-diazacyclohexane-3-carboxylate (10.9 g, 75.9 mmol) in DCM (400 mL) was added NMM (40.97 g, 405.08 mmol), HOBt (2.05 g, 15.19 mmol) and EDCI (19.41 g, 101.27 mmol). The reaction mixture was stirred overnight and then washed with saturated NH 4 The mixture was washed with aqueous Cl solution (2 x 200 mL) and brine (2 x 200 mL), and the mixture was washed with Na 2 SO 4 , filtered and concentrated under reduced pressure to obtain the product (14 g, 38.5% yield). LCMS (ESI) m / z [M+H] C 33 H 43 IN 4 O 6 Calculated value: 718.23; experimental value: 719.4.

[1014] Step 7. To a solution of (S)-methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3-(3-(3-(3-hydroxy-2,2-dimethylpropyl)-2-iodo-1H-indol-5-yl)phenyl)propanoyl)hexahydropyridazine-3-carboxylate (92 g, 128.0 mmol) in THF (920 mL) was added LiOH·H 2 O (26.86 g, 640.10 mmol) in H 2 O (640 mL). The reaction mixture was stirred for 2 hours and then concentrated under reduced pressure to give the product (90 g, crude). LCMS (ESI) m / z [M+H] C 32 H 41 IN 4 O 6 Calculated value: 705.22; experimental value: 705.1.

[1015] Step 8. To a solution of (3S)-1-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-[3-[3-(3-hydroxy-2,2-dimethylpropyl)-2-iodo-1H-indol-5-yl]phenyl]propanoyl]-1,2-diazacyclohexane-3-carboxylic acid (90 g, 127.73 mmol) in DCM (10 L) at 0°C was added HOBt (34.52 g, 255.46 mmol), DIPEA (330.17 g, 2554.62 mmol) and EDCI (367.29 g, 1915.96 mmol). The reaction mixture was stirred for 16 hours and then concentrated under reduced pressure. The mixture was extracted with DCM (2 x 2 L) and the combined organic layers were washed with brine (3 x 1 L), purified by chromatography on agarose gel (HPLC) for 1 h. 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel column chromatography (50% EtOAc / petroleum ether) to give the product (70 g, 79.8% yield). LCMS (ESI) m / z [M+H] C 32 H 39 IN 4 O 5 Calculated value: 687.21; experimental value: 687.1.

[1016] Step 9. Charge (6 3 S,4S)-1 2 -iodo-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-11 H-8-oxa-1(5,3)-indol-6(1,3)-pyridazin-2(1,3)-benzheterocycloundecyl-4-yl)carbamic acid tert-butyl ester (22.0 g, 32.042 mmol), toluene (300.0 mL), Pd 2 (dba) 3 (3.52g, 3.845mmol), S-Phos (3.95g, 9.613mmol) and KOAc (9.43g, 96.127mmol). 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (26.66g, 208.275mmol) was added dropwise to the mixture under stirring at room temperature. The resulting solution was stirred at 60 °C for 3 hours. The resulting mixture was filtered and the filter cake was washed with EtOAc. The filtrate was concentrated under reduced pressure and the remaining residue was purified by silica gel column chromatography to give the product (22g, 90% yield) as a solid. LCMS (ESI) m / z [M+H] C 38 H 51 BN 4 O 7 Calculated value: 687.3; experimental value: 687.4.

[1017] Step 10. In N 2 Atmosphere will ((6 3 S,4S)-10,10-dimethyl-5,7-dioxo-1 2 -(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6- 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-8-oxa-1(5,3)-indol-6(1,3)-pyridazin-2(1,3)-benzheterocycloundecyl-4-yl)carbamic acid tert-butyl ester (2.0 g, 2.8 mmol), 3-bromo-2-[(1S)-1-methoxyethyl]pyridine (0.60 g, 2.8 mmol), Pd(dppf)Cl 2 (0.39 g, 0.5 mmol) and K 3 PO 4 (1.2 g, 6.0 mmol) in dioxane (50 mL) and H 2 The mixture in 2% O (10 mL) was heated to 70 °C and stirred for 2 h. 2 O (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (3 x 50 mL) and purified by anhydrous Na2 SO 4 Dried and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give the product as a solid (1.5 g, 74% yield). LCMS (ESI) m / z [M+H] C 40 H 49 N 5 O 6 Calculated value: 695.4; experimental value: 696.5.

[1018] Step 11. Heat the mixture to ((6 3 S,4S)-1 2 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-8-oxa-1(5,3)-indol-6(1,3)-pyridazin-2(1,3)-benzheterocycloundecyl-4-yl)carbamic acid tert-butyl ester (20 g, 28.7 mmol) and Cs 2 CO 3 To a solution of 5-nitropropene (18.7 g, 57.5 mmol) in DMF (150 mL) was added a solution of EtI (13.45 g, 86.22 mmol) in DMF (50 mL). The resulting mixture was stirred at 35 °C overnight and then heated to 40 °C with H 2 The mixture was extracted with EtOAc (2 x 300 mL) and the combined organic layers were washed with brine (3 x 100 mL), purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel column chromatography to give the product (4.23 g, 18.8% yield) and atropisomer (5.78 g, 25.7% yield) as a solid. LCMS (ESI) m / z [M+H] C 42 H 53 N 5 O 6 Calculated value: 724.4; experimental value: 724.6.

[1019] Step 12. Replace ((6 3 S,4S)-1 1 -Ethyl-1 2 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-6 1 ,6 2,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 A mixture of tert-butyl H-8-oxa-1(5,3)-indol-6(1,3)-pyridazin-2(1,3)-benzheterocycloundecyl-4-yl)carbamate (1.3 g, 1.7 mmol) in TFA (10 mL) and DCM (20 mL) was stirred at 0° C. for 2 hours. The mixture was concentrated under reduced pressure to give the product as a solid (1.30 g, crude). LCMS (ESI) m / z [M+H] C 37 H 45 N 5 O 4 Calculated value: 623.3; experimental value: 624.4.

[1020] Intermediate 6: Synthesis of (S)-3-(5-bromo-1-ethyl-2-(5-iodo-2-(1-methoxyethyl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropyl acetate

[1021]

[1022] Step 1. To (S)-3-(5-bromo-1-ethyl-2-(2-(1-methoxyethyl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropan-1-ol (100 g, 224.517 mmol) and Et 3 To a stirred solution of N (45.44 g, 449.034 mmol) in DCM (1 L) were added DMAP (2.74 g, 22.452 mmol) and Ac in portions. 2 O (27.50 g, 269.420 mmol). The resulting mixture was stirred at room temperature for 3 hours. The resulting mixture was concentrated under reduced pressure and then diluted with EtOAc (1000 mL). The resulting mixture was washed with 1M HCl (500 mL) and then with saturated NaHCO 3 (500 mL) and brine (500 mL), washed with anhydrous Na 2 SO 4 After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by trituration with petroleum ether (500 mL) to give the product as a white solid (93.3 g, 85% yield). LCMS (ESI) m / z [M+H] C 25 H 31 Bn 2 O 3 Calculated value: 487.16; Experimental value: 489.2

[1023] Step 2. To (S)-acetic acid 3-(5-bromo-1-ethyl-2-(2-(1-methoxyethyl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropyl ester (93.3 g, 191.409 mmol) and B at room temperature under argon atmosphere was added 3-(5-bromo-1-ethyl-2-(2-(1-methoxyethyl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropyl ester (93.3 g, 191.409 mmol). 2 PIN 2 To a stirred solution of dtbpy (72.91 g, 287.113 mmol) in THF (370 mL) was added dtbpy (7.71 g, 28.711 mmol) and chloro(1,5-cyclooctadiene)iridium(I) dimer (6.43 g, 9.570 mmol) in multiple portions. The resulting mixture was stirred at 75 °C overnight. The resulting mixture was concentrated under reduced pressure to give the product as an oil (190 g, crude). LCMS (ESI) m / z [M+H]; C 25 H 32 BnB 2 O 5 Calculated value: 531.17; Experimental value: 533.3

[1024] Step 3. To a stirred solution of (S)-(5-(3-(3-acetoxy-2,2-dimethylpropyl)-5-bromo-1-ethyl-1H-indol-2-yl)-6-(1-methoxyethyl)pyridin-3-yl)boronic acid (110 g, 207.059 mmol) and chloramine-T trihydrate (349.96 g, 1242.354 mmol) in THF (550 mL) was added NaI (186.22 g, 1242.354 mmol) in H2O in multiple portions at 0 °C under air atmosphere. 2 O (225 mL). The resulting mixture was stirred at 50 °C under argon atmosphere overnight. The resulting mixture was concentrated under reduced pressure and then washed with CHCl 3 The resulting mixture was filtered and washed with CHCl 3 (3x250mL) to wash the filter cake. 3 The filtrate was extracted with (3 x 500 mL). The combined organic layers were washed with Na 2 S 2 O 3 (500 mL), washed with brine (2 x 200 mL), washed with anhydrous Na 2 SO 4 After drying and filtration, the filtrate was concentrated under reduced pressure.

[1025] The residue was purified by silica gel column

[1026] Intermediate 7: Synthesis of 3-(5-bromo-1-ethyl-2-(2-((S)-1-methoxyethyl)-5-((R)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropyl acetate

[1027]

[1028] Step 1. To the reaction mixture of 3-(5-bromo-1-ethyl-2-{5-iodo-2-[(1S)-1-methoxyethyl]pyridin-3-yl}indol-3-yl)-2,2-dimethylpropyl acetate (9 g, 14.674 mmol), (R)-octahydro-2H-pyrido[1,2-a]pyrazine (2.469 g, 17.609 mmol), Cs 2 CO 3 To a stirred solution of 4-(11.9523 g, 36.685 mmol) and BINAP (456.85 mg, 0.734 mmol) in toluene (63 mL) was added Pd(OAc)2 (329.44 mg, 1.467 mmol) in multiple portions. The resulting mixture was stirred at 100 °C for 6 hours, then the mixture was filtered and the filter cake was washed with EtOAc (100 mL). The filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (8% MeOH / DCM) to give the product as a solid (6 g, 65% yield). LCMS (ESI) m / z [M+H] C 33 H 45 Bn 4 O 3 Calculated value: 625.28; Experimental value: 627.4

[1029] Intermediate 8. Synthesis (6 3 S,4S)-4-amino-1 1 -Ethyl-2 5 -(Fluoromethyl)-1 2 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-8-Oxa-1(5,3)-indol-6(1,3)-pyridazin-2(1,3)-benzene heterocycle undecanoic acid-5,7-dione

[1030]

[1031] Step 1. To a solution of (3-bromo-5-iodophenyl)methanol (175.0 g, 559.227 mmol) in DCM (2 L) was added BAST (247.45 g, 1118.454 mmol) dropwise at 0°C. The resulting mixture was stirred at room temperature for 16 hours. The mixture was treated with saturated aqueous NaHCO at 0°C. 3 The reaction was quenched. The organic layer was treated with H 2 O (3 x 700 mL) and washed with anhydrous Na 2 SO 4 After drying, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (3% EtOAc / petroleum ether) to give the desired product (120 g, 68% yield).

[1032] Step 2. Add DMF (350.0 mL) containing Zn powder (32.40 g, 495.358 mmol) and I into a 1000 mL three-necked round-bottom flask. 2 (967.12mg, 3.810mmol). To the mixture was added a solution of (2R)-2-[(tert-butoxycarbonyl)amino]-3-iodopropionic acid methyl ester (27.0g, 82.03mmol) in DMF (10mL). The mixture was heated to 30 ° C for 10 minutes. Then a solution of (2R)-2-[(tert-butoxycarbonyl)amino]-3-iodopropionic acid methyl ester (54.0g, 164.07mmol) in DMF (20mL) was added to the mixture. The resulting mixture was stirred at room temperature for 30 minutes and filtered. The resulting solution was added to 1-bromo-3-(fluoromethyl)-5-iodobenzene (60g, 190.522mmol), tri(furan-2-yl)phosphine (2.65g, 11.431mmol) and Pd at room temperature under an argon atmosphere. 2 (dba) 3 (3.49 g, 3.810 mmol) in DMF (400 mL) and the reaction mixture was heated to 60 °C for 10 minutes, then the oil bath was removed. The resulting mixture was stirred for about 1 hour until the temperature cooled to 50 °C. 4 The reaction was quenched with aqueous Cl (3000 mL) and the resulting mixture was extracted with EtOAc (3 x 1000 mL). The combined organic layers were washed with brine (2 x 1000 mL) and purified by anhydrous Na 2 SO 4 After drying, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (9% EtOAc / petroleum ether) to give the desired product (45 g, 60% yield).

[1033] Step 3. Methyl (2S)-3-[3-bromo-5-(fluoromethyl)phenyl]-2-[(tert-butoxycarbonyl)amino]propanoate (75.28 g, 192.905 mmol), (S)-3-(1-ethyl-2-(2-(1-methoxyethyl)pyridin-3-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-3-yl)-2,2-dimethylpropan-1-ol (95 g, 192.905 mmol), Pd(dppf)Cl 2 (14.11 g, 19.291 mmol) and K 2 CO 3 (53.32 g, 385.810 mmol) in dioxane (900 mL) and H 2 O (180 mL) was stirred at 80 °C for 2 h. The resulting mixture was concentrated under reduced pressure and then washed with H 2 The resulting mixture was extracted with EtOAc (3 x 1200 mL) and the combined organic layers were washed with H 2 O (3 x 500 mL) and washed with anhydrous Na 2 SO 4 After drying, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50% EtOAc / petroleum ether) to give the desired product (105 g, 80% yield). LCMS (ESI) m / z: [M+H]C 39 H 50 FN 3 O 6 Calculated value: 676.38; experimental value: 676.1.

[1034] Step 4. To a stirred solution of (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(3-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)-5-(fluoromethyl)phenyl)propanoate (108 g, 159.801 mmol) in THF (500 mL) was added LiOH·H 2 O (11.48 g, 479.403 mmol) in H 2 O (500 mL). The resulting mixture was stirred at 0 ° C for 2 hours and then acidified to pH 6 with 1M HCl (aq). The mixture was extracted with EtOAc (3 x 800 mL) and the combined organic layers were washed with brine (2 x 200 mL) and purified by anhydrous Na 2 SO 4After filtration, the filtrate was concentrated under reduced pressure to obtain the desired product (101 g, crude). LCMS (ESI) m / z: [M+H] C 38 H 48 FN 3 O 6 Calculated value: 662.36; experimental value: 662.1.

[1035] Step 5. To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(3-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)-5-(fluoromethyl)phenyl)propanoic acid (103 g, 155.633 mmol) and NMM (157.42 g, 1556.330 mmol) in DCM (1200 mL) was added (3S)-methyl 1,2-diazacyclohexane-3-carboxylate (33.66 g, 233.449 mmol), HOBt (10.51 g, 77.816 mmol) and EDCI (59.67 g, 311.265 mmol) in portions at 0°C. The resulting mixture was stirred at room temperature for 16 hours. The organic layer was then washed with 0.5M HCl (2 x 1000 mL) and brine (2 x 800 mL), and then purified by anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel column chromatography (50% EtOAc / petroleum ether) to give the desired product (103 g, 83% yield). LCMS (ESI) m / z: [M+H]C 44 H 58 FN 5 O 7 Calculated value: 788.44; experimental value: 788.1.

[1036] Step 6. To a stirred solution of (S)-methyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3-(3-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)-5-(fluoromethyl)phenyl)propanoyl)hexahydropyridazine-3-carboxylate (103 g, 130.715 mmol) in THF (700 mL) at 0 °C was added LiOH. 2 O (27.43 g, 653.575 mmol) in H 2O (700 mL). The resulting mixture was stirred at 0 ° C for 2 hours and then neutralized to pH 6 with 1M HCl. The resulting mixture was extracted with EtOAc (3 x 800 mL) and the combined organic layers were washed with brine (2 x 600 mL), dried over anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to obtain the desired product (101 g, crude). LCMS (ESI) m / z: [M+H]C 43 H 56 FN 5 O 7 Calculated value: 774.43; experimental value: 774.1.

[1037] Step 7. To a stirred solution of (S)-1-((S)-2-((tert-butoxycarbonyl)amino)-3-(3-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)-5-(fluoromethyl)phenyl)propanoyl)hexahydropyridazine-3-carboxylic acid (101 g, 130.50 mmol) in DCM (5500 mL) was added DIPEA (227.31 mL, 1305.0 mmol) and HOBt (88.17 g, 652.499 mmol) and EDCI (375.26 g, 1957.498 mmol) at 0°C. The resulting mixture was stirred at room temperature overnight. The mixture was then washed with 0.5M HCl (2 x 2000 mL), brine (2 x 2000 mL), and washed with anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel column chromatography (50% EtOAc / petroleum ether) to give the desired product (68 g, 65% yield). LCMS (ESI) m / z: [M+H]C 43 H 54 FN 5 O 6 Calculated value: 756.42; experimental value: 756.4.

[1038] Step 8. Heat the mixture to ((6 3 S,4S)-1 1 -Ethyl-2 5 -(Fluoromethyl)-1 2 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,66 -Hexahydro-1 1 To a stirred solution of tert-butyl H-8-oxa-1(5,3)-indol-6(1,3)-pyridazin-2(1,3)-benzheterocycloundecyl-4-yl)carbamate (350 mg, 0.403 mmol) in DCM (4 mL) was added TFA (1.50 mL). The resulting mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to give the desired product (600 mg, crude). LCMS (ESI) m / z: [M+H] C 38 H 46 FN 5 O 4 Calculated value: 656.36; experimental value: 656.4.

[1039] Intermediate 9. Synthesis of methyl (3S)-1-((2S)-3-(5-bromo-3-((tert-butyldiphenylsilyl)oxy)-3,6-dihydropyridin-1(2H)-yl)-2-((tert-butoxycarbonyl)amino)propanoyl)hexahydropyridazine-3-carboxylate

[1040]

[1041] Step 1. To a stirred solution of 3,5-dibromopyridine (48 g, 202.6 mmol, 1 eq.) in ACN (480 mL) was added BnBr (51.9 g, 303.9 mmol, 1.5 eq.) dropwise at room temperature. The resulting mixture was stirred at 60 °C overnight and then concentrated under reduced pressure to give 1-benzyl-3,5-dibromopyridin-1-ium (76 g, crude) as a white solid. ESI-MS m / z=325.9 [M] + ,327.9[M+2] + ,329.9[M+4] + ; MW calculated value: 325.9

[1042] Step 2. To a stirred mixture of 1-benzyl-3,5-dibromopyridin-1-ium (40 g, 121.9 mmol, 1.00 equiv) in DCM (400 mL) and EtOH (80 mL) at 0 °C was added NaBH(AcO) in multiple portions. 3 (129.2 g, 609.7 mmol, 5 eq.) The resulting mixture was stirred at room temperature under argon atmosphere for 4 h, and then saturated brine (3 x 40 mL) was added. The aqueous phase was washed with CH 2 Cl 2 (4x50 mL) and extracted with anhydrous Na 2 SO 4Dried and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography to give 1-benzyl-3,5-dibromo-1,2,3,6-tetrahydropyridine (19.1 g, 47.4% yield) as a yellow oil. ESI-MS m / z=330.2 [M+H] + ,332.2[M+H+2] + ,334.2[M+H+4] + ; MW calculated value: 328.9

[1043] Step 3. 1-Benzyl-3,5-dibromo-1,2,3,6-tetrahydropyridine (17.4 g, 52.6 mmol, 1.0 equiv) in ACN (87 mL) and H 2 To the stirred mixture in 2% CO (87 mL) was added NaHCO in multiple portions. 3 (22.08g, 262.800mmol, 5 equivalents). The resulting mixture was stirred at 60 ° C under an argon atmosphere for 3 hours. The mixture was then diluted with brine (300mL) and the aqueous layer was extracted with EtOAc (4x 100mL). The combined organic layers were concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography to give 1-benzyl-5-bromo-1,2,3,6-tetrahydropyridine-3-ol (10g, 70.9% yield) as a yellow oil. ESI-MS m / z=268.1[M+H] + ; MW calculated value: 267.0.

[1044] Step 4. To a stirred mixture of imidazole (5.1 g, 74.6 mmol, 2 eq.) and 1-benzyl-5-bromo-1,2,3,6-tetrahydropyridine-3-ol (10 g, 37.3 mmol, 1.01 eq.) in DCM (100 mL) was added TBDPSCl (15.4 g, 55.9 mmol, 1.5 eq.) dropwise at room temperature. The resulting mixture was stirred overnight at room temperature under an argon atmosphere and then concentrated under reduced pressure. The residue was purified by chromatography to give 1-benzyl-5-bromo-3-((tert-butyldiphenylsilyl)oxy)-1,2,3,6-tetrahydropyridine (18 g, 95.2% yield) as a yellow oil. ESI-MS m / z=506.4 [M+H] + ; MW calculated value: 505.1.

[1045] Step 5. To a stirred solution of 1-benzyl-5-bromo-3-((tert-butyldiphenylsilyl)oxy)-1,2,3,6-tetrahydropyridine (11.7 g, 23.1 mmol, 1.0 equiv) in DCM (1.2 L) was added dropwise 2-chloroethyl chloroformate (13.2 g, 92.4 mmol, 4 equiv) at 0 °C under argon atmosphere. The resulting mixture was stirred at 40 °C under argon atmosphere for 4 hours and concentrated under reduced pressure. MeOH (1.2 L) was then added dropwise at room temperature under argon atmosphere and stirred at 70 °C under argon atmosphere for 2 hours, and the resulting mixture was then concentrated under reduced pressure. The remaining residue was purified by chromatography to give 5-bromo-3-((tert-butyldiphenylsilyl)oxy)-1,2,3,6-tetrahydropyridine (6.2 g, 64.4% yield) as a yellow oil. ESI-MS m / z=416.2[M+H] + ; MW calculated: 415.1.

[1046] Step 6. To 5-bromo-3-((tert-butyldiphenylsilyl)oxy)-1,2,3,6-tetrahydropyridine (11.2 g, 26.9 mmol, 1.0 equiv) in ACN (90 mL) and H 2 To a stirred solution in 2% CO (30 mL) was added (S)-tert-butyl (2-oxooxetan-3-yl)carbamate (6.1 g, 32.4 mmol, 1.2 equiv) and Cs 2 CO 3 (21.9 g, 67.5 mmol, 2.5 equiv.). The resulting mixture was stirred at 40 °C for 4 hours and concentrated under reduced pressure. The remaining residue was purified by chromatography to give (2S)-3-(5-bromo-3-((tert-butyldiphenylsilyl)oxy)-3,6-dihydropyridin-1(2H)-yl)-2-((tert-butoxycarbonyl)amino)propanoic acid (11.2 g, 68.7% yield) as a white solid. ESI-MS m / z=603.0 [M+H] + ; MW calculated value: 602.2.

[1047] Step 7. To a stirred solution of (2S)-3-(5-bromo-3-((tert-butyldiphenylsilyl)oxy)-3,6-dihydropyridin-1(2H)-yl)-2-((tert-butoxycarbonyl)amino)propanoic acid (5.5 g, 9.2 mmol, 1 eq) in DCM (55 mL) was added DIEA (47.5 g, 367.1 mmol, 40 eq), (S)-methyl hexahydropyridazine-3-carboxylate (1.9 g, 13.8 mmol, 1.5 eq) and CIP (3.3 g, 11.9 mmol, 1.3 eq) at 0°C. The resulting mixture was stirred at 0°C for 2 hours. The mixture was then diluted with brine (500 mL) and the aqueous layer was extracted with DCM (3 x 400 mL). The combined organic layers were concentrated under reduced pressure and the resulting residue was purified by chromatography to give (3S)-methyl 1-((2S)-3-(5-bromo-3-((tert-butyldiphenylsilyl)oxy)-3,6-dihydropyridin-1(2H)-yl)-2-((tert-butoxycarbonyl)amino)propanoyl)hexahydropyridazine-3-carboxylate (2.2 g, 32.8% yield) as a white solid. ESI-MS m / z=729.1 [M+H] + ; MW calculated value: 728.3.

[1048] Intermediate 10. Synthesis (6 3 S)-4-amino-1 1 -Ethyl-1 2 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-2 1 ,2 2 ,2 3 ,2 6 ,6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Decahydrogen-1 1 H-8-Oxa-1(5,3)-indol-6(1,3)-pyridazin-2(5,1)-pyridine heterocycle undecanoic acid-5,7-dione

[1049]

[1050] Step 1. To a solution of (tert-butoxycarbonyl)-L-serine methyl ester (10 g, 45 mmol) in anhydrous MeCN (150 mL) was added DIPEA (17 g, 137 mmol). The reaction mixture was stirred at 45 °C for 2 hours to give the product in solution. LCMS (ESI) m / z [M+Na] C 9 H 15 NO4 Calculated value: 201.1; experimental value: 224.1.

[1051] Step 2. To a solution of methyl 2-((tert-butoxycarbonyl)amino)acrylate (12 g, 60 mmol) in anhydrous MeCN (150 mL) at 0 °C was added DMAP (13 g, 90 mmol) and (Boc) 2 O (26 g, 120 mmol). The reaction was stirred for 6 h and then heated with H 2 O (100 mL) and extracted with DCM (3 x 200 mL). The combined organic layers were washed with brine (150 mL) and purified by anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel column chromatography to give the product as a solid (12.5 g, 65% yield). LCMS (ESI) m / z [M+Na] C 14 H 23 NO 6 Calculated value: 301.2; experimental value: 324.1.

[1052] Step 3. To a mixture of 5-bromo-1,2,3,6-tetrahydropyridine (8.0 g, 49 mmol) in MeOH (120 mL) was added methyl 2-{bis[(tert-butoxy)carbonyl]amino}prop-2-enoate (22 g, 74 mmol) under Ar atmosphere. The mixture was stirred for 16 hours, then concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give the product as an oil (12 g, 47% yield). LCMS (ESI) m / z [M+H] C 19 H 31 Bn 2 O 6 Calculated value: 462.1; experimental value: 463.1.

[1053] Step 4. To methyl 2-(bis(tert-butoxycarbonyl)amino)-3-(5-bromo-3,6-dihydropyridin-1(2H)-yl)propanoate (14 g, 30 mmol) in dioxane (30 mL) and H 2 To the mixture in 4% 4% HCl (10% ethanol, 1% sodium bicarbonate) was added LiOH (3.6 g, 151 mmol). The mixture was heated to 35°C and stirred for 12 hours, then 1M HCl was added and the pH was adjusted to about 3-4. The mixture was extracted with DCM (2 x 300 mL) and the combined organic layers were washed with anhydrous Na 2 SO 4 The mixture was dried and filtered. The filtrate was concentrated under reduced pressure to give the product as a solid (10 g, 85% yield). LCMS (ESI) m / z [M+H] C 13 H 21Bn 2 O 4 Calculated value: 348.1; experimental value: 349.0.

[1054] Step 5. To a mixture of 3-(5-bromo-3,6-dihydropyridin-1(2H)-yl)-2-((tert-butoxycarbonyl)amino)propanoic acid (10 g, 30 mmol), DIPEA (12 g, 93 mmol) and (3S)-1,2-diazacyclohexane-3-carboxylic acid methyl ester (5.4 g, 37 mmol) in DMF (100 mL) was added HATU (13 g, 34 mmol) at 0° C. under Ar atmosphere. The mixture was stirred at 0° C. for 2 h, and then H 2 O, and the mixture was extracted with EtOAc (2 x 300 mL). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter, concentrate the filtrate under reduced pressure and purify the residue by reverse phase chromatography to give the product as a solid (9.0 g, 55% yield). LCMS (ESI) m / z [M+H] C 19 H 31 Bn 4 O 5 Calculated value: 474.1; experimental value: 475.1.

[1055] Step 6. Under Ar atmosphere, (3S)-methyl 1-(3-(5-bromo-3,6-dihydropyridin-1(2H)-yl)-2-((tert-butoxycarbonyl)amino)propanoyl)hexahydropyridazine-3-carboxylate (9.0 g, 18 mmol), K 2 CO 3 (4.5 g, 32 mmol), Pd(dppf)Cl 2 DCM (1.4 g, 2 mmol), 3-(1-ethyl-2-{2-[(1S)-1-methoxyethyl]pyridin-3-yl}-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indol-3-yl)-2,2-dimethylpropan-1-ol (9.8 g, 20 mmol) in dioxane (90 mL) and H 2 The mixture in 2% O (10 mL) was heated to 75 °C and stirred for 2 h. 2 O and the mixture was extracted with EtOAc (3 x 200 mL). The combined organic layers were purified by Na 2 SO 4 Dry, filter, concentrate the filtrate under reduced pressure and purify the residue by silica gel column chromatography to give the product as a solid (4.0 g, 25% yield). LCMS (ESI) m / z [M+H] C 42 H 60 N6 O 7 Calculated value: 760.5; experimental value: 761.4.

[1056] Step 7. To a mixture of (3S)-1-(2-((tert-butoxycarbonyl)amino)-3-(5-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)-3,6-dihydropyridin-1(2H)-yl)propanoyl)hexahydropyridazine-3-carboxylic acid methyl ester (4.1 g, 5.0 mmol) in THF (35 mL) at 0°C was added LiOH (0.60 g, 27 mmol). The mixture was stirred at 0°C for 1.5 hours, then 1 M HCl was added to adjust the pH to about 6-7 and the mixture was extracted with EtOAc (3 x 200 mL). The combined organic layers were purified by NaOH. 2 SO 4 Dry, filter and concentrate the filtrate under reduced pressure to give the product as a solid (3.6 g, 80% yield). LCMS (ESI) m / z [M+H] C 41 H 58 N 6 O 7 Calculated value: 746.4; experimental value: 747.4.

[1057] Step 8. To a mixture of (3S)-1-(2-((tert-butoxycarbonyl)amino)-3-(5-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)-3,6-dihydropyridin-1(2H)-yl)propanoyl)hexahydropyridazine-3-carboxylic acid (3.6 g, 5.0 mmol) and DIPEA (24 g, 190 mmol) in DCM (700 mL) was added EDCI HCl (28 g, 140 mmol) and HOBt (6.5 g, 50 mmol) under Ar atmosphere. The mixture was heated to 30° C. and stirred at 30° C. for 16 h, then concentrated under reduced pressure. The residue was diluted with EtOAc (200 mL) and washed with H 2 O (2 x 200 mL), brine (200 mL), and Na 2 SO 4 Dried and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give the product as a solid (1.45 g, 40% yield). LCMS (ESI) m / z [M+H] C 41 H 56 N 6 O 6 Calculated value: 728.4; experimental value: 729.4.

[1058] Step 9. Heat the mixture to ((6 3 S)-1 1 -Ethyl-1 2 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-2 1 ,2 2 ,2 3 ,2 6 ,6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Decahydrogen-1 1 To a mixture of tert-butyl H-8-oxa-1(5,3)-indol-6(1,3)-pyridazin-2(5,1)-pyridine heterocycle undecyl-4-yl)carbamate (130 mg, 0.20 mmol) in DCM (1.0 mL) was added TFA (0.3 mL). The mixture was warmed to room temperature and stirred for 2 hours, then concentrated under reduced pressure to give the product, which was used directly in the next step without further purification. LCMS (ESI) m / z [M+H] C 36 H 48 N 6 O 4 Calculated value: 628.4; experimental value: 629.4.

[1059] Intermediate 11. Synthesis (6 3 S,4S)-4-amino-1 1 -Ethyl-1 2 -(2-((S)-1-methoxyethyl)-5-((R)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)pyridin-3-yl)-10,10-dimethyl-2 1 ,2 2 ,2 3 ,2 6 ,6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Decahydrogen-1 1 H-8-Oxa-1(5,3)-indol-6(1,3)-pyridazin-2(5,1)-pyridine heterocycle undecanoic acid-5,7-dione

[1060]

[1061] Step 1. To 3-(5-bromo-1-ethyl-2-(2-((S)-1-methoxyethyl)-5-((R)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylpropyl acetate (1 g, 1.598 mmol) and B 2 Pin 2 To a stirred solution of KOAc (0.39 g, 3.995 mmol) and Pd(dppf)Cl 2 (0.12 g, 0.16 mmol). The mixture was stirred at 90 °C under nitrogen atmosphere for 2 h. Then, saturated NaHCO 3 The mixture was basified to pH 8 with aqueous solution. The resulting mixture was extracted with DCM (3 x 40 mL) and the combined organic layers were washed with brine (3 x 40 mL) and purified by anhydrous Na 2 SO 4 After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2% MeOH / DCM) to give the product as a solid (0.9 g, 83% yield). LCMS (ESI) m / z [M+H] C 39 H 57 BN 4 O 5 Calculated value: 673.45; Experimental value: 673.6

[1062] Step 2. To the reaction mixture was added 3-(1-ethyl-2-(2-((S)-1-methoxyethyl)-5-((R)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)pyridin-3-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-3-yl)-2,2-dimethylpropyl acetate (0.9 g, 1.338 mmol), (3S)-1-[(2S)-3-(3-bromo-5,6-dihydro-2H-pyridin-1-yl)-2-[(tert-butoxycarbonyl)amino]propanoyl]-1,2-diazacyclohexane-3-carboxylic acid methyl ester (1.02 g, 2.141 mmol), K 2 CO 3 (0.46 g, 3.345 mmol) and X-Phos (0.26 g, 0.535 mmol) in toluene (13.5 mL), dioxane (90 mL) and H 2 Pd was added to a stirred solution of 20% HO (4.5 mL). 2 (dba) 3 (0.37 g, 0.401 mmol). The mixture was stirred at 70 °C under nitrogen atmosphere for 2 h. Then saturated NaHCO3 The mixture was basified to pH 8 with aqueous solution. The resulting mixture was extracted with DCM (3 x 100 mL) and the combined organic layers were washed with brine (3 x 100 mL) and purified by anhydrous Na 2 SO 4 After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2% MeOH / DCM) to give the product as a solid (1.1 g, 87% yield). LCMS (ESI) m / z [M+H] C 52 H 76 N 8 O 8 Calculated value: 941.59; Experimental value: 941.8

[1063] Step 3. To a stirred solution of (S)-methyl 1-((S)-3-(5-(3-(3-acetoxy-2,2-dimethylpropyl)-1-ethyl-2-(2-((S)-1-methoxyethyl)-5-((R)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)pyridin-3-yl)-1H-indol-5-yl)-3,6-dihydropyridin-1(2H)-yl)-2-((tert-butoxycarbonyl)amino)propanoyl)hexahydropyridazine-3-carboxylate (1.1 g, 1.169 mmol) in THF (8 mL) was added dropwise LiOH (0.14 g, 5.845 mmol) in H2O at 0 °C under nitrogen atmosphere. 2 O (8 mL). The reaction mixture was stirred for 16 hours. The mixture was then acidified to pH 6 with concentrated HCl. The resulting mixture was extracted with DCM (3 x 50 mL) and washed with anhydrous Na 2 SO 4 After filtration, the filtrate was concentrated under reduced pressure to give the product as a solid (1.0 g, 96% yield), which was used directly in the next step without further purification. LCMS (ESI) m / z [M+H] C 49 H 72 N 8 O 7 Calculated value: 885.56; Experimental value: 885.5

[1064] Step 4. To a stirred solution of (S)-1-((S)-2-((tert-butoxycarbonyl)amino)-3-(5-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)-5-((R)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)pyridin-3-yl)-1H-indol-5-yl)-3,6-dihydropyridin-1(2H)-yl)propanoyl)hexahydropyridazine-3-carboxylic acid (1.0 g, 1.13 mmol) and HOBt (0.76 g, 5.65 mmol) in DCM (100 mL) was added dropwise EDC·HCl (6.06 g, 31.64 mmol) and DIPEA (5.11 g, 39.55 mmol) at 0°C under nitrogen atmosphere. The reaction mixture was stirred for 16 h and then washed with saturated NaHCO 3 The mixture was basified to pH 8 with aqueous solution. The resulting mixture was extracted with DCM (3 x 100 mL) and the combined organic layers were washed with brine (3 x 100 mL) and purified by anhydrous Na 2 SO 4 After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (3% MeOH / DCM) to give the product as a solid (650 mg, 66% yield). LCMS (ESI) m / z [M+H] C 49 H 70 N 8 O 6 Calculated value: 867.55; Experimental value: 867.5

[1065] Step 5. Add (6) to the mixture at 0°C under nitrogen atmosphere. 3 S,4S)-1 1 -Ethyl-1 2 -(2-((S)-1-methoxyethyl)-5-((R)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-2 1 ,2 2 ,2 3 ,2 6 ,6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Decahydrogen-1 1To a stirred solution of tert-butyl H-8-oxa-1(5,3)-indol-6(1,3)-pyridazin-2(5,1)-pyridinyl)carbamate (300 mg, 0.346 mmol) in DCM (3 mL) was added TFA (3 mL) dropwise. The resulting mixture was stirred at 0° C. for 1 hour. Then, saturated NaHCO 3 The mixture was basified to pH 8 with aqueous solution. The resulting mixture was extracted with DCM (3 x 50 mL) and the combined organic layers were washed with brine (3 x 50 mL) and purified by anhydrous Na 2 SO 4 After filtration, the filtrate was concentrated under reduced pressure to give the product as a solid (260 mg, 98% yield), which was used directly in the next step without further purification. LCMS (ESI) m / z [M+H] C 44 H 62 N 8 O 4 Calculated value: 767.50; Experimental value: 767.2

[1066] Intermediate 12. Synthesis (2 2 S,6 3 S,4S)-4-amino-1 1 -Ethyl-1 2 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-6 1 ,6 2 ,6 3 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 H-8-Oxa-2(4,2)-morpholino-1(5,3)-indol-6(1,3)-pyridazineheterocyclic undecanoic acid-5,7-dione

[1067]

[1068] Step 1. To a solution of tert-butyl (2R)-2-(hydroxymethyl)morpholin-4-ylcarboxylate (50 g, 230 mmol) in EtOAc (1 L) was added TEMPO (715 mg, 4.6 mmol) and NaHCO at room temperature. 3 (58 g, 690 mmol). The mixture was cooled to -50 °C and then TCCA (56 g, 241 mmol) in EtOAc (100 mL) was added dropwise over 30 minutes. The reaction mixture was warmed to 5 °C for 2 hours and then treated with 10% Na 2 S 2 O 3The mixture was quenched with 4% paraformaldehyde (200 mL) and stirred for 20 minutes. The resulting mixture was filtered and the organic phase was separated. The aqueous phase was extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with H 2 O (100 mL) and brine (100 mL), then washed with anhydrous Na 2 SO 4 The organic layer was concentrated under reduced pressure to give the product (50 g, crude) as an oil.

[1069] Step 2. Tetramethylguanidine (35 g, 306 mmol) was added to a solution of tert-butyl (2R)-2-formylmorpholin-4-ylcarboxylate (49 g, 153 mmol) and methyl 2-{[(benzyloxy)carbonyl]amino}-2-(dimethoxyphosphoryl)acetate (60 g, 183 mmol) in MeCN (300 mL) at 0-10°C. The reaction mixture was stirred at 10°C for 30 minutes and then warmed to room temperature for 2 hours. The reaction mixture was diluted with DCM (200 mL) and treated with 10% citric acid (200 mL) and 10% NaHCO 3 The organic phase was concentrated under reduced pressure and purified by silica gel column chromatography to give the product as a solid (36 g, 90% yield). LCMS (ESI) m / z [M+Na] C 21 H 28 N 2 O 4 Calculated value: 420.2; experimental value: 443.1

[1070] Step 3. To a solution of tert-butyl (S,Z)-2-(2-(((benzyloxy)carbonyl)amino)-3-methoxy-3-oxoprop-1-en-1-yl)morpholine-4-carboxylate (49 g, 0.12 mol) in MeOH (500 mL) was added (S,S)-Et-DUPHOS-Rh (500 mg, 0.7 mmol). The mixture was stirred at room temperature under H 2 (60 psi) atmosphere for 48 hours. The reaction was concentrated and purified by silica gel column chromatography to give the product as a solid (44 g, 90% yield). LCMS (ESI) m / z [M+Na] C 21 H 30 N 2 O 7 Calculated value: 422.2; experimental value: 445.2.

[1071] Step 4. To a stirred solution of (S)-tert-butyl 2-((S)-2-(((benzyloxy)carbonyl)amino)-3-methoxy-3-oxopropyl)morpholine-4-carboxylate (2.2 g, 5.2 mmol) in EtOAc (2 mL) was added HCl / EtOAc (25 mL) at 15°C. The reaction was stirred at 15°C for 2 hours and then concentrated under reduced pressure to give the product as an oil (1.51 g, 90% yield). LCMS (ESI) m / z [M+H] C 16 H 22 N 2 O 5 Calculated value: 322.1; experimental value: 323.2.

[1072] Step 5. To a solution of 3-(5-bromo-1-ethyl-2-{2-[(1S)-1-methoxyethyl]pyridin-3-yl}indol-3-yl)-2,2-dimethylpropan-1-ol (100 g, 0.22 mol) and imidazole (30.6 g, 0.45 mol) in DCM (800 mL) was added TBSCl (50.7 g, 0.34 mol) in DCM (200 mL) at 0°C. The reaction was stirred at room temperature for 2 h. The resulting solution was treated with H 2 O (3 x 300 mL) and brine (2 x 200 mL), washed with anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The residue was purified by silica gel column chromatography to give the product as a solid (138 g, 90% yield). LCMS (ESI) m / z [M+H] C 29 H 43 Bn 2 O 2 Calculated value of Si: 558.2; experimental value: 559.2.

[1073] Step 6. Heat the mixture at 105°C in N 2To a stirred solution of (S)-5-bromo-3-(3-((tert-butyldimethylsilyl)oxy)-2,2-dimethylpropyl)-1-ethyl-2-(2-(1-methoxyethyl)pyridin-3-yl)-1H-indole (50 g, 89.3 mmol) in dioxane (500 mL) was added methyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(2S)-morpholin-2-yl]propanoate (31.7 g, 98.2 mmol), RuPhos (16.7 g, 35.7 mmol), di-μ-chlorobis(2-amino-1,1-biphenyl-2-yl-C,N)dipalladium(II) (2.8 g, 4.4 mmol) and cesium carbonate (96 g, 295 mmol) under atmosphere, followed by RuPhos-Pd-G2 (3.5 g, 4.4 mmol). The reaction mixture was heated at 105 °C under N 2 The mixture was stirred for 6 hours under an atmosphere of 40 °C. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC chromatography to give the product as a solid (55 g, 73% yield). LCMS (ESI) m / z [M+H] C 45 H 64 N 4 O 7 Calculated value of Si: 800.5; experimental value: 801.5.

[1074] Step 7. To a solution of methyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(2S)-4-(3-{3-[(tert-butyldimethylsilyl)oxy]-2,2-dimethylpropyl}-1-ethyl-2-{2-[(1S)-1-methoxyethyl]pyridin-3-yl}indol-5-yl)morpholin-2-yl]propanoate (10 g, 12 mmol) in THF (270 mL) was added LiOH (1.3 g, 31 mmol) in H2O at room temperature. 2 O (45 mL). The reaction was stirred at room temperature for 2 hours and then treated with 1N HCl at 0-5°C to adjust the pH to 4-5. The resulting mixture was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4 The organic phase was then concentrated under reduced pressure to give the product as a solid (9.5 g, 97% yield). LCMS (ESI) m / z [M+H] C 44 H 62 N 4 O 7 Calculated value of Si: 786.4; experimental value: 787.4.

[1075] Step 8. To a stirred solution of (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(2S)-4-(3-{3-[(tert-butyldimethylsilyl)oxy]-2,2-dimethylpropyl}-1-ethyl-2-{2-[(1S)-1-methoxyethyl]pyridin-3-yl}indol-5-yl)morpholin-2-yl]propanoic acid (10 g, 12.7 mmol) in DMF (150 mL) was added (S)-methyl hexahydropyridazine-3-carboxylate (2 g, 14 mmol), then cooled to 0°C, DIPEA (32.8 g, 254 mmol) was added, followed by HATU (9.7 g, 25.4 mmol) at 0-5°C. The reaction mixture was stirred at 0-5°C for 1 hour. The resulting mixture was washed with EtOAc (500 mL) and H 2 The organic layer was separated and diluted with H 2 O (2 x 100 mL) and brine (100 mL), dried over anhydrous sodium sulfate. The solution was filtered and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give the product. LCMS (ESI) m / z [M+H] C 50 H 72 N 6 O 8 Calculated value of Si: 912.5; experimental value: 913.4.

[1076] Step 9. To a solution of (S)-1-((S)-2-(((benzyloxy)carbonyl)amino)-3-((S)-4-(3-(3-((tert-butyldimethylsilyl)oxy)-2,2-dimethylpropyl)-1-ethyl-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)morpholin-2-yl)propanoyl)hexahydropyridazine-3-carboxylic acid methyl ester (8.5 g, 9 mmol) in THF (8 mL) was added a mixture of tetrabutylammonium fluoride (1 M in THF, 180 mL, 180 mmol) and AcOH (11 g, 200 mmol) at room temperature. The reaction mixture was stirred at 75 °C for 3 h. The resulting mixture was diluted with EtOAc (150 mL) and washed with H 2 O (6 x 20 mL). The organic phase was concentrated under reduced pressure to give the product as a solid (7.4 g, 100% yield). LCMS (ESI) m / z [M+H] C 44 H 58 N 6 O 8 Calculated value: 799.4; experimental value: 798.4.

[1077] Step 10. To a solution of (S)-methyl 1-((S)-2-(((benzyloxy)carbonyl)amino)-3-((S)-4-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)morpholin-2-yl)propanoyl)hexahydropyridazine-3-carboxylate (8 g, 10 mmol) in THF (200 mL) was added LiOH (600 mg, 25 mmol) in H 2 O (30 mL). The reaction mixture was stirred at room temperature for 1 hour, then treated with 1N HCl at 0-5°C to adjust the pH to 4-5, and extracted with EtOAc (2 x 500 mL). The organic phase was washed with brine and concentrated under reduced pressure to give the product as a solid (8 g, crude). LCMS (ESI) m / z [M+H] C 43 H 56 N 6 O 8 Calculated value: 784.4; experimental value: 785.4.

[1078] Step 11. To a stirred solution of (S)-1-((S)-2-(((benzyloxy)carbonyl)amino)-3-((S)-4-(1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-(2-((S)-1-methoxyethyl)pyridin-3-yl)-1H-indol-5-yl)morpholin-2-yl)propanoyl)hexahydropyridazine-3-carboxylic acid (8 g, 10.2 mmol) and DIPEA (59 g, 459 mmol) in DCM (800 mL) was added EDCI (88 g, 458 mmol) and HOBt (27.6 g, 204 mmol) at room temperature under argon atmosphere. The reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to give the product as a solid (5 g, 66% yield); LCMS (ESI) m / z [M+H] C 43 H 54 N 6 O 7 Calculated value: 766.4; experimental value: 767.4.

[1079] Step 12. Heat the mixture in H 2 The atmosphere is downward ((2 2 S,6 3 S,4S)-1 1 -Ethyl-1 2 -(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-6 1 ,6 2 ,63 ,6 4 ,6 5 ,6 6 -Hexahydro-1 1 To a solution of benzyl H-8-oxa-2(4,2)-morpholino-1(5,3)-indol-6(1,3)-pyridazineheterocycleundecanoyl-4-yl)carbamate (400 mg, 0.5 mmol) in MeOH (20 mL) was added Pd / C (200 mg) and ammonium acetate (834 mg, 16 mmol) and the mixture was stirred for 2 hours. The resulting mixture was filtered and concentrated under reduced pressure. The residue was dissolved in DCM (20 mL) and washed with H 2 O (5 mL x 2), then concentrated under reduced pressure to give the product as a solid (320 mg, 97% yield). LCMS (ESI) m / z [M+H] C 35 H 48 N 6 O 5 Calculated value: 632.4; experimental value: 633.3.

[1080] Intermediate 13. Synthesis ((...

Claims

1. A compound having a structure of Formula I, or a pharmaceutically acceptable salt thereof: wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene; L 1 Not present or a joint; W is a crosslinking group comprising vinyl ketone, vinyl sulfone, alkynyl ketone or alkynyl sulfone; R 1 is hydrogen, optionally substituted 3- to 10-membered heterocycloalkyl, or optionally substituted C1-C6 heteroalkyl; R 2 is an optionally substituted C1-C6 alkyl; and R 3 is an optionally substituted C1-C6 alkyl group or an optionally substituted C1-C3 heteroalkyl group.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is optionally substituted thiazole-diyl, optionally substituted oxazole-diyl, optionally substituted morpholine-diyl, optionally substituted pyrrolidine-diyl, optionally substituted pyridine-diyl, optionally substituted azetidine-diyl, optionally substituted pyrazine-diyl, optionally substituted pyrimidine-diyl, optionally substituted piperidine-diyl, optionally substituted oxadiazole-diyl, optionally substituted thiadiazole-diyl, optionally substituted triazole-diyl, optionally substituted thiomorpholine-diyl, or optionally substituted phenylene.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 2 yes:

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 3 is an optionally substituted C1-C6 alkyl group.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein A is an optionally substituted 5- to 10-membered heteroarylene.

6. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein A is an optionally substituted phenylene group.

7. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein A is an optionally substituted 3- to 6-membered heterocycloalkylene.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein the linker is a structure of Formula III: A 1 -(B 1 ) f -(C 1 ) g -(B 2 ) h -(D 1 )-(B 3 ) i -(C 2 ) j -(B 4 ) k –A 2 Formula III, Among them A 1 The linker and CH(R 3 ) between the keys; A 2 is the bond between W and the linker; B 1 , B 2 , B 3 and B 4 are each independently selected from optionally substituted C1-C2 alkylene, optionally substituted C1-C3 heteroalkylene, O, S and NR N ; Each R N are independently hydrogen, optionally substituted C 1– C4 alkyl, optionally substituted C2-C4 alkenyl, optionally substituted C2-C4 alkynyl, optionally substituted 3 to 14 membered heterocycloalkyl, optionally substituted 6 to 10 membered aryl, or optionally substituted C1-C7 heteroalkyl; C 1 and C 2 are each independently selected from carbonyl, thiocarbonyl, sulfonyl or phosphoryl; f, g, h, i, j and k are each independently 0 or 1; and D 1 is an optionally substituted C1-C 10 Alkylene, optionally substituted C2-C 10 Alkenylene, optionally substituted C2-C 10 alkylene, optionally substituted 3- to 14-membered heterocycloalkylene, optionally substituted 5- to 10-membered heteroarylene, optionally substituted 3- to 8-membered cycloalkylene, optionally substituted 6- to 10-membered arylene, optionally substituted C2-C 10 Polyethylene glycol or optionally substituted C1-C 10 Heteroalkylene, or connected to A 1 -(B 1 ) f -(C 1 )g -(B 2 ) h -with-(B 3 ) i -(C 2 ) j -(B 4 ) k –A 2 chemical bonds.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein the linker has a structure of Formula IIIa: Where o is 0 or 1; R 7 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted 3- to 8-membered cycloalkylene, or optionally substituted 3- to 8-membered heterocycloalkylene; X 1 absent, optionally substituted C1-C4 alkylene, O, NCH3, or optionally substituted C1-C4 heteroalkylene; Cy is optionally substituted 3 to 8 membered cycloalkylene, optionally substituted 3 to 12 membered heterocycloalkylene, optionally substituted 6-10 membered arylene, or optionally substituted 5 to 10 membered heteroarylene; and L 2 is absent, -SO2-, -NH-, optionally substituted C1-C4 alkylene, optionally substituted C1-C4 heteroalkylene, or optionally substituted 3- to 6-membered heterocycloalkylene.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein the compound is not a compound of Table 2.

11. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-5: Among them, Cy 1 is optionally substituted spirocyclic 8 to 11 membered heterocycloalkylene or optionally substituted bicyclic 7 to 9 membered heterocycloalkylene; and wherein W comprises vinyl ketone or vinyl sulfone.

12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein Cy 1 is an optionally substituted spirocyclic 10- to 11-membered heterocycloalkylene.

13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, having a structure of Formula II-5a: Where X 2 is O, C(R 11 )2. NR 12 , S or SO2. r is 1 or 2; Each t is independently 0, 1, or 2; R 11 and R 12 are each independently hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C2-C4 heteroalkyl, or optionally substituted 3- to 5-membered cycloalkyl; and Each R 13 is independently -CH3.

14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, having a structure of Formula II-5b: Where X 2 is O, C(R 11 )2. NR 12 , S or SO2. r is 1 or 2; s and t are each independently 0, 1 or 2; R 11 and R 12 each is independently hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C2-C4 heteroalkyl, optionally substituted 3 to 6 membered heterocycloalkyl, or optionally substituted 3 to 5 membered cycloalkyl; and Each R 13 are independently -CH3, F, or two R attached to the same atom 13 Together with the atoms to which they are attached, they form an optionally substituted C3-C6 cycloalkyl group, or two R attached to the same atom 13 Together with the atoms to which it is attached it forms an optionally substituted 3- to 6-membered heterocycloalkyl.

15. The compound of claim 13 or 14, or a pharmaceutically acceptable salt thereof, having a structure of Formula II-5c:

16. The compound of claim 13 or 14, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-5d:

17. The compound of claim 13 or 14, or a pharmaceutically acceptable salt thereof, having a structure of Formula II-5e:

18. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein W is a cross-linking group comprising a vinyl ketone.

19. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein W is a cross-linking group comprising vinyl sulfone.

20. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein W is a cross-linking group comprising an alkynone.

21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, having the structure of Formula II-6: Where Q 1 It is CH2, NR N or O; Q 2 CO、NR N or O; and Z is optionally substituted 3- to 6-membered heterocycloalkylene or optionally substituted 5- to 10-membered heteroarylene; or Where Q 1 -Q 2 -Z is optionally substituted 9- to 10-membered spirocyclic heterocycloalkylene.

22. A compound or a pharmaceutically acceptable salt thereof, wherein the compound or a pharmaceutically acceptable salt thereof is selected from Table 1.

23. A pharmaceutical composition comprising the compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

24. A conjugate or a salt thereof, comprising a structure of formula V: MLP Formula V, Where L is the connector; P is a monovalent organic moiety; and M has the structure of Formula VIa: wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene; R 2 is an optionally substituted C1-C6 alkyl group; R 3 is optionally substituted C1-C6 alkyl or optionally substituted C1-C3 heteroalkyl; X 2 is O, C(R 11)2. NR 12 , S or SO2; r is 1 or 2; Each t is independently 0, 1, or 2; R 11 and R 12 are each independently hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C2-C4 heteroalkyl, or optionally substituted 3- to 5-membered cycloalkyl; Each R 13 are independently -CH3; and R 4 , R 5 and R 6 Each is independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or R 4 and R 6 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or M has the structure of Formula VIb: wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene; R 2 is an optionally substituted C1-C6 alkyl group; R 3 is optionally substituted C1-C6 alkyl or optionally substituted C1-C3 heteroalkyl; R 14 is fluorine, hydrogen or C1-C3 alkyl; u is 0 or 1; and R 4 , R 5 and R 6 Each is independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or R 4 and R 5together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or R 4 and R 6 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or M has the structure of Formula VIc: wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene; R 2 is an optionally substituted C1-C6 alkyl group; R 3 is optionally substituted C1-C6 alkyl or optionally substituted C1-C3 heteroalkyl; and R 4 , R 5 and R 6 Each is independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or R 4 and R 6 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or M has the structure of Formula VId: wherein A is optionally substituted 3 to 6 membered heterocycloalkylene, optionally substituted 3 to 6 membered cycloalkylene, optionally substituted 6 membered arylene, or optionally substituted 5 to 10 membered heteroarylene; R 2 is an optionally substituted C1-C6 alkyl group; R 3 is optionally substituted C1-C6 alkyl or optionally substituted C1-C3 heteroalkyl; and R 4 , R 5 and R 6Each is independently selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted 3 to 6 membered cycloalkyl, optionally substituted 3 to 6 membered heterocycloalkyl; or R 4 and R 5 together with the atoms to which it is attached, form an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl; or R 4 and R 6 Together with the atoms to which it is attached, it forms an optionally substituted 3 to 8 membered cycloalkyl or an optionally substituted 3 to 8 membered heterocycloalkyl.

25. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 22 or a pharmaceutical composition according to claim 23.

26. The method of claim 25, wherein the cancer is pancreatic cancer, colorectal cancer, non-small cell lung cancer, or endometrial cancer.

27. The method of claim 25 or 26, wherein the cancer comprises a Ras mutation.

28. A method for treating a Ras protein-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 23.

29. A method for inhibiting Ras protein in a cell, the method comprising contacting the cell with an effective amount of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 22 or the pharmaceutical composition according to claim 23.